Annual Report 2021

Our Mission RHÖN-KLINIKUM AG is one of the largest healthcare providers in Germany. We offer excellent medical care with a direct tie-in to universities and research facilities. With our campus approach we are setting standards for excellent, cross-sector medical and therapeutic care – and that not just in rural areas. Our five maximum- and intermediate-care hospital sites – Campus Bad Neustadt, Klinikum Frankfurt (Oder), Giessen and Marburg University Hospitals as well as Zentralklinik Bad Berka – are attractive employers and training centres. People from over 70 nations work there for our Company. Our activities are underpinned by common values such as integrity, responsibility, compassion, care and respect. Sustainability is an essential part of our identity. It is a reflection of how we create a sound environment for our patients, employees, business partners and investors. At the same time, it enables us to safeguard our success on a sustainable basis. RHÖN-KLINIKUM AG | Annual Report 2021 1

LETTER TO SHAREHOLDERS We have learned to live with the pandemic. We have developed a certain routine. Nonetheless, we remain steadfast in our hope that this emergency situation, the likes of which we have never seen before, will soon come to an end. Here, our confidence is bolstered by the vaccines as we are firmly convinced of their effectiveness. As one of Germany’s largest hospital operators, we have performed over 48,000 vaccinations at our facilities for several thousand of our employees and their relatives over the past months. In this way, we have significantly reduced the work- load of vaccination centres and doctors’ practices and made an important contribution to society towards fighting the pandemic. Therefore, the only appeal we can make to you now is: get your jab and assume responsibility for our society! The development over the past financial year would not have been possible without the tireless efforts made by our employees: they are the backbone of RHÖN-KLINIKUM AG. Economic development over the past year Despite the considerable obstacles faced as a result of the pandemic, we treated 845,642 patients on an inpatient and out patient basis at our facilities. This is an increase of 36,987 persons treated, or 4.6 per cent, com- pared with financial year 2020. With the current situation of our hospitals, we remain confident that we will be able to provide a high level of care to all patients, particularly also to those not infected with COVID-19. With consolidated EBITDA of roughly 101.2 million euros and revenues of 1.4 billion euros, we achieved our adjusted financial targets. Consolidated profit of 30.2 million euros is 27.8 million euros above the level of previous year. The figures are encour - a ging and confirm that we are on the right track with the measures we have taken. Nonetheless, we have not yet reached the goal of our strategic reorientation, which we are pursuing together with Asklepios Kliniken GmbH & Co. KGaA. #teamrhön The development over the past financial year would not have been possible without the tireless efforts made by our employees: they are the backbone of RHÖN-KLINIKUM AG. We must strengthen them, especially during the pandemic with the greater professional and personal burdens it has brought. That is why, in 2021, we introduced the new Employee Assistance Program (EAP). This advisory programme assists our employees and their relatives in personal, professional, health or family matters and thus also helps us in our efforts to protect the health of our staff. RHÖN-KLINIKUM AG | Annual Report 2021 3

LETTER TO SHAREHOLDERS In Germany, we have a hospital system with well-trained, highly qualified and dedicated professionals. To make sure it stays that way in the future, this heavily regulated system must be funded in line with the principle of dual financing for all hospitals. Dual financing means that the operating costs (costs for current patient care) in the form of what are referred to as DRGs (diagnosis-related groups) are covered by the healthcare funds and the investment costs (buildings, medical equipment, etc.) by the federal states. This holds true for all hospitals, regardless of their care category and ownership type, i.e. regardless of whether they are public basic- and standard-care facilities, non-profit intermediate care hospitals or privately run university hospitals. But according to the German Hospital Association (Deutsche Krankenhausgesellschaft, DKG), there is still a huge billion-euro gap between the investment required and the fund- ing actually being provided by the federal states. For example, the investment requirement for the hospitals calculated for 2020 is more than six billion euros. This is set against only around three billion euros that the federal states have provided for hospital investments. It is therefore vital for the federal states to better fulfil their statutory responsibility to assume the investment costs and thus ensure the future viability of hospitals in Germany – in the interests of healthcare workers and patients alike. As the operator of several systemically relevant hospitals, we also consider it essential to call on federal politicians to likewise undertake an all-encompassing reform of healthcare planning and funding. The current rules are characterised by obstacles and barriers between the outpatient and inpatient sectors which are now outdated and obsolete. Moreover, they fail to adequately reflect the cost structures of the intermediate- and maximum-care providers and in particular university medicine. The reform announced by the traffic light coalition partners must be clarified promptly with the involvement of representatives of service providers and then implemented without any further delays. We will further press ahead with digitalisation. Our employees still spend a significant part of their working time on unnecessary documentation tasks. RHÖN-KLINIKUM AG | Annual Report 2021 5

LETTER TO SHAREHOLDERS RHÖN’s strategic partner: Asklepios Kliniken Asklepios and RHÖN-KLINIKUM AG have already been acting as strategic partners for more than a year. With the many areas we have in common as well as our shared visions, we have already embarked on a path of cooperation together: by working together, we will be able to gain a stronger position on the market and mutually benefit from the exchange of expertise. Already today, for example, we are Europe’s biggest provider in the area of cardiology and neurology, making us attractive for development partnerships with industry. Particularly in the field of tumour medicine, there are significant overlaps and areas of potential that we can jointly leverage. This is enabling us to further expand our care offering, to effectively promote our specialisation in certain areas and moreover provide fresh impetus to scientific research. For example, the Comprehensive Cancer Center (CCC) of the Giessen and Marburg University Hospitals and the Asklepios Tumour Centre of Hamburg are already stepping up their cooperation. For us, one thing is sure: we need the best of both worlds, medical care and research, for our patients but also for our employees – not just on paper. The training area also benefits from the merger of RHÖN and Asklepios. Last year in Hesse, a cooperation scheme aimed at better coordinating the offerings of our training centres and providing joint courses was agreed. Our employees are learning new insights and subject areas which otherwise would not be available within a hospital’s own continued training programmes, and are increasingly growing together into one big team. The past year has been very demanding for us. However, we have been steadfast and determined in overcoming each wave. That gives us courage and strength for the future. Dear Shareholders, I would like to thank you for your trust as well as your interest in RHÖN-KLINIKUM AG. Stay well. Yours sincerely, Dr Christian Höftberger Chairman of the Board of Management RHÖN-KLINIKUM Aktiengesellschaft Bad Neustadt a. d. Saale, March 2022 RHÖN-KLINIKUM AG | Annual Report 2021 7

REPORT OF THE SUPERVISORY BOARD Work of the Supervisory Board in the committees and plenary session With a view to performing its tasks and assuming its responsibility in the best possible way, the Supervisory Board has set up standing committees whose members possess specific expertise and experi- ence for the special issues dealt with in the committees. The committees prepare resolutions and issues to be decided in the plenary session of the Supervisory Board. They act as bodies with power to pass resolutions within the scope prescribed by law, the Articles of Association – also in lieu of the Supervisory Board – and the Terms of Reference of the latter to the extent consistent with statute and previously defined by the Supervisory Board. The committees generally meet separately from plenary sessions. Meetings were also held as conference calls convened on short notice or – in view of the COVID-19 pandemic – in the form of a video conference as required. Information on the composition of the Supervisory Board and the committees as well as attendance of the individual members in the meetings can be found in the overview at the end of this Report. Work of the Supervisory Board in the committees At a meeting by video conference, the Personnel Affairs Committee prepared subjects relating to personnel matters of the Board of Management for the Supervisory Board and, to the extent required, adopted resolutions and made recommendations to the Supervisory Board on the adoption of resolutions. During the past financial year, the Mediation Committee (pursu- ant to section 27 (3) of the Co-Determination Act (MitBestG)) did not meet. The Audit Committee of the Supervisory Board met five times in the year under review. All meetings were attended by representatives of the Board of Management. One meeting was attended by the statu- tory auditor for financial year 2020, PricewaterhouseCoopers GmbH Wirtschaftsprüfungsgesellschaft (“PwC”). At another meeting, KPMG AG Wirtschaftsprüfungsgesellschaft (“KPMG”) attended as auditor for the review of the interim report for the first half of financial year 2021. The Committee notably was responsible for review and preliminary consultation for the RHÖN-KLINIKUM Aktiengesellschaft consolidat- ed annual financial statements for financial year 2020. The Audit Committee assessed the independence of KPMG desig nated for auditing the consolidated financial statements and the Group Management Report as well as the annual financial state ments and the management report for financial year 2021 and for the review of the half-year financial report, obtained the state- ment regarding the auditor’s independence, recommended to the plenary session of the Supervisory Board a proposal for the election of the auditor to be submitted to the Annual General Meeting and – after the election – issued the statutory auditor with the audit man- date and concluded with it a reasonable fee agreement for the same. KPMG moreover reported to the Committee on orders for services performed in addition to the auditing services rendered. The quali- fication of the statutory auditor was monitored by the Committee. A list of audit items was once again prepared and defined for the audit in 2021. Questions of fundamental importance relating to accounting, cor- porate planning, the capital base, the supervision of the accounting process, as well as the effectiveness of the internal controlling sys- tem, risk management system (including special business risks) and the internal audit system were discussed with the Board of Manage- ment and in some cases also with the statutory auditor. The interim reports were thoroughly discussed on a regular basis with the Board of Management prior to their publication, as well as the half-year financial report with the Board of Management and in the presence of KPMG giving due regard to the review by the latter. The Group controlling report on performance and finance controlling submitted quarterly, which forms part of our risk management system, was thoroughly discussed in each case with the Board of Management. Here, the development of service volumes and earnings of the Group and of the individual Group hospitals was also analysed, scrutinised and discussed with the Board of Management, also with regard to deviations from targets. The body kept itself regularly informed by the responsible member of the Board of Management and by reports submitted by the head of Internal Auditing about the activity of the internal auditing department as well as the expansion of cooperation with Asklepios Kliniken GmbH & Co. KGaA in this area, and examined the auditing plan for 2021 as well as its update. The auditing plan for 2022 was approved. The audit reports of the internal auditing department as well as the 2020 activity report were then submitted in the Committee and discussed with the Board of Management. The Board of Management kept itself informed of the implementation of the recommendations by the internal auditing department by obtaining information on the results of follow-up reporting and review. We once again satisfied ourselves of the effectiveness of the internal auditing department. RHÖN-KLINIKUM AG | Annual Report 2021 9

REPORT OF THE SUPERVISORY BOARD ates (dependent company report) and resolved – on recommenda- tion by the Audit Committee – that no objections were to be raised against the declaration made by the Board of Management at the end of the report. The Supervisory Board also adopted approval resolutions for the Declaration on Corporate Governance pursuant to section 289f of the German Commercial Code (Handelsgesetz- buch, HGB) and on the Report of the Supervisory Board for finan- cial year 2020. Another item addressed at the meeting was the preparation of the Annual General Meeting. In this regard, we as the Supervisory Board approved the holding of the Annual General Meeting as a virtual Annual General Meeting as well as the agenda and the resolutions proposed to the Annual General Meeting. In the context of the adoption of the new remuneration scheme and following the meeting on 23 April 2021, the Declaration of Compliance of 5 November 2020 was updated during the year under way with respect to the recommendations of the German Corporate Governance Code (“GCGC”). At the meeting on 1 July 2021, the Supervisory Board once again examined the position of the Company as well as the current position and economic performance of key operative companies and discussed this thoroughly with the Board of Management. Furthermore, we looked at developments in areas of human resources and collective agreements and were provided with reporting on progress made in strategic areas of activity. In this context, the Supervisory Board approved the establishment of several subsidiaries for providing business services, purchasing and supply as well as IT services. It was also informed of the execution of the assignment of interests held by co-shareholders of Rhön-Innovations GmbH. At the meeting on 10 November 2021, the Supervisory Board together with the Board of Management discussed the interim report for the quarter ending on 30 September 2021 and primarily dealt with the preliminary economic and investment planning for financial year 2022. The Board of Management also reported on current cooperation schemes, projects and strategic areas of ac- tivity – particularly also in the context of the COVID-19 pandemic. At this meeting the Supervisory Board also examined the imple- mentation of the recommendations and suggestions of the GCGC. On the recommendation of the Audit Committee, the Declaration of Compliance issued during the year under way on 23 April 2021 pursuant to section 161 of the Stock Corporation Act (Aktiengesetz, AktG) was revised as planned – following a previous resolution adopted for this purpose – by a Declaration of Compliance issued on 10 November 2021 by the Board of Management and the Supervisory Board. Examination and approval of the 2021 financial statements The Board of Management adopted the financial statements of the Company and the management report for the year ended 31 De- cember 2021 in accordance with the provisions of the HGB, while the consolidated financial statements as at 31 December 2021 and Group Management Report for financial year 2021 were adopted pursuant to section 315e HGB in accordance with the principles set out in the International Financial Reporting Standards (IFRS). The auditors, KPMG, examined the annual financial state ments and the management report of the Company for financial year 2021 as well as the consolidated financial statements and Group Management Report for financial year 2021. The statutory auditors issued an unqualified auditor’s report in each case. The financial statements and management report of the Company, the consolidated financial statements and Group Management Report as well as the reports of the auditors KPMG as statutory auditors on the result of their audit were received by all members of the Supervisory Board together with the Board of Management’s proposal for the appropriation of the net distributable profit for the year. These documents were examined by the Supervisory Board and extensively discussed by the Audit Committee and by the Supervisory Board with representatives of the auditors at the respective balance sheet meetings. As part of the audit, the Audit Committee and the Supervisory Board examined both the accounting findings and the procedures and processes relating to the accounting findings. As the standard of their review, they primarily applied the criterion of legality and verified whether the documents submitted comply with legislation in force and in par- ticular with applicable accounting rules. Furthermore, in addition to their review of legality they also conducted an expediency review in terms of accounting, financial and business policy aspects. Based on the findings of the preliminary review by the Audit Committee, the Supervisory Board concurred with the findings of the auditors and, having conducted its own review, determined that it also sees no grounds for objections. The Supervisory Board approved the annual financial statements of the Company and the consolidated financial statements prepared by the Board of Management at the meeting on 23 March 2022 on recommendation of the Audit Committee; the annual financial statements of the Company are thus adopted as final. The Super- visory Board approved the Board of Management’s proposals for the appropriation of net distributable profit. Moreover, the Supervisory Board, together with the Board of Manage ment, adopted the remuneration report for financial year 2021 in accordance with section 162 AktG. RHÖN-KLINIKUM AG | Annual Report 2021 11

REPORT OF THE SUPERVISORY BOARD The personal details of the members of the Supervisory Board in 2021 are set out in the notes to the consolidated financial state- ments. The section also provides information on the professional qualifications of the Supervisory Board members as well as their further mandates. The organisational structure of the Supervisory Board and the composition of the committees during the past financial year are set out in the overview provided following this Report. One change in the Supervisory Board occurred after the end of financial year 2021: Ms Nicole Mooljee Damani notified the Company on 8 December 2021 that she was resigning her mandate as member of the Supervisory Board of the Company, and accordingly left the Supervisory Board with effect from 8 January 2022. The Supervisory Board therefore resolved on 1 February 2022 on the recommendation of the Nomination Committee to propose Dr Cornelia Süfke, head of the Medical Law, Compliance and Insurance division of Asklepios Kliniken GmbH & Co. KGaA, Hamburg, for the election to be held at the 2022 Annual General Meeting, to succeed Nicole Mooljee Damani as member of the Supervisory Board of RHÖN-KLINIKUM AG for the remaining term of office. For the period until then, the Local Court of Schweinfurt, by Decision of 2 March 2022 issued on the application by the Board of Management based on a correspond- ing proposal of the Supervisory Board, appointed Dr Cornelia Süfke as member of the Supervisory Board of the Company. The Supervisory Board thanks the members of the Board of Management, all employees of the Group as well as the employee representatives of all Group companies for their tremendous commitment and work performed during the past financial year, which presented huge challenges for everyone. The Supervisory Board Dr Jan Liersch Chairman Bad Neustadt a. d. Saale, 23 March 2022 RHÖN-KLINIKUM AG | Annual Report 2021 13

REPORT OF THE SUPERVISORY BOARD 2. Composition of the standing committees Personnel Affairs Committee Dr Jan Liersch, Chairman Members Peter Ducke Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Medical Innovation and Quality Committee Prof. Ehninger, Chairman (until 14 January 2021) No chairman elected (from 15 January 2021) Number of meetings: 1 Members Attendance Number of meetings: 0 Attendance 1 1 1 1 100 % 100 % 100 % 100 % Prof. Dr Leopold Eberhart Prof. Dr Gerhard Ehninger (until 14 January 2021) Dr Martin Mandewirth Nicole Mooljee Damani Mediation Committee Dr Jan Liersch, Chairman Nomination Committee Dr Jan Liersch, Chairman Members Number of meetings: 0 Members Attendance Kai Hankeln Dr Jan Liersch Hafid Rifi Number of meetings: 1 Attendance 1 1 1 100 % 100 % 100 % Kai Hankeln Dr Jan Liersch Dr Thomas Pillukat Georg Schulze Audit Committee Hafid Rifi, Chairman Committee for Decisions on Related-Party Transactions Dr Jan Liersch, Chairman Members Number of meetings: 5 Members Peter Berghöfer Regina Dickey Prof. Dr Leopold Eberhart Irmtraut Gürkan Dr Jan Liersch Hafid Rifi Attendance 5 5 5 5 5 5 100 % 100 % 100 % 100 % 100 % 100 % Nicole Mooljee Damani Dr Jan Liersch Oliver Salomon Georg Schulze Number of meetings: 0 Attendance RHÖN-KLINIKUM AG | Annual Report 2021 15

THE RHÖN-KLINIKUM SHARE Performance of stock markets In the 2021 stock market year the German leading index DAX®, despite the adverse effects on the global economy brought about by the COVID-19 pandemic, reached a new all-time high of 16,251 points. Overall, the DAX® recorded a gain in the 2021 stock market year of 15.8 per cent, closing the year at 15,885 points. With a trend that was slightly disproportionately moderate compared with the DAX®, the second-tier German index SDAX® saw a gain of 11.2 per cent and closed the year at 16,415 points. During the same period, the European leading index DJ EURO STOXX 50® rose by 20.6 per cent. The benchmark index for European stocks from the healthcare industry, DJ EURO STOXX Healthcare®, saw a 14.6 per cent increase. RHÖN-KLINIKUM SHARE ISIN Ticker symbol Registered share capital (€) Number of shares Share prices (€) Closing price High Low Market capitalisation (€ m) DE0007042301 RHK 167,406,175 66,962,470 01.01.–31.12.2021 01.01.–31.12.2020 14.38 16.30 14.30 31.12.2021 962.92 16.50 18.56 14.72 31.12.2020 1,104.88 Shareholder structure According to the notifications of voting rights pursuant to section 33 et seq. of the German Securities Trading Act (Wertpapier handels- gesetz, WpHG), the shareholder structure of RHÖN-KLINIKUM AG is as follows. SHAREHOLDER STRUCTURE OF RHÖN-KLINIKUM AG As at 31 December 2021 (on the basis of the most recent notification of voting rights to the company) C: 0.04% B: 6.58% A: AMR Holding GmbH, Dr Bernard große Broermann B: Free float C: Treasury stock A: 93.38% RHÖN-KLINIKUM AG | Annual Report 2021 17

Corporate Social Responsibility Report Sustainability management and organisation Patients Employees Compliance Environmental protection Supplier management 21 26 33 39 41 45 RHÖN-KLINIKUM AG | Annual Report 2021 RHÖN-KLINIKUM AG | Geschäftsbericht 2021 19 19

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Corporate Social Responsibility Report SUSTAINABILITY MANAGEMENT AND ORGANISATION For us, sustainability has long formed an integral part of our corporate strategy. In addition to medical aspects, other areas that play an important role are the environment, governance and social issues. Responsibility lies with the Board of Management | With RHÖN-KLINIKUM AG, responsibility for sustainability lies with the full Board of Management, because this subject was not made an integral part of our corporate strategy merely by the statutory require- ments. For us as a healthcare Group, our success is inseparably bound up with medical, ecological and social responsibility. | Our Corporate Code sets out both the fundamental conduct of all employees amongst one another as well as the relationship between employees and patients. Acting with integrity at all times is part of our self-perception at RHÖN-KLINIKUM AG. Group-level works council agreements between the Board of Management and the employee representatives moreover ensure that the personal integrity of our employees is also safeguarded whenever we cooperate with external entities. These Group-level works council agreements relate, for exam- ple, to our cooperation with industry or serve to prevent corruption, and are regularly adapted. In reporting year 2021 we entered into a new Group-level works council agreement to implement an Employee Assistance Program (EAP). For more detailed information, please refer to the section “Employees”. Our sustainability reporting | The present Corporate Social Responsibility Report (CSR Report) also includes the separate condensed Non-financial Report (NFR) in accor- dance with sections 315b in conjunction with sections 289b to 289e of the German Commercial Code (Handelsgesetzbuch, HGB). Moreover, the reporting requirements of the HGB are met. Unless otherwise indicated, all information stated refers to the parent (AG) and the Group equally. Above and beyond the statutory requirements, we voluntarily report on specific employee issues as well as on supplier management. For us, sustainability has long formed an integral part of our corporate strategy. | The reporting period is from 1 January to 31 December 2021. The NFR covers all Group subsidiaries included in the consolidated finan- cial statements. You will find information on the business model in the Group Management Report of this Annual Report in section 1 "Basic Characteristics of the RHÖN-KLINIKUM Group" and on the internet under the link www.rhoen-klinikum-ag.com. | The paragraphs marked with an ( ) form the NFR and were r eviewed by the accounting firm KPMG in accordance with the audit- ing standard ISAE 3000 (Revised) with limited assurance (in this regard see Auditor’s Report). | This year also, the option of orienting ourselves on general report- ing frameworks on sustainability subjects when preparing the NFR was not exercised since our sustainability management is currently being expanded and medical subjects are not reflected in the relevant frame- works. We regularly review this decision. | References to statements outside the Group Management Report constitute additional information and are not an integral part of the NFR. RHÖN-KLINIKUM AG | Annual Report 2021 21

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation | The numerator results from an analysis of the assets relating to the expenditures recorded in the aforementioned accounts for their tax- onomy eligibility based on Annex I (substantial contribution to climate change mitigation) and Annex II (substantial contribution to climate change adaptation) of Delegated Regulation (EU) 2020/852. Our material subjects in 2021 | In 2017 we identified the subjects that are material for us within the meaning of the HGB. Since then, the environment in which we operate has undergone further changes and we entered into a strategic partnership with the Asklepios Group in the middle of 2020. As part of that, we also updated the materiality analysis. | In 2021 the Asklepios Group conducted a detailed materiality anal- ysis voluntarily taking into account the requirements of the HGB. This produced a clustered list of issues (short list) which included the CSR issues of relevance for RHÖN-KLINIKUM AG up to 2020 as well as the potentially material issues (long list). In a meeting, the Board of Mana- gement of RHÖN-KLINIKUM AG reviewed the list and the Asklepios Group’s results of the materiality analysis. This reflects the increasing cooperation and joint strategic orientation of both companies. | The following issues are material for RHÖN-KLINIKUM AG: – Patient safety – Patient satisfaction – Employee health – Reducing waste (including food waste) – Reducing water consumption – CO2 reduction – Strengthening awareness of Code of Conduct/principles of action Capex ratio | The capex ratio states the share of capital expenditures (capex) which is associated with either a taxonomy-eligible economic activity or with a capital expenditure plan for expanding or achieving an environmentally sustainable economic activity, or which relates the purchase of products and services from a taxonomy-eligible economic activity. Capex ratio 50.9 % Taxonomy-eligible capital expenditures €38.4 million Total capital expen- ditures acc. to EU Taxonomy Regulation €75.3 million | Capital expenditures according to the EU Taxonomy Regulation total €75.3 million. | Based on the project description of the additions, an analysis for taxonomy eligibility and a comparison with Annex I (substantial con- tribution to climate change mitigation) and Annex II (substantial con- tribution to climate change adaptation) of Delegated Regulation (EU) 2020/852 are made. The total of all additions which reflect a taxono- my-eligible capital expenditure is the numerator of the capex key ratio. Opex ratio | The opex ratio states the share of operating expenditures within the meaning of EU taxonomy associated with taxonomy-eligible economic activities, with a capex plan described above or with the purchase of products from a taxonomy-eligible economic activity. Opex ratio 15.1 % Taxonomy-eligible op- erating expenditures €8.7 million Direct, non-recognised costs (R&D, building modernisation measures, leases, servicing and preventive maintenance) €57.7 million | To determine the denominator, those accounts reflecting the direct, non-recognised costs for research and development expendi- tures, building modernisation measures, short-term leases, servicing and preventive maintenance expenditures were considered. RHÖN-KLINIKUM AG | Annual Report 2021 23

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Sustainability management and organisation Our stakeholders | The first and foremost concern for us is always our patients and their well-being. That is why their feedback is especially important to us. But also maintaining a continuous exchange with our stakeholders – i.e. the relatives of our patients, (potential) employees, the general public, shareholders and investors, as well as the members of our network – is important to us. It is only thanks to the wide range of different views and sometimes even conflicting interests that we are provided with valuable ideas and constructive criticism enabling us to improve even further. Suggestions and possible improvements are promptly implemented and monitored by our quality management department. | Moreover, we are continuously striving to improve communication with our stakeholders and enhance specific aspects of our communica- tion. Also in 2021, this exchange was made for the most part on a digital basis due to the COVID-19 pandemic. Many events, such as job fairs, events for patients and their relatives, or also excursions for trainees and students as well as press conferences, were held only to a limited extent or had to be replaced by digital offerings. | You will find further information on patient communication in the section “Patients” on the following pages of this Report. | FORMS OF DIALOGUE WITHIN STAKEHOLDER ENVIRONMENT Employee magazine WIR Social media Internet Internal newsletters Intranet Press releases Trade fairs Citizens’ events Conferences Open house Magazines General public (Potential) employees E-learning Partnerships with schools and universities Social media Recruiting events and drives Company events Internet Conference calls Presentations Press releases Conferences Annual General Meeting Shareholders and investors Patients and relatives Network partners Social media Internet Magazines Brochures Patient events Patient surveys Seeking personal contact through Management Project managers, etc. Head physicians The formats in boldface could take place only to a limited extent due to the COVID-19 pandemic and the related regulations in 2021 or were replaced by digital substitute formats such as video conferences, webcasts, podcasts and telephone consultations. RHÖN-KLINIKUM AG | Annual Report 2021 25

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients | MEDICAL BOARD – ADVISORY BODY MADE UP OF TOP-RANKING PHYSICIANS Neuromedicine Oncology Cardiovascular Medicine Musculoskeletal Surgery Laboratory Medicine MEDICAL BOARD Anaesthesia Emergency Medical Care Intensive Medical Care Hygiene Psychiatry/ Psychosomatics expert panels | Following the harmonisation of medical bodies with our strategic partner Asklepios Group, each expert panel was expanded by two to three members from various Asklepios hospitals. This made it possible to promote Group-wide networking of medical experts and knowl- edge transfer. Moreover, the number of expert panels was reduced from twelve to currently ten. Three expert panels were dissolved and one new one was established. The existing expert panels Nursing Management as well as Quality and Clinical Risk Management were dissolved and replaced by new formats. In their stead, a Forum for Quality Management and Clinical Risk Management was introduced, which meets four times a year. This increased the opportunity to ex- change information with a view to pooling the wealth of knowledge and experience of both Group areas together with the Group division Quality at Asklepios. In this way we also harmonise the systems of quality management and those systems ensuring the greatest pos- sible safety for patients and employees within the Asklepios Group. | The expert panel Nursing Management, previously assigned to the Medical Board, was dissolved and replaced by a new Nursing Management Board format. From an organisational standpoint, the new body is assigned to the head of nursing process management, patient processes and process control in the area of organisation- al development. Outpatient medical care is a permanent agenda item of all clinical expert panels. This means that the subject area is assessed specifically for each specialist field. A separate expert panel for outpatient medical care thus no longer exists. In addition, a new Emergency Medical Care expert panel was established. | The Medical Board will be phased out in its function at the end of April 2022. In future, work in medical bodies will take place at an operative level in meetings of the medical management boards and directors with the Medical division and via the proven medical expert panels. Cross-medical strategic consultations within the context of the entire Asklepios Group will take place in the Medical Advisory Board of Asklepios and will include representatives from MediClin, Asklepios and RHÖN-KLINIKUM AG. This will be supplemented by regular consultations of the Medical divisions. Scope for interfacility exchange of experience for outpatient care | In future, the existing semi-annual dialogues of the medical care centres (MVZs) will take place together with the Asklepios Group as annual MVZ conferences. These will continue to be held for the pur- pose of facilitating the interfacility exchange of experience with the aim of jointly developing best-practice approaches for the MVZs. The focus of the agenda of this year’s conference is on subjects such as management and organisation of medical practices, outpatient oper- ations, change management, digitalisation and artificial intelligence. RHÖN-KLINIKUM AG | Annual Report 2021 27

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients Rehab offering expanded | In the middle of August 2021, we opened the new building for Psychosomatic Rehabilitation at RHÖN-KLINIKUM Campus Bad Neustadt. Rehabilitation rounds off the existing offering in acute care and the day clinic for the treatment of psychological and psy- chosomatic conditions. At the same time this is consistent with our “digital – outpatient – acute-inpatient – rehabilitative” RHÖN-Campus concept being implemented at the Bad Neustadt site. Expansion of medical treatment offering of paediatric and adolescent medicine | The incidence of chronic inflammatory bowel diseases in children and adolescents has seen an increase over the past decades. The Klinik für Kinder- und Jugendheilkunde, a clinic for paediatric and adoles- cent medicine, at Klinikum Frankfurt (Oder) has responded to this by expanding its medical treatment offering. Up to now, children and adolescents with gastroenterological diseases had to drive to Potsdam for treatment. Since September such treatment is now also available in Frankfurt (Oder). Moreover, the hospital is planning a new ward for paediatric psychosomatics to be put into service in 2022. Cooperation efforts stepped up | During the reporting year, we steadily enhanced our cooperation with our strategic partner, Asklepios Group. After completing a thor- ough and careful exploratory stage, numerous potential areas for syn- ergies were identified. In some areas this is already being successfully implemented in cooperation efforts that are proving constructive – for example when it comes to reporting on medical quality and the use of software for ensuring and enhancing patient safety. Medical excellence can be achieved only if we take advantage of all available technical support means and always ensure that our equipment is state of the art. | Moreover, we embrace the concept of networking and are also cooperating with external partners. Since the middle of April 2021, experts from the gynaecological hospital Würzburger Universitäts- frauenklinik in Bad Neustadt have been offering a special consultation for patients with breast cancer or other gynaecological tumours. The aim of the new cooperation is to further improve the care provided within the Rhön-Grabfeld region to women suffering from breast cancer and other gynaecological tumour diseases close to where they live. Forging ahead with digitalisation | Medical excellence can be achieved only if we take advantage of all available technical support means and always ensure that our equipment is state of the art. | For example, we succeeded in further developing the area of teledermatology. The dermatology unit of UKGM Marburg offers its tele-consulting service to the acute clinic of Campus Bad Neustadt as well as to its psychosomatic clinics. Through the fast, digital exchange of data and the involvement of the experts from Marburg University, we save precious time in the treatment process and thus improve the quality of diagnosis and care. Despite the physical distance sep- arating them, the Marburg dermatologists are in direct contact with the patient and assist their colleagues with diagnosis and therapy. A twice-weekly telemedical consultation was set up specifically for this purpose. Images and data are exchanged and discussed amongst the doctors by live video transmission, for example in an electronic visit made right at the patient’s bedside. Any photos and relevant information relating to the patient can be sent in advance. At the end of the reporting period, a new technical platform was installed at UKGM Marburg, and the related equipment installed at the hospital in Bad Neustadt. We are also in negotiations with further potential cooperation partners. | We are also making progress with our sekTOR- HF project launched in the middle of 2020. It brings a significant improvement in the treatment of patients suffering from left ventricular failure. The goal is to reduce the mortality rate and hospital referrals through optimum care and coordinated cooperation amongst all service pro- viders – such as GPs or specialists, hospitals, specialist post-care pro- viders – whilst at the same time raising the quality of life of patients suffering from cardiac failure. The patient and telemedicine play an active role in this. In a training course, each participant learns how to send his or her vital signs or details about their current state of health via app or internet portal to the competent doctors and a network contact. If monitoring reveals any anomalies, the network contact can define specifically adapted measures and coordinate individual treatment recommendations with the physicians involved. At the be- ginning of the project each patient is given comprehensive training in the use of the telemedical devices and in self-management. At the same time, another goal we are pursuing with the sekTOR -HF project is to establish a cross-sector care model by which the under- lying processes thus can be coordinated and remunerated on a new RHÖN-KLINIKUM AG | Annual Report 2021 29

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Patients RHÖN QUALITY CONCEPT Internet pages of selected service areas Statutory quality reports Statutory quality assurance Selected service areas Transparency RHÖN Quality Cockpit Quality comparison IQM findings RHÖN QUALITY CONCEPT Medical nursing care Combined RHÖN Review Structured RHÖN Quality Dialogue Documentation, coding Management, medical directorship, hospital directorship Recommendations Unusual medical findings By site, facility-specific 18 European research institutions from the areas of physical and biologi- cal basic research as well as clinical research. They include the four clinical centres in Europe where patients are irradiated with carbon ions. In terms of evidence-based medicine, close transnational and interdisciplinary cooperation in the project will further promote the improvement and expansion of the therapy offering for patients by expanding the scientific infrastructure. RHÖN Quality Concept | With our RHÖN Quality Concept we are pursuing the goal of steadily improving our medical quality through a comprehensive ap- proach. It is a key tool for further enhancing patient safety. Together with the Group division Quality of our strategic partner Asklepios Group, we are currently working on modifications to be rolled out gradually over the coming three years. These include, among others, harmonising various issues in the area of quality management and clinical risk management. | The RHÖN-Qualitäts-Konzept is based on four core elements: the RHÖN Quality Cockpit, the structured RHÖN Quality Dialogues, the combined RHÖN Reviews and transparency. Its results are regularly presented to the Medical division of the Board of Management and in some cases also discussed in the Medical Board. | The RHÖN Quality Cockpit helps us direct and guide our med- ical quality. We measure and continually assess defined quality indicators from which we derive measures for improvement. The RHÖN Quality Cockpit was thus adopted by the Group division Quality of the Asklepios Group as a template for an Asklepios-internal quality reporting system. Together, content was structured and supplement- ed uniformly so that both companies benefit from this result. | The structured RHÖN Quality Dialogues enabling the Board mem- ber for the Medical division to liaise with the hospitals on quality assurance and implement the quality strategy was suspended in 2021 due to the corona pandemic. RHÖN-KLINIKUM AG | Annual Report 2021 31

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees EMPLOYEES Highly trained and efficient employees in good health are the backbone of our hospital operations and our most valuable asset. In our health management approach we make sure to be attentive to our employees’ needs. RHÖN -KLINIKUM AG’s attractiveness as an employer is further enhanced by its comprehensive offering of further, continued and higher-qualification training for its employees. | With 18,227 employees, we are one of Germany’s biggest healthcare groups. Over financial year 2021 we have taken a variety of measures to recruit new, qualified staff. Thanks to the strategic partnership with Asklepios from the second half of 2020, the range of opportunities we can offer has grown further. Together, we have developed and implemented some concepts making us even more attractive as an employer. Our human resources management | During the 2021 reporting period, our two-tier organisation and human resources management approach has once again proven itself. Each of our hospitals has its own human resources department that reports to the respective hospital management. Under this decentralised structure, operative decisions producing the best outcomes for the hos- pital site can be made. By contrast, any strategically important decisions are made centrally with the involvement of Group Human Resources. For example, the orientation of the Group’s human resources policy as well as the establishment and further development of the employer branding concept are defined at the Group level. In this regard we al- ways maintain a close exchange with our strategic partner, Asklepios Group. This has led to a further professionalisation and improvement in HR management. Our cooperation is based on a high level of trust and on promoting increasingly close ties. For example, in the past financial year we purchased new e-learning software to be implemented in 2022. We have also come up with a sensible way of harmonising the various bonus and employee benefits programmes. | For 2022, we have identified further areas in which we would like to cooperate even more closely with the Asklepios Group. One example of this relates to the respective trainee programmes, particularly at the management level of both organisations. These are to be harmonised so that young talent can feel part of an increasingly integrated, close-knit corporate group from the outset. Strategic partnership expands scope of action and increases our attractiveness as an employer | RHÖN- KLINIKUM AG is an independent employer brand operating under the umbrella of the Asklepios Group. Working in close cooperation with the latter we have expanded our continued training and employee advisory offerings and now post job offers across the entire corporate group. In the middle of 2020 we established an Employee Assistance Program (EAP) which is available to advise and assist the Company’s employees and executive staff. | For years we have been committed to excellent medical care, competence and know-how as well as maintaining a close relation- ship based on a human approach. We have a high level of digitalisa- tion, act responsibly and have a highly efficient and sound structure. As a corporate group with a network of hospitals, we offer good personal development opportunities at the various sites as well as throughout the group. That is something that is particularly valued by doctors in Germany. As large intermediate- and maximum-care fa- cilities with access to university medicine, our hospitals are attractive and have a unique selling point. That is something we are proud of. We are paving the way for the integration of new employees from Germany and abroad | In 2021, we took numerous measures to recruit new employees and provide them with continued and higher-qualification training in order to retain them in our Company. In this regard we are specifically looking to attract new staff from abroad. We meet the related chal- lenges with the support of committed colleagues from the specialist and HR departments. Here we are particularly interested in taking account of cultural differences, overcoming language barriers as well as enabling the smoothest possible integration. | For example, we entered into an agreement with Amesol Akade- mie in Hamburg, which has committed itself to providing assistance to international healthcare specialists in close cooperation with hospi- tals and long-term care facilities. The specific programme developed by Amesol promotes the long-term, successful qualification and in- tegration of international healthcare specialists qualified as nurses, anaesthesia technical assistants (ATA), operation technical assistants (OTA) and physiotherapists. RHÖN-KLINIKUM AG | Annual Report 2021 33

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees Promoting health with the Employee Assistant Programme | In 2021, we decided in a Group-wide agreement to introduce the Employee Assistance Program (EAP) as part of a Group-level works agreement supported by the Group-level works council and estab- lished it at the hospital sites of Frankfurt (Oder), Giessen and Marburg. The sites of Bad Neustadt and Bad Berka are to follow suit early in 2022. This measure is also part of our aim to promote the health of our employees. Under the EAP, employees of RHÖN-KLINIKUM AG can take advantage of consultations with the trained and knowledgeable staff of the Fürstenberg Institute whenever they find themselves in difficult personal situations. Employees are thus provided with assistance in finding their way out of their current difficulties. | The EAO concept has proven itself and is being used by employ- ees from all areas. Frequently, employees also reach out for help to prevent mental health issues and stress-related health risks as well as the related problems of work performance and sickness-related absences. | Moreover, the EAP is specifically used to train executive staff, HR departments and works councils in managing employees dealing with psychological stress and addiction-related problems. | We have noticed that the EAP has helped some employees better identify with the Company whilst boosting their motivation and, as a result, also their performance. | Employees may have an individual consultation at the hospital premises, by phone, or by video conference via a specific password- protected internet link to the cooperation partner Fürstenberg Institute. | Currently, employees can make use of this offering at the Giessen and Marburg University Hospitals as well as at Klinikum Frankfurt (Oder), with the programme to be rolled out at all sites by March 2022. Work–life balance of our employees | We realise that keeping a work–life balance is of key importance when it comes to maintaining stable mental and physical health. That is why we see it as our duty to create the environment in which our employees can succeed in harmonising their professional and personal life. We achieve this by ensuring the most flexible working hours possible, and have provisions in place for our employees to perform their work under trust-based, flexitime or part-time schemes. In 2021, 8,083 employees (roughly 45 per cent) were employed part- time. We have entered into individual agreements for each site in which we take greater account of employees’ personal priorities. In this regard we have adopted clear staffing back-up rules, try to take personal requests into account and have established on-call service or stand-in employee pools. Whenever possible, we also allow our employees to work from home. | We moreover provide our employees and their families with an extensive childcare offering, for example by running our own kinder- gartens, cooperating with facilities locally, and providing for individ- ual childcare options for employees attending continued training or mandatory events. For employees providing nursing care to relatives, we help them cope with balancing their work with looking after their relatives. UKGM has been certified as a family-friendly employer already since 2009. RHÖN-KLINIKUM Campus Bad Neustadt joined Familienpakt Bayern (Bavarian Pact for the Family) at the end of 2021. Challenges of the COVID-19 pandemic once again managed together | Another positive outcome from the good cooperation with the Asklepios Group is the harmonisation of measures to manage the COVID-19 pandemic. Sufficient capacities of protective equipment and instruments for performing infection tests were available at all times and at all sites throughout the Group. Moreover, the manage- ment bodies and HR departments worked together to provide em- ployees with the best possible support in managing the additional challenges arising from the special social behaviour measures brought in to contain the pandemic. We allowed our employees to perform their work at home wherever working procedures permitted. To make things as easy as possible for the parents among our employees, we organised emergency childcare at times when day-care centres were closed. In addition, we have offered all colleagues a first and second vaccination dose since January 2021, and since late autumn this was supplemented by the booster shot. | During the reporting period, the workload for those employees who treated COVID-19 patients directly was particularly high. Here we sought to boost staffing capacities and to provide for offsetting measures for overtime. | We sought to introduce quick and effective countermeasures to address an increase in psychological stress resulting, for example, from homeschooling. In addition to measures from the EAP, at a number of sites we offer our employees training programmes on the issues of stress and burnout, for example. RHÖN-KLINIKUM AG | Annual Report 2021 35

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Employees We meet all requirements for generalist training of nurses In 2021, training of geriatric, healthcare and paediatric nurses was merged under the degree of nursing expert (Pflegefachkraft). Thanks to our early preparations we were able to satisfy all requirements for the new nursing expert training programme in accordance with the new Care Professions Reform Act (Pflegeberufereformgesetz, PflBRefG) and to fully secure the training programme. In particular, we succeeded in finding suitable cooperation partners for all training fields. We continued the collaborative training agreements from 2020 also in 2021 and entered into new partnerships. We are bringing about rising attendance and digitalisation at our in-house schools As a healthcare Group, we operate several schools to train qualified staff ourselves. These include schools for nursing care, physiotherapy, ergotherapy, speech therapy, dietician services, for medical assistance professions in the areas of functional diagnosis (MTAF), laboratory (MTLA), radiology (MTRA) and medical documentation (MDA). We also provide training in the business, gastronomy and IT fields. We also report successes in further digitalising the learning environ- ment of our schools, promoting the quality of our training offerings. The “Team Digital” established in 2019 equipped all classrooms so that classes could continue to be held without interruption in the event of schools being locked down again. By availing ourselves of all state and federal programmes for funding the digitalisation of the schools, we were able to procure sufficient quantities of laptops to be loaned permanently to students, and to provide each instructor with their own work laptop. We promote dual training at our campus academy In the course of 2021, we completed the planned change in owner- ship of the schools from ESB-Gemeinnützige Gesellschaft für berufli- che Bildung mbH to RHÖN-KLINIKUM AG. This change took effect on 1 January 2022. With the change in ownership and the combining of theoretical and practical training at Campus Bad Neustadt, we pooled and integrated further, continued and higher-qualification training. Our students benefit from these synergies. Already during the train- ing, we can provide them with guidance on prospects for their future professional life and work together with them to plan their careers. We also decided to pool all measures of further, continued and high- er-qualification training at Campus Bad Neustadt under a campus academy. Attractive employer We embrace diversity During the reporting period, people from over 70 nations worked for our Group. Regardless of their age, gender, qualification or what their interests may be, they work in a team daily and perform outstanding work. The basis for that is respectful and fair dealings with one anoth- er. For us this is all just a self-evident part of our day-to-day hospital activities. We are committed to such diversity and oppose discrimi- nation or harassment in any form. We maintain the principle of equal opportunities by filling positions exclusively on the basis of qualifi- cations. Almost 40 per cent of executives at the three management levels below the Board of Management are women. We also make sure that our teams are made up of both young and experienced employees. During the reporting period, people from over 70 nations worked for our Group. EXECUTIVE EMPLOYEES BY MANAGEMENT LEVEL IN 2021 Headcount 1st management level 2nd management level 3rd management level Total Total Female Male 43 243 1,080 1,366 11 55 472 538 32 188 608 828 RHÖN-KLINIKUM AG | Annual Report 2021 37

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Compliance COMPLIANCE At RHÖN-KLINIKUM AG, compliance is about promoting fair dealings – both within the Company and in the relationship with our external stakeholders. | The relationship of trust between hospital staff and patients is of tremendous importance for our day-to-day work. It is reflected in the principle “Don’t do to others what you would not like done to yourself, and don’t leave off doing anything that you would like done to yourself” and is binding on all our employees. Compliance rules for appropriate conduct in inter- nal and external relationship | We have in place a compliance management system in which the principles and rules of legally compliant behaviour, fair dealings and responsible corporate governance are defined. The compliance management system is being continuously enhanced. In our Group- wide compliance rules, requirements setting out the relationships with our patients, customers, suppliers, shareholders and the general public as well as the conduct of employees amongst one another are described. The highest level of responsibility for compliance is held by the Chairman of the Board of Management, who reports to the Audit Committee of the Supervisory Board. A central compliance department for establishing the compliance framework is set up at the Group level. The relationship of trust between hospital staff and patients is of tremendous importance for our day-to-day work. | RHÖN-KLINIKUM AG is an independent Company operat- ing under the umbrella of Asklepios Kliniken GmbH & Co. KGaA. RHÖN-KLINIKUM AG and Asklepios Kliniken GmbH & Co. KGaA form the effective corporate group within the meaning of sections 311 et seq. of the German Stock Corporation Act (Aktiengesetz, AktG). As part of this cooperation, the central compliance department of RHÖN-KLINIKUM AG was restructured in 2021. | Within the RHÖN/Asklepios Group, the compliance management system will and must be harmonised. This is aimed at exploiting syn- ergies as well as bringing compliance “under one roof” to reduce compliance risks for directors, officers and employees. A first measure was to expand the Central Compliance department at RHÖN and to appoint the Head of Compliance of Asklepios Kliniken GmbH & Co. KGaA as Head of Central Compliance at RHÖN-KLINIKUM AG. More- over, the organisational principles of the compliance were revised. At the time of editorial closing, the measures had not yet been com- pleted and will still result in changes in 2022. During the reporting period, compliance queries and reports of RHÖN subsidiaries were processed at the level of the Central Compliance function, and spe- cific compliance measures were implemented. As a result of the still ongoing harmonisation, the compliance programme expanded along very selective lines. | The central compliance department is supported locally by com- pliance officers. They report to the central compliance department and act as contacts on-site. The compliance officers receive further training on a regular basis, most recently in an in-person training course in October 2021. | To ensure an ongoing exchange between the risk manage- ment, internal auditing and compliance departments, there is also a Compliance Committee that meets each quarter and deals with compliance cases and their risk assessment. RHÖN-KLINIKUM AG | Annual Report 2021 39

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection ENVIRONMENTAL PROTECTION As a modern hospital group, we use innovative technology for the well-being of our patients and to take good care of the environment. We see making responsible use of energy and water resources as something self-evident and thus also as a guiding principle for environmental protection at our Company. Moreover, we are wholly committed to keeping our waste and emissions levels as low as possible. Environmental management is a top priority for us | Protecting the well-being of our patients and taking good care of the environment are a top priorities for RHÖN-KLINIKUM AG. That is why we have firmly integrated environmental management into our organisational structure. Our main focus and concern in this regard is to reduce CO2, waste volumes and water consumption without compromising on ensuring the care and comfort of our patients. | Based on its decentralised structure, environmental manage- ment at RHÖN- KLINIKUM AG is established at two levels: firstly in the technical control departments of the hospitals, and secondly at the Group division Construction and Technology. Overall responsibility lies with the Board of Management. The respective technical control department is responsible for the hospital’s safe operation: it monitors all technical and medical-technical equipment and systems but also construction projects, and assumes the task of energy controlling as well as modernisation and optimisation planning. Where required, it is assisted in all measures by the Group division Construction and Technology: it advises the hospitals of RHÖN- KLINIKUM AG on ques- tions of energy management and provides assistance with major investment measures at the hospital sites, above all modernisation and extension measures. | Already since the end of 2016 we have pooled procurement of energy Group-wide in the company “RHÖN Energie für Gesundheit GmbH”. This enables us to obtain more attractive purchasing prices for electricity and gas and gives us a centralised overview of the en- ergy consumed and monthly controlling. As part of the change in management, RHÖN-KLINIKUM Energie für Gesundheit GmbH has decided to instruct an external service provider with, among other things, the task of allocating and charging the energy purchased to the facilities of RHÖN-KLINIKUM AG, as well as appropriately advising the management and informing it in good time of any changes in legislation. AKTIF GmbH already acts for the Asklepios Group as an expert in the energy sector and is now slated to provide assistance in transforming the energy management area. After the expiry of the existing contracts for gas and electricity purchases, these energy requirements are to be covered jointly on the market. Currently, the fixed-price contracts will continue until the end of 2023. Our main focus in this regard will be on ensuring the most efficient electricity consumption possible in our operative business so as to achieve our primary goal of minimising unnecessary energy consumption inde- pendent of the energy mix. Nonetheless, in future tenders we will endeavour to further optimise the ecological and economic targets and to increase even further the current share of renewable energy. | In 2015/2016 we conducted an energy audit to DIN EN 162471 for the first time. In 2020, we conducted and successfully concluded the energy audit once again. The next audit is planned for 2023. Protecting the well-being of our patients and taking good care of the environment are a top priorities for RHÖN-KLINIKUM AG. RHÖN-KLINIKUM AG | Annual Report 2021 41

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Environmental protection construction stages, this site will see its four existing cogeneration plants replaced, existing heating boilers adapted to the new require- ments and the central cooling unit brought in line with the new operating environment. In future, CO2 emissions will be significantly reduced and energy costs reduced annually by roughly 340,000 euros once the project has been completed. | At the Frankfurt (Oder) site during the reporting year, the re- placement of the lighting system was continued as part of the refur- bishment project, and the instrumentation and control technology system was modernised. | In Marburg, replacement investment measures during the re- porting year allowed us to reduce energy consumption by replacing some large medical equipment units with more energy-efficient ones. For example, the new MRI unit dispenses with helium cooling, the new CT angio unit is operated as a synergy concept, and the new linear accelerator features a particularly high operating efficiency. For the newly constructed clinic for paediatric and juvenile psychiatry, a photovoltaic system with an output of 40 kWp (kilowatt peak) is to cover part of the energy requirement when the clinic is put into operation in 2022. | In all new construction and modernisation measures, we provide for redundancy and availability of the technical facilities to make sure we are ready for any failure of the external energy supply grid. Two emergency power generators per hospital ensure self-sufficiency in electricity for several days. With oil-operated back-up boilers, we moreover ensure a supply with sufficient heat and, where applicable, steam. We are thus able to ensure safe patient care in the event of protracted external supply failures. Environmentally sound alternatives for private transport | We are aware that CO2 emissions arise whenever our employees, patients and their visitors travel to and from a hospital using their own private vehicles. That is why we took various measures during the re- porting period to limit private transport, to offer alternatives and to thus make transfers more environmentally friendly. | Already in previous years, for example, we have improved the connection to local public transport (Bad Berka), set up a free shuttle service (Frankfurt (Oder)), and provided additional bicycle stands on the hospital grounds in Bad Berka and Frankfurt (Oder). From 2022, our employees at the Marburg and Giessen sites will be able to take advantage of a free ticket for local public transport and will also be able to enjoy the benefits of a job-bike offer. We promote electrical mobility by gradually installing additional charging stations for the electrical vehicles of our employees and guests. Tangible results1, 2 | In 2021, we generated with combined heat and power units a total of 39,607 megawatt hours (MWh) (previous year: 40,250 MWh) of electricity, covering roughly 34 per cent (previous year: 35 per cent) of our requirements. This is cost-efficient and saves roughly 5,926 t in CO2 emissions each year as compared with conventional energy sup- ply. Compared with the previous year, electricity the consumption at RHÖN-KLINIKUM AG in 2021 saw a minor increase of roughly 0.4 per cent to 109,657 MWh (previous year: 109,227 MWh). | Heat consumption increased by around 3.0 per cent to 87,528 MWh (previous year: 84,975 MWh). | The higher energy requirements of our hospitals are also resulting in a rise in CO2 emissions. What are referred to as Scope 1 emissions are produced directly on-site in our own heat and electricity gener- ation. During the reporting period, these amounted to over 48,803 t of CO2 (previous year: 41,473 t of CO2). Scope 2 emissions cover all indirect emissions from district heating and electricity deliveries. In 2021 they amounted to around 35,553 t of CO2 (previous year: 26,201 t of CO2). Reducing waste volumes through waste avoidance and recycling | Waste is unavoidable, especially in hospitals with their stringent hygiene requirements. Given the special situation of COVID-19 and the huge hygiene requirements associated with it, achieving a generalised reduction in waste is currently not possible. This situation did not im- prove during the reporting year either. | Nevertheless, our goal is to reduce waste in the medium term. That is why RHÖN-KLINIKUM AG recognises the tremendous importance of avoiding and recycling waste as far as possible as well as ensuring proper sorting and disposal of waste. The waste officers at each of our sites monitor compliance with the regulations and train new employ- ees and apprentices in the careful management of consumables (waste avoidance), proper sorting (recycling of raw materials) as well as the correct disposal methods for different types of waste. In the current pandemic situation the possibility of holding such events in-person in 2020 and 2021 was greatly limited. The training is therefore offered under an interprofessional continued training programme and over the intranet. Where required in specific cases, training takes place in small groups: in 2021, for example, training in the management of COVID-19 waste was prioritised for all departments concerned. 1 Environmental data of previous year (2020) not verified. 2 Deviations from the figures given in the 2020 Report result from a new calculation method. RHÖN-KLINIKUM AG | Annual Report 2021 43

CORPORATE RESPONSIBILITY | Corporate Social Responsibility Report | Supplier management SUPPLIER MANAGEMENT We give top priority to actively maintaining ties to our suppliers. To obtain the highest quality of products at the lowest prices, we have centralised our supplier management activities for the entire Group and work together closely with the purchasing managers of the hospitals. This practice has stood us in good stead. We also benefit in this area from cooperation with our strategic partner, Asklepios Group. Long-term partnerships with our suppliers Over the years, those relationships with our suppliers of a purely busi- ness nature in some cases have ended up turning into partnerships based on mutual trust. This allows us to fully meet our requirements in terms of quality, reliability of deliveries and efficiency. This is also helped by the assessment of our main suppliers we perform each year. A big advantage in this regard is the cooperation with the purchasing department of our strategic partner Asklepios Group, which we have been pursuing since October 2020. This department is also responsi- ble for entering into new contractual agreements. As experience has shown, this has given us an even stronger position in contract nego- tiations with our partners. Apart from purely economic effects from synergies, this also promotes knowledge growth, which we achieve by pooling the know-how found in both company groups. Cooperation has had an extremely positive effect for the avoidance of supply shortages. For example, by working beyond the bounds of the Company and across our sites, we have been able to find solutions for what are now particularly rare goods. We also reduce supply short- ages by working together with at least two suppliers for each product group. In this way, any short-term supply difficulties can usually be bridged through inventory or alternative products (generics). Challenges as a result of COVID-19 The impact of the COVID -19 pandemic is still presenting us with challenges, albeit different from the ones we had to deal with in early 2020 when the COVID-19 wave first hit Europe. At that time products providing protection against the virus, including surgical masks, surgical caps, FFP2 masks as well as protective gowns, were often in short supply due to the exploding demand. Over the years, those relationships with our suppliers of a purely business nature in some cases have ended up turning into partnerships based on mutual trust. Today, we face a massive rise in transport costs, above all in container freight, but also due to significantly higher fuel prices. Comparable to other sectors, we are also feeling the effects of firming commodities prices, which has significantly driven up prices of, for example, medi- cal products containing plastic. Lastly, the Medical Device Regulation, an EU regulation that has been in force in Germany since May 2021, is raising the prices of many medical devices. It provides for a costly certification process which passes on the costs of those products or results in the products being removed from the market, thus reducing the supply of alternative products. RHÖN-KLINIKUM AG | Annual Report 2021 45

Group Management Report 1 | Basic characteristics of the RHÖN-KLINIKUM Group 1.1 Overview 1.2 Future of the Group 1.3 Objectives and strategies 1.4 Controlling system 1.5 Quality 1.6 Medical research and its transfer into practice 1.7 Compliance 1.8 Corporate Governance 1.9 Declaration on Corporate Governance 2 | Economic report 2.1 Macroeconomic conditions 2.2 Sector-specific conditions 2.3 Business performance 3 | Forecast report 3.1 Strategic objectives 3.2 Economic and legal environment 3.3 Forecast 4 | Opportunities and risk report 4.1 Risk report 4.2 Report on opportunities 5 | Reporting pursuant to section 315 (4) of the German Commercial Code (Handelsgesetzbuch, HGB) 49 49 49 50 51 52 52 52 53 55 55 55 55 56 61 61 61 61 62 62 67 68 RHÖN-KLINIKUM AG | Annual Report 2021 47 47

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group 1 | BASIC CHARACTERISTICS OF THE RHÖN-KLINIKUM GROUP 1.1 Overview Within the Group of RHÖN-KLINIKUM AG, essentially cross-sector (i. e. inpatient, semi-inpatient and outpatient) healthcare services are pro- vided. With a few exceptions, the Group has a single-tier structure. With the exception of Campus Bad Neustadt, the individual hospital companies are organised in the form of legally independent corpora- tions having their registered office at the respective facility sites and are managed as direct subsidiaries of RHÖN-KLINIKUM AG (ultimate Group parent company). The ultimate Group parent company has its registered office in Bad Neustadt a. d. Saale, Federal Republic of Germany. With our eight hospitals and 5,420 beds/places at a total of five sites in four federal states, we are one of the largest hospital operators in Ger- many. A total of 845,642 patients (previous year: 808,655) were treated in our facilities in financial year 2021. With revenues of €1,402.0 million (previous year: €1,360.1 million), we generated EBITDA amounting to €101.2 million (previous year: €80.2 million) despite the considerable obstacles resulting from the pandemic. At the balance sheet date, the Group employed 18,227 persons (31 December 2020: 18,449). Future of the Group 1.2 In financial year 2021, RHÖN-KLINIKUM AG’s vigorous efforts to cope with the COVID-19 pandemic have continued undiminished. In this context, all hospital sites drew on their extensive experience the previous year, working together with the respective government authorities as well as medical networks to flexibly respond to the respective regional increases in case numbers. Our most pressing tasks within the Company include the following areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities, and pooling special know-how, e.g. at the (in some cases newly established) service com- panies providing in-house services. We are tackling these areas with the involvement of our employees, being helped by our collaboration with the companies of the Asklepios Kliniken GmbH & Co. KGaA group. As a result of the cooperation with Asklepios, RHÖN-KLINIKUM AG is in the midst of a comprehensive process of transformation. The feeling of belonging and togetherness as well as new networks are steadily growing within the new corporate group. In addition to the targeted economies of scale in the areas of purchasing and IT, we are also fo- cusing our joint efforts on further optimising clinical procedures and processes. At the same time, new prospects and areas of activity are emerging for us as an employer. Attractiveness as an employer RHÖN-KLINIKUM AG is among Germany’s most attractive employ- ers. “Innovative. Digital. Sustainable” – that was confirmed for our Company by the study of a leading German management and eco- nomic research institute in February 2021. We work hard in this area and are investing in our employees – whether through numerous professional qualification offerings, training courses at our hospitals’ own training centres, recruiting nurses within Germany and from abroad, or promoting a better work–life balance of all colleagues. In 2021, we introduced a new Employee Assistance Program (EAP), which is available to advise and assist the Company’s employees and executive staff. This programme offers employees and their relatives assistance in personal, professional, health or family matters. It thus supports our aim of protecting and improving the health of our staff in the best possible way – especially during the pandemic given the greater professional and personal burdens it has created. Moreover, we took numerous measures to recruit new employees, provide them with continued and higher-qualification training and retain them in our Company. Here, we are specifically looking to at- tract new staff from abroad and have thus entered into an agreement with Amesol Akademie in Hamburg. Amesol’s mission is to provide support to international healthcare specialists qualified as nurses, anaesthesia technical assistants (ATA), operation technical assistants (OTA) and physiotherapists and closely cooperates in this area with hospitals and long-term care facilities on a cross-provider basis. Medical and nursing excellence Doctors of RHÖN-KLINIKUM AG are among Germany’s top medical practitioners. Their expertise is moreover in demand both throughout Germany and beyond its borders and they enjoy the trust of patients. Our hospitals are attested a high standard of treatment quality, and many of them hold multiple certifications. The strong interdisciplin- ary cooperation enabling specific therapies for our patients based on state-of-the-art diagnostics ensures individual, holistic patient care to high quality standards. Since 2021, the University Hospital of Marburg, together with the Uni- versity Hospital of Frankfurt am Main, has gained recognition as one of the top 14 oncology centres in Germany. This distinction comes after many years of outstanding work and research at the highest level, and is a testament to its medical excellence. The nursing and functional service is vital to our hospitals which we want to further strengthen. Consequently, last year we introduced the new Nursing Management Board at Group level. Its importance is seen from the fact that the chairman of the Board of Management is directly responsible for this body. It is made up of representatives from all hospitals who meet regularly to discuss and consult on the very broad subject of nursing. In the specialist bodies, specific aspects are further elaborated and best-practice examples identified. RHÖN-KLINIKUM AG | Annual Report 2021 49

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group Intent (LoI) with Universitätsklinikum Gießen und Marburg (UKGM): RHÖN-KLINIKUM AG reached an agreement with the Hesse State Government, UKGM as well as Asklepios Kliniken GmbH & Co. KGaA on a Letter of Intent regarding the future financing of investments at both university hospitals and on further joint cooperation. In the event a follow-on agreement to the LoI is successfully concluded, the State of Hesse over the next ten years intends to make a total investment of nearly half a billion euros in the further development of the Giessen and Marburg hospital sites. During the ten-year period of the contemplated agreement UKGM in return would, in addition to providing optimum healthcare and ensuring the quality of research and teaching, also guarantee to refrain from redundancies and from outsourcing business units. This Letter of Intent, which in the coming weeks is to be set out in the form of a concrete contractual agree- ment, is intended to provide UKGM with a solid future prospect as well as planning certainty. Nonetheless, the funding commitment alone would not be enough to cover the high investments that are absolutely necessary, for example for buildings or state-of-the-art medical equipment. It is only by combining state funding and prof- its generated by UKGM that we will be able in the coming years to actually implement all necessary investments. In this context, the integration of UKGM into the RHÖN-KLINIKUM Group offers the right opportunities to achieve this: for example, we will further lower costs by centralising our purchasing within the Group network, thus freeing up resources for further investments. We see some of our most pressing tasks in the Company in the follow- ing areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities, further optimising processes as well as pooling know-how, e.g. at the (in some cases newly established) service companies providing in-house services. Together with Asklepios, we can and will gain a stronger position on the market and benefit from each other’s know-how. In the medi- cal area and particularly in the field of tumour medicine, there are significant overlaps and thus potential that can be jointly leveraged to further expand the care offering for patients, to more effectively further promote specialisation and moreover to provide fresh impetus to scientific research. As one example of this, the Comprehensive Cancer Center (CCC) of the Giessen and Marburg University Hospitals and the Asklepios Tumour Centre of Hamburg are already stepping up their cooperation. It is moreover our goal to move ahead even faster with digitalisation. Our employees still spend a significant part of their working time on documentation. That is something we want to change and continue to invest in this area to reduce the workload on staff, to standardise structures and clinical processes and thus ultimately improve the quality of healthcare even further. One main area of focus in this regard is on introducing and strengthening telematics infrastructure, one of the strongest and most future-oriented trends in healthcare. The merger of RHÖN and Asklepios also provides benefits in the area of training. Last year in Hesse a cooperation scheme was agreed that is aimed at better coordinating training offerings and providing joint courses. This enables employees to learn new perspectives and subjects which would otherwise not be available within the Group’s own continued training programmes, and to form one big team. Our continued objective is to pursue new paths to uphold the stand- ard of offering patients the best medical care. In this way, we can better respond to the changes and increasing requirements as com- pared with the market as a whole thanks to the merger with Asklepios and our large sites with highly specialised centres. In future, too, we will vigorously and undauntedly pursue the necessary task of restruc- turing the healthcare system and implementing our corporate goals. 1.4 Controlling system The RHÖN-KLINIKUM Group is directed and controlled by the Board of Management of RHÖN-KLINIKUM AG. The Group is controlled giving due regard to medical, strategic and financial targets. The target system defines key figures of relevance for control such as revenues and EBITDA, as well as key figures for quality and growth in medical service volumes and consolidated profit. Key ratios are monitored by the Board of Management. Monthly reporting to the Board of Management includes the hospitals. Group management costs are fully distributed to the operative segments. The monthly target-to-actual and actual-to-actual comparison in the report to the Board of Management, by aggregating the operative segments into one reporting segment, serve to control the targets published in the Company forecast. It is our firm view that profitable growth in our service volumes, number of cases or our valuation ratios as well as our revenues are important factors when it comes to increasing our enterprise value. Valuation ratios are key figures used to account for medical services at hospitals. For each group of patients, the respective valuation ratio is obtained in combination with the case-mix index (variable indicat- ing average case severity in the system of diagnosis related groups, DRGs). The valuation ratio is thus a measure of the medical severity of a treatment case and also of cost expenditure. If the valuation ra- tios are multiplied by the state base rate, the material amount that a payer (health insurance fund) has to pay to a hospital for an inpatient treatment case is obtained. Through supplementary fees and remu- neration, e.g. for new forms of treatment, this amount may increase even further in certain cases. Even if the share of outpatient revenues in controlling-relevant total revenues is increasingly rising, inpatient revenues still represent the most important indicator of financial performance. For the purposes of measuring and controlling, revenues as a general rule are adjusted for consolidation effects so as to calculate organic growth. RHÖN-KLINIKUM AG | Annual Report 2021 51

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group 1.8 Corporate Governance Issued share capital The subscribed capital of RHÖN-KLINIKUM AG stated in the consolidat- ed financial statements is completely made up of 66,962,470 ordinary voting bearer shares (non-par shares) each having a nominal share in the registered share capital of €2.50. Restrictions on voting rights or the transfer of shares – even if these may result from agreements of shareholders – do not exist or are not known to us. None of our shares are issued with special rights that confer on its holder special powers of control. Employees who hold shares exercise their voting right freely. Shareholders may exercise their voting rights themselves at the Annual General Meeting or through proxies appointed for this purpose. Based on the threshold events notified to us, the following picture pursuant to section 33 f. of the WpHG in terms of shareholder structure emerges as at the relevant key date of 31 December 2021: Person subject to notification requirement Published on Held directly % Attributed % Voting rights held % Date that interest exceeds/falls below the threshold Interest exceeding/ falling below threshold in the case of Notification pursuant to section 33 et seq. WpHG Attributin pursuant to WpHG/ additional information Dr Bernard große Broermann/ Eugen Münch; AMR Holding GmbH 23 July 2020/ 24 July 2020 0.0005 93.37 93.38 22 July 2020 > 75% Attributed (section 34 WpHG): AMR Holding GmbH Consolidated financial statements, communication with shareholders and analysts The consolidated financial statements are drawn up in accordance with the provisions of International Financial Reporting Standards (IFRS) applicable within the European Union and applying section 315e of the HGB, and audited in accordance with both national and international auditing standards. When issuing auditor mandates, due care is taken to ensure the requisite independence of the auditors appointed. The audit mandate for the annual financial statements and for the half- year financial statements of the Group as well as for the Group’s ultimate parent company is issued by the chairman of the Audit Committee after due examination pursuant to the resolutions adopted at the Annual General Meeting. We publish our consolidated financial statements in March of the fol- lowing financial year. The Annual General Meeting normally takes place within the first six months of the new financial year. We announce our forecasts for the respective financial years in accordance with the requirements. We conduct analyst and analysis and investor discussions and also report on business performance in analyst conference calls. With our financial calendar published in the Annual Report and in the Internet on our homepage, we inform our shareholders, shareholder associations, analysts and the media of all other recurring key dates. RHÖN-KLINIKUM AG | Annual Report 2021 53

GROUP MANAGEMENT REPORT | Basic characteristics of the RHÖN-KLINIKUM Group | Economic report Other contracts containing a change-of-control clause The company purchase agreements of the hospitals acquired by us contained provisions according to which, subject to the condition of a change of control as a result of a takeover bid for RHÖN-KLINIKUM AG, a retransfer of the company shares can be demanded. This rang true in particular for Universitätsklinikum Gießen und Marburg GmbH up to the end of financial year 2019. As at the balance sheet date of 31 December 2021, no such provisions exist. As a precaution we point out that the Board of Management of RHÖN-KLINIKUM AG and the management body of Universitäts- klinikum Gießen und Marburg GmbH (UKGM) on 14 January 2022 decided to sign a Letter of Intent of the Federal State of Hesse with regard to the grant of investment funding for UKGM. The Letter of In- tent contains among other things provisions in the event of a change of control. All provisions stipulated in the Letter of Intent are subject to the condition of a legally binding agreement being entered into between RHÖN-KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH, the Federal State of Hesse and the Universities of Giessen and Marburg with their faculties of medicine. Various contracts relating to financial instruments exist in which the lenders may demand immediate repayment in the event of a change of control. In this regard, a change of control is defined as the takeover of more than 50% of the interests in RHÖN-KLINIKUM AG. For the former anchor shareholders B. Braun Melsungen AG/Asklepios Kliniken GmbH & Co. KGaA/Mr. Münch (HCM SE) and Ms. Münch, exceptions did and do exist in the promissory note loan agreement from financial year 2018 and the registered bond from financial year 2019. According to the contract documentation, no change of control exists if one or more of the former anchor shareholders acquire(s) more than 50%, but no more than 70.1% maximum (promissory note loan agreement 2018) and 70.3% maximum (registered bond 2019), respectively, of the voting shares in RHÖN-KLINIKUM AG within the group of anchor shareholders. Declaration on Corporate Governance 1.9 The Declaration on Corporate Governance, in addition to the Declara- tion of Compliance of the Board of Management and the Supervisory Board pursuant to section 161 of the AktG, also contains information on corporate governance practices, the work approach of the Board of Management and the Supervisory Board as well as the committees established by them, and reports on equal participation of men and women in management positions as well as the diversity concept. For further details, please visit our website www.rhoen-klinikum-ag. com where the Declaration on Corporate Governance is made acces- sible to the public under the Corporate Governance section. 2 | ECONOMIC REPORT 2.1 Macroeconomic conditions After the sharp fall in economic output in Germany in 2020 due to the COVID-19 pandemic, gross domestic product rose in financial year 2021 by 2.7%, with economic output subsiding somewhat in the last quarter of 2021. Sentiment amongst companies was wan- ing slightly as the year drew to a close. After hitting 96.6 points in November 2021, the ifo business climate index declined slightly to 94.7 points in December. After the German labour market in 2020 was clearly impacted by the COVID-19 pandemic and gripped by the pandemic and the measures taken to combat it, a recovery began to take hold in the summer which also continued through to the end of the year. On average for 2021, the number of unemployed decreased by 82,000 to 2.613 million compared with the previous year. The jobless rate stood at 5.1% in December 2021. In December of the previous year, the rate was 5.9%. Sector-specific conditions 2.2 As a result of overall decline in COVID-19 cases and a rising rate of vaccination – and thus also fewer COVID-19 patients in hospitals – in the first half of the year, the claim for relief payments for beds kept available introduced by the Third Civil Protection Act (Drittes Bevölkerungsschutzgesetz, BSchG) was initially ended with effect from 15 June 2021. When the fourth wave of the COVID-19 pandemic came in the autumn of 2021, the German legislator in November initially intro- duced a new care surcharge for COVID-19 patients admitted from 1 November 2021 to 19 March 2022. Its amount is calculated based on the average inpatient duration of stay of COVID patients and is staggered by the respective daily lump sum amounts on which the relief payments are based. Just before the end of the year, the German Federal Parliament (Bundestag), with the Act Strengthening Vaccine Protection against COVID-19 and Amending Further Regulations in connection with the COVID-19 Pandemic (Gesetz zur Stärkung der Impfprävention gegen COVID-19 und zur Änderung weiterer Vorschriften im Zusammenhang mit der COVID-19-Pandemie), more- over decided to once again grant hospitals, with retroactive effect to 15 November 2021, relief payments for beds kept available if they postponed elective operations or procedures to make capacities avail- able for COVID-19 patients. This provision, which was initially limited in term to 31 December 2021, has since been extended to 19 March 2022 by the Second Regulation Amending the Regulation on Further Measures to Safeguard the Economic Viability of Hospitals (zweite Verordnung zur Änderung der Verordnung zur Regelung weiterer Maßnahmen zur wirtschaftlichen Sicherung der Krankenhäuser). RHÖN-KLINIKUM AG | Annual Report 2021 55

GROUP MANAGEMENT REPORT | Economic report As at 31 December 2021, we operate nine medical care centres with a total of 58.75 specialist practices: 2.3.3 Results of operations For computational reasons rounding differences of ± one unit (€, %, etc.) may occur in the tables below. If data are provided below on individual companies, these are values before consolidation. Medical care centres Specialist practices Consolidated performance figures developed as shown below: As at 31 December 2020 Opened/acquired MVZ Bad Berka MVZ Frankfurt (Oder) Disposals MVZ Bad Berka MVZ Gießen MVZ Marburg As at 31 December 2021 9 – 1 – – –1 9 1.00 5.25 –0.75 –0.50 –1.00 58.75 Patient numbers at our hospitals and medical care centres developed as follows: 54.75 in € million January to December 2021 2020 in % Change Income Revenues Other income Total Expenditure Materials and consumables used Employee benefits expense Other expenditure Result of impairment on financial assets 1,402.0 1,360.1 198.5 196.3 1,600.5 1,556.4 430.4 921.4 147.3 422.4 906.7 146.6 41.9 2.2 44.1 8.0 14.7 0.7 3.1 1.1 2.8 1.9 1.6 0.5 0.2 –0.2 0.4 –200.0 1,499.3 1,475.5 23.8 1.6 January to December 2021 2020 absolute in % Change Total Inpatient and semi-inpatient treatments at our Acute hospitals 191,076 190,093 Rehabilitation hospitals and other facilities 4,505 4,079 983 426 195,581 194,172 1,409 Outpatient attendances at our Acute hospitals 439,714 426,410 13,304 Medical care centres 210,347 188,073 22,274 Total 650,061 614,483 35,578 845,642 808,655 36,987 0.5 10.4 0.7 3.1 11.8 5.8 4.6 Expense from deconsolidation of subsidiaries – 0.7 –0.7 –100.0 EBITDA 101.2 80.2 21.0 26.2 Depreciation/amortisation and impairment EBIT Finance result EBT Income taxes Consolidated result 70.7 30.5 –3.1 27.4 –2.8 30.2 69.6 10.6 –6.7 3.9 1.4 2.5 1.1 1.6 19.9 187.7 3.6 23.5 –4.2 53.7 602.6 –300.0 27.7 1,108.0 Compared with the same period of the previous year, the number of inpatient and semi-inpatient treatments saw a moderate increase of +1,409 or +0.7% as a result of a slight rise in the provision of elective services. Moreover, the COVID-19 pandemic and the further upward trend in outpatient medical care impacted has had an impact on the outpatient area where patient numbers increased by +35,578 or +5.8%. Compared with financial year 2020, revenues witnessed a rise of €41.9 million or 3.1%. The revenues of financial year 2021 include an amount of €61.7 million (previous year: €90.6 million) in relief payments of the legislature, netted with the counter-effect of revenue-offsetting obligations, in connection with the COVID-19 pandemic. The reimbursements are essentially attributable to relief amounts for beds kept available. As in the same period of the previous year, income from the invoicing of an additional remuneration RHÖN-KLINIKUM AG | Annual Report 2021 57

GROUP MANAGEMENT REPORT | Economic report 2.3.4 Net assets and financial position in € million in € million 31 Dec. 2021 31 Dec. 2020 31 Dec. 2021 31 Dec. 2020 Assets Non-current assets Current assets Liabilities Shareholders’ equity Long-term loan capital Short-term loan capital in % 1,054.5 611.1 63.3 36.7 1,063.2 566.5 in % 65.2 34.8 Current cash Current fixed term deposits Non-current fixed term deposits 1,665.6 100.0 1,629.7 100.0 Cash, fixed term deposits 1,224.8 167.5 273.3 73.5 10.1 16.4 1,190.2 166.1 273.4 73.0 10.2 16.8 1,665.6 100.0 1,629.7 100.0 Current financial liabilities Non-current financial liabilities Liabilities under leases Financial liabilities 126.3 165.8 0.0 292.1 1.0 148.6 10.1 159.7 91.0 166.4 0.0 257.4 0.9 148.5 11.2 160.6 Compared with the balance sheet date of 31 December 2020, the balance sheet total rose by €35.9 million or 2.2% to €1,665.6 million (previous year: €1,629.7 million). The origin and appropriation of our liquidity are shown in the following overview: Net liquidity 132.4 96.8 The equity capital ratio saw a slight rise compared with the last reporting date, from 73.0% to 73.5%, and remains at a high level. As at 31 December 2021, equity stands at €1,224.8 million (previous year: €1,190.2 million). The increase in equity capital compared with the reporting date of 31 December 2020 by €34.6 million results from con- solidated profit of financial year 2021 (€30.2 million), gains from the change in the fair value through other comprehensive income (FVOCI) (€4.7 million), and gains from the revaluation of defined benefit pension plans (€0.0 million), on the one hand, and the equity-decreasing effects from dividend payments to non-controlling interests (€0.3 million), on the other. 132.0% (previous year: 127.6%) of non-current assets is nominally cov- ered by equity and non-current liabilities at fully matching maturities. As at 31 December 2021, we report net liquidity of €132.4 million (31 December 2020: €96.8 million). Net liquidity is calculated as follows: in € million January to December Cash generated from (+)/cash used in (–) operating activities Cash generated from (+)/cash used in (–) investing activities Cash generated from (+)/cash used in (–) financing activities Change in cash and cash equivalents Cash and cash equivalents as at 1 January Cash and cash equivalents as at 31 December 2021 2020 97.5 113.3 –58.3 –135.2 –3.9 35.3 91.0 –15.1 –37.0 128.0 126.3 91.0 Cash and cash equivalents increased in financial year 2021 by €35.3 million (previous year: decrease by €37.0 million). In this context, a positive operating cash flow was achieved in the amount of €97.5 million (previous year: €113.3 million). The decline in operating cash flow by €15.8 million over the previous year compares with a €76.9 million decrease in cash used in investment activity as well as a €11.2 million decline in cash used in financing activity, in each case compared with the previous year. RHÖN-KLINIKUM AG | Annual Report 2021 59

GROUP MANAGEMENT REPORT | Forecast report 3 | FORECAST REPORT 3.1 Strategic objectives Together with Asklepios, our objective is to develop and promote path breaking concepts of healthcare delivery to ensure we can continue providing excellent medical care. Particularly in the context of an increasingly tighter regulatory and demographic environment in the hospital sector, we will strategically complement each other at all levels and act within the network. To this end – in addition to the targeted economies of scale includ- ing in the areas of purchasing, hospital information systems and discharge management – we are also focusing our joint efforts on further optimising clinical procedures and processes in the best in- terests of our patients. With a view to continuing to improve patient care along the lines of our campus approach to ensure cross-sector and future-viable health- care provision in Germany, we are also looking at further developing innovative remuneration and care models. RHÖN-KLINIKUM AG is pursuing the objective of achieving the best medical care for our patients, diagnosing and treating them with the latest, scientifically sound therapy procedures with state-of-the-art medical technology. Thanks to the interdisciplinary collaboration and strong networking with all our facilities, this equally benefits our patients and employees. For further information, please also refer to section 1.3 “Objectives and strategies” in this Group Management Report. 3.2 Economic and legal environment The German economy continued to struggle with the effects of the fourth wave of the COVID-19 pandemic. In its annual economic re- port, the German government expects gross domestic product to grow by 3.6%. Economic growth is being hampered longer than ex- pected in particular by persistent international supply chain problems and the fourth wave of the COVID-19 pandemic. Research institutes and leading economists had lowered their forecasts unanimously already in December. Inflation, which saw a spike in 2021 due to supply problems as well as high energy prices, will remain at a high level. The forecast jobless rate, according to the German government, will decline to 5.1% in 2022 as the employment rate is expected to increase. The tightened regulatory environment for hospitals will continue to drive market consolidation. According to the Hospital Rating Report, the service volume will no longer reach the pre-crisis level of 2019 but stagnate at the level of 2021 and rise only marginally up to 2030. According to RWI health experts, the share of hospitals threatened by insolvency will likely rise further in the coming two years. Providing care across sectors and digitalisation are important examples of how to improve the situation of hospitals and patients. As for the entire industry as well, rising demand for specialists and the related shortage of qualified staff are issues of key importance for us. Particularly during the COVID-19 pandemic, weaknesses in staffing within the German healthcare system have become and are becoming particularly visible. Technical innovations – innovations from the areas of digitalisation, telemedicine, artificial intelligence, robot assistance – will become increasingly important when it comes to reducing the workload of doctors and nurses. For hospitals to remain economically viable and efficient, they have to gear their strategic targets to the current and future challenges, such as social and demographic change, advances in medical care and technology as well as digitalisation. The latter is providing medicine the opportunity to diagnose and treat patients in future more individually and with greater precision. 3.3 Forecast Also in the coming year, the economic basis of the RHÖN-KLINIKUM Group will be provided by its five large sites in four federal states counting some 5,400 beds and roughly 18,230 employees. That ranks us amongst the large hospital operators in Germany. For the coming financial year, we expect revenues of €1.4 billion with- in a range of plus or minus 5%. For earnings before interest, tax and depreciation/amortisation (EBITDA), we expect a level of between €92 million and €102 million. This forecast reflects the further heightened regulatory interference by the German legislator, such as the Regulation on Nursing Staff Floors (Pflegepersonaluntergrenzen-Verordnung, PpUGV) and the Nursing Staff Strengthening Act (Pflegepersonal-Stärkungsgesetz, PpSG). We point out that our outlook is further subject to considerable un- certainties in connection with the further course of the COVID-19 pandemic and any regulatory measures impacting our remuneration structure in 2022. RHÖN-KLINIKUM AG | Annual Report 2021 61

GROUP MANAGEMENT REPORT | Opportunities and risk report These processes are to ensure that potential risks are made manage- able and opportunities are identified. All risks meeting the definitions of the Group risk guideline are to be reported. At the same time, our risk management function relates not only to financial risks but also all manner of risks within the Company. We regard the risk posed to the life and health of our patients potentially resulting in a medical intervention as the greatest risk. With us, identifying risks and recognising opportunities are integrated into our standard business procedures, since it is only when we are aware of risks and opportunities that we can manage and control them. Risk identification encompasses the systematic and structured documentation of all relevant risks in the Company, with risk class- es always being assessed in terms of their strategic and operative impacts as well as in view of the risks of reporting and potential compliance risks. Given constantly changing circumstances and re- quirements, risk identification is an ongoing task, and is performed on a decentralised basis in accordance with responsibilities defined in the individual Company divisions. Any relevant risks identified are categorised and recorded within the risk management system in a centrally predefined risk catalogue. Risks identified are systematically analysed and evaluated in the con- text of the individual risk bearing capacity by those entrusted with such tasks. In the risk analysis, risks identified are aggregated and analysed for the purpose of early detection to determine whether individual risks of secondary importance when viewed in isolation may lead to a higher or existential risk by reason of their combined or cumulative effects over time. We classify developments with an expected risk value of 10% or more of EBITDA as existential risks when set against with the individual risk bearing capacity. The risk bearing capacity of RHÖN-KLINIKUM AG and its subsidiaries is determined from the comparison between risk cover amount and risk exposure. The expected risk value (product of damage amount and probability of occurrence) is the expected damage extent giving due regard to the probability of occurrence and refers to the target values (EBITDA) for the respective financial year. Not all risks are to be weighted equally. To ensure efficient risk man- agement, we perform a systematic assessment of the risks identified. Within the context of risk evaluation, the probability of occurrence and potential monetary damage amount of the risk are determined, also giving due regard to already existing and planned measures. Using a risk matrix, probability of occurrence and damage amount are classified to the four levels: low, medium, high and very high. Probability of occurrence is assigned to the following categories depending on the amount: – Low > 0% to < 30% – Moderate 30% to < 60% – High 60% to < 80% – Very high 80% to < 100% The potential damage amount refers to the target values for the respective financial year and is always calculated as a negative impact on EBITDA. Classification to the impact categories takes place independent of EBITDA: – Low up to 5% of EBITDA – Moderate up to 10% of EBITDA – High up to 25% of EBITDA – Very high from 25% of EBITDA In this regard, the evaluation of a risk differs from its evaluation according to the status quo (gross evaluation) and target (net evaluation/accepted risk). Status quo is the current evaluation of the risk after deducting all effective measures as at the relevant inven- tory date. The target describes the risk evaluation to be achieved after implementation of all measures, stating by when this is to be achieved. The evaluation is made with reference to the future for the relevant duration observing criteria specified for ensuring a uniform evaluation. In risk control and management, it is analysed by what measures risks can be controlled. For this, suitable measures for each identified risk are to be recorded with the expected effect of the measures. The pri- mary objective of risk management is to minimise, and where possi- ble, prevent risks, whilst always keeping in mind the opportunities as- sociated with the risks. From the effects expected from the measures it is possible to determine how effective the measures are and the need for further measures. In this regard, the measures contemplated are to be weighed up in terms of cost-benefit aspects and selected in such a way that the expected probability of occurrence and/or amount of damage are brought to within the Company’s own limits of risk tolerance. Risk communication is performed at every phase of the risk manage- ment process. All risk managers are required to review their poten- tial risk issues regularly during the year under way as well as in the risk inventories, to update risks and to follow up on measures. Acute occurrence of risks that might jeopardise a company’s existence (ad hoc risks) must be reported to the chairman of the Board of Manage- ment as quickly as possible. RHÖN-KLINIKUM AG | Annual Report 2021 63

GROUP MANAGEMENT REPORT | Opportunities and risk report The regulatory and industry risks relate both to the strategic and the operative risks as well as the compliance risks of our Group. Risks to service volumes In Germany, hospitals approved under state hospital planning enjoy de facto state regulated protection in their respective catchment area. Traditional market and revenue risks exist only where site closures are ordered or a hospital’s quality is assessed by referring physicians or by patients as significantly worse than that of neighbouring hospitals. In the latter case, that results in large numbers of patients switching to other hospitals. The increasing inspection activities of the Medical Review Board (of the Statutory Health Insurance Funds) (MDK), in par- ticular for services and/or cases exhibiting a high degree of severity, are also making themselves felt. Fluctuations in service volumes at our facilities, shifts in service vol- umes from the inpatient to outpatient sector, but also to nearby fa- cilities of other companies (also as a result of refurbishment works during ongoing operations), pricing regulation as well as possible quality-related discounts may result in losses in revenues and cost increases, and consequently to a decrease in earnings. Through regular period-based and inter-operation comparisons with regard to service volumes, revenues and earnings as well as selected business ratios and other indicators, it is possible for us to identify adverse developments early. Where it is appropriate and necessary, we can take corrective action and manage a reasonably low risk potential in terms of the operative risks as well as risks of reporting. To ensure our efficiency also in future and to further improve profit- ability, RHÖN-KLINIKUM AG is working together with the subsidiaries of the Group of Asklepios Kliniken GmbH & Co. KGaA on various opti- misation measures. The risks to service volumes relate in particular to the operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. Operating risks We see some of our most pressing tasks for our Company in the fol- lowing three areas of action: strengthening nursing and medical care, ensuring that hospitals concentrate on their core activities and pooling special know-how. We are tackling these areas with the involvement of all our employees, helped by our collaboration with the companies of the Asklepios facilities. Advances in medicine and the call for a holistic approach to diagnosing and treating patients (instead of diagnosis and treatment being limited to certain aspects) are requiring increasingly strong interdisciplinary processes characterised by a division of labour. In this regard, coopera- tion is needed not only at the hospital but also between outpatient and inpatient care and also for digital care. Whenever these processes are disrupted, this carries risks for patients, our partners from the area of community-based practitioners and the hospital. We attach the utmost importance to minimising such risks by ensuring the quality of treatment with qualified and trained staff through guideline- oriented procedures in safe and hygienic hospital buildings. Permanent mon- itoring of all procedures and processes involved in the treatment of patients as well as the consistent orientation of all efforts to the needs of our patients create a high level of treatment quality and limit existing operating risks. Particularly in the Group division of Patient Safety, Quality Management and Hygiene, further development of quality management is given top priority. This is the goal being pursued by our Quality Management and Clinical Risk Management expert panel. Thanks to the interdisci- plinary collaboration in the areas of quality management and medical controlling, scientific quality indicators can be compared with routine data from the invoicing of medical services to gain important insights. To ensure the highest standard of patient safety, we furthermore train clinical risk managers who exchange know-how in an interfacility ex- pert group. They perform, among other things, structured risk audits by which we can identify relevant risks as well as establish and implement risk reduction measures. In addition to the typical clinical risk fields in the area of patient safety (hygiene, nursing and medical care), potential risks are also seen, as in previous years, in infrastructure (such as fire risks) and in technical equipment. According to the new General Data Protection Regulation (GDPR), companies dealing with personal health data are subject to a particularly high degree of accountability and must be able to furnish proof of the “integrity and confidentiality” of data processing. We are well prepared for this level of IT security and should be able to reason- ably withstand any targeted attacks. Overall, we rate the risk position in this area as low, particularly given the existing measures in place. For risks in the clinical area that cannot be fully averted, the Group has adequate insurance coverage which is regularly reviewed and updated. The operating risks relate in particular to the operative risks of the Group subsidiaries of RHÖN-KLINIKUM AG. RHÖN-KLINIKUM AG | Annual Report 2021 65

GROUP MANAGEMENT REPORT | Opportunities and risk report 4.2 Report on opportunities To take advantage of opportunities, it is sometimes necessary to de- liberately accept potential risks. Taking just one example: any medical intervention will expose patients to a risk, but at the same time also holds out the prospect or opportunity of recovery and/or cure. Our management of opportunities thus covers the totality of all measures promoting the systematic and transparent handling of opportunities. The process and communication paths involved are similar to risk management. Similar to the concept of risks, we understand opportunities as events and potential developments within and outside RHÖN-KLINIKUM AG that might favourably impact the achievement of the Company’s stated objectives, future performance of tasks as well as the quality and reputation of RHÖN-KLINIKUM AG. The strategic partnership with, and under the umbrella of, Asklepios opens up new prospects for pursuing joint objectives, with each of the two companies complementing each other strategically on sev- eral levels. As one of the leading providers of healthcare in Germany, we as RHÖN-KLINIKUM AG play a trailblazing role in the healthcare industry with our campus and digitalisation strategy. Our campus approach taking a comprehensive view of patients is a viable care model of the future. We are thus setting standards for excellent med- ical care – not just in rural areas. On 14 January 2022, the Board of Management of RHÖN-KLINIKUM AG and the management body of Universitätsklinikum Gießen und Marburg GmbH (UKGM) decided to sign a Letter of Intent of the Federal State of Hesse with regard to the grant of investment fund- ing for UKGM. In this Declaration of Intent, the Federal State of Hesse offered the prospect of investment funding for UKGM of up to €45 million per year for a period of ten years, to be increased over the term in the first five years by 1.5% p.a. and in the five years after that by 2.5% p.a. The prospective investment funding offered can cover part of the investment that will be needed to maintain the university hospital structures. Continuation of the existing separate accounting scheme is also planned. At the same time, the Declara- tion of Intent provides for numerous provisions on further matters, including an obligation to reinvest profits of UKGM during this period, provisions in the event of a change in control, as well as a prohibition on outsourcing and the exclusion of redundancies. All provisions stip- ulated in the Letter of Intent are subject to the condition of a legally binding agreement being entered into between RHÖN-KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universitätsklinikum Gießen und Marburg GmbH, the Federal State of Hesse and the Universities of Giessen and Marburg with their faculties of medicine. The conclusion of this agreement is moreover subject to the condition precedent of the required funds being approved by the budgetary legislator of the Federal State of Hesse. We see a tremendous need for healthcare policy reform. That is why we wholly welcome the wish of the governing parties to make pre- paredness and prevention a guiding principle of German healthcare policy. The basic idea of more cross-sector cooperation is also a sensi- ble one, but should be accompanied by a radical reduction in sectoral boundaries – particularly between outpatient and inpatient care – as it is worked out in detail. We will seize the opportunities this affords and realise them in the best interests of our patients. Steadily increasing regulation from new legislation, especially in the field of nursing financing, is putting the hospital sector before tre- mendous challenges which will foreseeably lead to a fundamental change in the hospital sector. However, the Group subsidiaries of RHÖN-KLINIKUM AG are well prepared for these changes thanks to their medical expertise, extensive service offerings of the individual sites and the optimisation processes initiated by the individual sites. In the best interests of our patients we are exploiting the opportunities of digitalisation. In addition to the advance in digitalisation, the conceptual and con- structional modernisation of our sites continues to be a major issue. Our extensive investments at almost all sites of the Group will result in positive impacts on medical care for patients. Overall, we see ourselves very well positioned thanks to the partner- ship with Asklepios. Also in future, we will continue to be amongst the major hospital operators in Germany operating as an efficient, homogenous Group with a consistent orientation and focus on cutting-edge medicine geared towards maximum care as well as the further strengthening of treatment excellence and patient care through our focus on digitalisation and network medical care. To this end we avail ourselves of all opportunities presented to us and thus counteract the potential risks with a practised and functioning risk management. RHÖN-KLINIKUM AG | Annual Report 2021 67

Consolidated financial statements Consolidated balance sheet Consolidated income statement Consolidated statement of comprehensive income Statement of changes in equity Statement of cash flows Notes Contents of the consolidated financial statements General information Accounting policies Critical estimates and assessments in accounting and valuation Company acquisitions Notes to the consolidated income statement Notes to the consolidated balance sheet Statement of cash flows Shareholdings Other disclosures Corporate bodies of RHÖN-KLINIKUM AG Responsibility statement Independent auditor’s report 70 72 73 74 75 76 78 78 93 96 98 103 124 126 128 140 143 144 RHÖN-KLINIKUM AG | Annual Report 2021 69

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated balance sheet Notes 31 Dec. 2021 31 Dec. 2020 6.12 6.13 6.14 6.17 6.13 6.16 6.19 6.15 6.17 6.18 167,406 574,168 456,821 –76 167,406 574,168 423,831 –76 1,198,319 1,165,329 26,460 24,892 1,224,779 1,190,221 148,564 1,365 17,576 167,505 997 72,492 14,577 32,200 12,068 140,979 273,313 148,460 1,114 16,498 166,072 943 80,707 11,388 32,393 14,922 133,024 273,377 1,665,597 1,629,670 EQUITY AND LIABILITIES in € ’000 Shareholders’ equity Issued share capital Capital reserve Other reserves Treasury shares Equity attributable to shareholders of RHÖN-KLINIKUM AG Non-controlling interests in equity Non-current liabilities Financial liabilities Provisions for post-employment benefits Other financial liabilities Current liabilities Financial liabilities Trade payables Current income tax liabilities Other provisions Other financial liabilities Other liabilities RHÖN-KLINIKUM AG | Annual Report 2021 71

CONSOLIDATED FINANCIAL STATEMENTS | Consolidated statement of comprehensive income Consolidated statement of comprehensive income 1 JANUARY TO 31 DECEMBER 2021 in € ’000 Consolidated profit of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Changes in fair value through other comprehensive income (FVOCI) Income taxes Other comprehensive income (changes in fair value through other comprehensive income) not subsequently reclassified to income statement Revaluation of defined benefit pension plans Income taxes Other comprehensive income (revaluation of pension plans) not subsequently reclassified to income statement 6.5 6.3 6.14 6.3 Other comprehensive income 1 of which non-controlling interests shareholders of RHÖN-KLINIKUM AG Total comprehensive income of which non-controlling interests shareholders of RHÖN-KLINIKUM AG 1 Sum of value changes recognised directly at equity. Notes 2021 2020 30,227 2,463 1,932 28,295 5,551 –878 4,673 27 –5 22 1,012 1,451 2,489 –394 2,095 331 –52 279 4,695 2,374 – 4,695 – 2,374 34,922 4,837 1,932 32,990 1,012 3,825 RHÖN-KLINIKUM AG | Annual Report 2021 73

CONSOLIDATED FINANCIAL STATEMENTS | Statement of cash flows Notes 2021 Statement of cash flows in € million Earnings before taxes Finance result (net) Depreciation/amortisation and impairment and gains/losses on disposal of assets Change in net current assets Change in inventories Change in trade receivables Change in other financial assets and other assets Change in trade payables Change in other net liabilities/other non-cash transactions Change in provisions Income taxes paid Interest paid Cash generated from operating activities Investments in property, plant and equipment and in intangible assets Government grants received to finance investments in property, plant and equipment and in intangible assets Change in investments in fixed term deposits Investments in financial assets Acquisition of subsidiaries, net of cash acquired Sale of subsidiaries, net of cash sold Sale proceeds from disposal of assets Interest received Cash used in investing activities Transaction costs of borrowing/of repayment of financial liabilities Repayment of financial liabilities Principal payments for leases Payments to non-controlling interests in equity Cash used in financing activities Change in cash and cash equivalents Cash and cash equivalents as at 1 January Cash and cash equivalents as at 31 December RHÖN-KLINIKUM AG | Annual Report 2021 5.9 5.5 6.6 6.7 6.8 et seq. 6.16 6.15/6.17 et seq. 6.14 et seq. 5.10 6.1 et seq. 6.5/6.8 6.5 4 4 6.13 6.13 9.3 6.12 6.11 2020 3.9 6.7 69.8 80.4 –6.8 32.7 11.5 10.6 –0.5 –1.6 –9.5 –3.5 113.3 –97.0 23.2 –57.0 0.1 –5.0 –1.0 0.7 0.8 27.4 3.1 70.2 100.7 2.1 –18.9 8.3 –2.4 7.0 0.1 4.4 –3.8 97.5 –77.8 16.7 – 0.1 –0.4 – 2.7 0.4 –58.3 –135.2 – – –3.5 –0.4 –3.9 35.3 91.0 126.3 –1.0 –10.0 –3.4 –0.7 –15.1 –37.0 128.0 91.0 75

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Contents 98 98 98 99 99 99 99 100 100 100 101 102 102 103 103 106 107 108 108 109 109 109 110 111 112 112 112 113 114 115 117 6.15 Other provisions 118 6.16 Trade payables 118 6.17 Other financial liabilities 119 6.18 Other liabilities 119 6.19 Current income tax liabilities 6.20 Derivative financial instruments 119 6.21 Additional disclosures regarding financial instruments 120 6.21.1 Carrying amounts, recognised figures and fair values according to measurement categories 120 6.21.2 Net gains or losses by measurement category 123 6.21.3 Financial liabilities (maturity analysis) 124 7 | Statement of cash flows 8 | Shareholdings 8.1 Companies included in the consolidated annual report 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB 9 | Other disclosures 9.1 Average annual number of employees 9.2 Other financial obligations 9.3 Leases within the Group 9.4 Related parties 9.5 Total payments of Supervisory Board, the Obligations of lessees Investment property 9.3.1 9.3.2 Board of Management and the Advisory Board 9.6 Declaration of Compliance with the German Corporate Governance Code 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors 9.8 Events after the reporting date 10 | Corporate bodies of RHÖN-KLINIKUM AG 124 126 126 127 128 128 128 129 129 129 130 134 139 139 139 140 77 Notes to the consolidated income statement 5.1 Revenues 5.2 Other income 5.3 Materials and consumables used 5.4 Employee benefits expense 5.5 Depreciation and impairment 5.6 Other expenses 5.7 Result from impairment on financial assets 5.8 Research costs 5.9 Finance result – net 5.10 Income taxes 5.11 Profit to non-controlling interests 5.12 Earnings per share 6.4.2 Associated companies Other financial assets (non-current) 6.5 6.6 Inventories 6.7 Trade receivables 6.8 Other financial assets (current) 6.9 Other assets (current) 6.10 Current income tax assets 6.11 Cash and cash equivalents 6.12 Equity 6.13 Financial liabilities 6.14 Provisions for post-employment benefits Notes to the consolidated balance sheet 6.1 Goodwill and other intangible assets 6.2 Property, plant and equipment 6.3 Deferred tax assets 6.4 Financial investments accounted for using the equity method 6.4.1 Investments accounted for using the equity method 5 | 6 | RHÖN-KLINIKUM AG | Annual Report 2021

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies The Standards and Interpretations adopted by the European Union are explained below: Amendments to IFRS 9, IAS 39, IFRS 7, IFRS 4, IFRS 16: “IBOR Reform – Phase 2” The amendments to Phase 2 of the IASB project on the Interest Rate Benchmark Reform provide for reliefs from accounting for changes in contractual cash flows and hedging relationships having become necessary in connection with the IBOR Reform, i.e. which are neces- sary as a direct consequence of the IBOR Reform and for which the new and old basis for determining contractual cash flows is econom- ically balanced. In the case of changes in contractual cash flows it may in some cases not be required based on the adjustments to adjust or derecognise the carrying value of financial instruments. Instead, there is the option of adjusting the effective interest rate to reflect the change in the alternative interest rate if certain conditions are met. With regard to hedge accounting it is not required on the basis of the changes, where certain conditions are met, to terminate a hedging relationship designated for hedge accounting purposes based on adjustments triggered by the reform of reference interest rates. New risks arising from the reform and, beyond that, from how the transition to alternative interest rates will be handled, are to be disclosed. Apart from adjustments to Standards IFRS 9, IAS 39 and IFRS 7, the IASB adopted minor amendments to IFRS 4 and IFRS 16. The amendments are to be applied to financial years commencing on or after 1 January 2021, and have no material impact on the net assets, financial position and results of operations of RHÖN-KLINIKUM AG. Amendments to IFRS 4: “Insurance Contracts” IFRS 17 “Insurance Contracts” in future will replace IFRS 4 “Insurance Contracts”. All companies to be accounted for in accordance with the IFRSs which issue insurance contracts, including those companies outside the insurance industry issuing such insurance contracts, are affected by the Amendments to IFRS 17. The mandatory initial adop- tion date of IFRS 17, including the amendments, was postponed by two years to financial years beginning on or after 1 January 2023. The defined expiry of the temporary exemption from adoption of IFRS 9 in IFRS 4 was accordingly postponed to financial years beginning on or after 1 January 2023. Up to that date, insurers are exempted from the adoption of IFRS 9. IFRS 4 and IFRS 17 are of no practical relevance for RHÖN-KLINIKUM AG. Amendment to IFRS 16: “Leases – COVID-19- Related Rent Concessions beyond 30 June 2021” The amendment to IFRS 16 “Leases” extends the optional expedient existing for lessees for assessing whether a rent concession in con- nection with COVID-19 is a modification. IFRS 16 contains provisions relating to the presentation of changes in lease payments (including rent) by the lessee. As a general rule, the lessee must assess for each lease whether the rent concessions granted constitute a modification of the lease and must remeasure the lease modification resulting from any such modifications. The amendment to Standard IFRS 16 grants a practical expedient in the event rent concessions are utilised. These are subject to certain re- quirements and limited in term. The expedient permits lessees to ac- count for rent concessions granted in connection with the COVID-19 pandemic not in accordance with the rules on lease modifications but rather as though there had been no modification to the lease. The amendment takes effect for reporting periods beginning on or af- ter 1 April 2021. It is of no practical relevance for RHÖN-KLINIKUM AG. RHÖN-KLINIKUM AG | Annual Report 2021 79

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Amendments to IFRS 3: “Business Combinations” The amendments to IFRS 3 “Business Combinations” relate to a refer- ence within the Standard to the conceptual framework of IFRS (2018). Furthermore, the Standard was supplemented by the requirement for purchasers to apply the provisions of IAS 37 or IFRIC 21 instead of the conceptual framework when identifying obligations assumed that fall under the scope of application of IAS 37 or IFRIC 21. By way of exception, this does not apply to contingent liabilities, to which the exemption of IFRS 3.23 will continue to apply. Moreover, the Stan- dard was supplemented by an explicit recognition prohibition for acquired contingent assets. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IFRS 16: “Property, Plant and Equipment” The amendments to IAS 16 “Property, Plant and Equipment” clarify that proceeds an entity has received from selling items produced while bringing an asset into the location and condition necessary for it to be capable of operating in the manner intended and the costs associated therewith are to be recognised in profit or loss. It is not permissible to recognise such amounts in determining acquisition cost. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments to IAS 37: “Provisions, Contingent Liabilities and Contingent Assets” By the amendments to IAS 37: “Provisions, Contingent Liabilities and Contingent Assets” it is clarified that all costs of fulfilling a contract directly attributable to the contract are to be included in the deter- mination of whether the contract is onerous as defined in IAS 37. Costs directly attributable to the contract, in addition to the costs additionally incurring to an entity as a result of the contract (incre- mental cost) such as direct wage and material costs, also include oth- er costs directly attributable to the fulfilling of the contract such as a proportionate depreciation charges of an item of property, plant and equipment used in fulfilling the contract. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for RHÖN-KLINIKUM AG. Amendments: “Annual Improvements to IFRS, 2018–2020 Cycle” On 14 May 2020, the IASB, as part of its annual improvements, pub- lished minor amendments to Standards IFRS 1, IFRS 9, IFRS 16 and IAS 41. The amendments to IFRS 1 relate to the treatment of cumula- tive currency differences in the initial adoption of IFRS by a subsidiary. In IFRS 9 it was clarified which fees are to be included if a “10% test” is applied in assessing whether to derecognise a financial liability. Moreover, in IFRS 16 an example was removed from the Appendix to the Standard to provide for greater clarity. In IAS 41 an adjustment was made to ensure consistency with the provisions in IFRS 13 when determining fair values. The amendments adopted into European law on 28 June 2021 are to be applied to financial years beginning on or after 1 January 2022 and are of no practical relevance for, or have no material impact on, the net assets and results of operations of RHÖN-KLINIKUM AG. By the end of the date of preparation of the consolidated finan- cial statements, the other Standards and Interpretations were not yet adopted by the European Union. For that reason, no detailed explanation of these Standards and Interpretations is given. c) Estimates Preparing consolidated financial statements in accordance with IFRS requires assumptions and estimates to be made. Moreover, the appli- cation of Group-wide accounting policies means that management has to exercise reasonable judgment. Areas that call for a greater degree of judgment to be exercised or that are characterised by a higher degree of complexity, or areas for which assumptions and estimates are of decisive importance for the consolidated financial statements, are set out and explained. The preparation of the con- solidated financial statements was based on historical cost, qualified by the financial assets and financial liabilities recognised at fair value through profit or loss as well as the equity investments measured directly in equity. Reference is moreover made to Note 3 “Critical es- timates and assessments in accounting and valuation” in these Notes. d) Publication The consolidated financial statements adopted by the Board of Management at the date of signing the financial statement will be adopted, approved and released for publication by the Supervisory Board on 23 March 2022. RHÖN-KLINIKUM AG | Annual Report 2021 81

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Unrealised intercompany profits or losses from transactions between Group companies and associated companies or joint ventures are eliminated on a pro rata basis if the underlying circumstances are material. In an impairment test, the carrying amount of a company accounted for using the equity method is compared with its recoverable amount. If the carrying amount exceeds the recoverable amount, an impair- ment equal to the difference must be recognised. If the reasons for a previously recognised impairment have ceased to exist, the impair- ment is reversed through the income statement. The financial statements of investments accounted for using the equity method are prepared using uniform accounting principles within the Group. Associated companies whose individual or overall impact on the net assets and results of operations is not material are not accounted for using the equity method. They are included in the consolidated financial statements at fair value. Immaterial equity interests are measured at fair value through profit or loss. Sale of subsidiaries and associated companies 2.3.3 If the Group loses either control or material influence over a company, the remaining interest is remeasured at fair value and the resulting difference recognised as profit or loss. Fair value is the fair value cal- culated upon the initial recognition of an associate, joint venture or financial asset. Moreover, all amounts stated in other income are recognised with reference to such company in the same way as would be required if the related assets and liabilities had been sold by the parent company directly. That means that a profit or loss previously recognised under other income is transferred to the income state- ment. If it cannot be transferred to the income statement, it remains in equity (e.g. actuarial profits or losses from pensions). 2.3.4 Segment reporting According to IFRS 8 “Operating Segments”, segment information on operating segments is to be presented in accordance with the internal reporting to the chief operating decision maker (management approach). An operating segment is a company component – which carries out business activities from which revenue is earned and for which expenses may be incurred. For us these include all revenues relating to services provided directly and indirectly for patients, as well as all expenses necessary for providing services, – whose operating result is regularly reviewed by the company’s chief decision maker to make decisions about resources to be allocated to this segment and assess its earnings strength, and – for which separate financial information is available. The chief decision-making body in our Group is the Board of Man- agement. It is in this body that the strategic decisions are made for the Group and to this body that the key ratios of the hospitals, which represent our operating segments, are reported. Monthly reporting to the Board of Management includes the hospi- tals. Group management costs are fully distributed to the operative segments. The monthly target-to-actual and actual-to-actual com- parison in the report to the Board of Management, by aggregating the operative segments into one reporting segment, serves to con- trol the targets published in the Company forecast, in particular the EBITDA margin. Given our understanding of an integrated healthcare services offering, we do not make any distinction in control by whether the services as defined in German social insurance legislation are attributed to the inpatient or the outpatient sector, or to the rehab or nursing sector. All expenses and income which are directly or indirectly related to patients are included under the operating segments. RHÖN-KLINIKUM AG | Annual Report 2021 83

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies are reversed, in which case such reversal may not exceed the carry- ing amount that would have resulted if no impairment had been recognised in the previous periods. 2.7 Impairment of property, plant and equipment and intangible assets (excl. goodwill) Land is not depreciated. All other assets are depreciated using the straight-line method, with costs being depreciated over the expected useful lives of the assets so as to write down the value of the assets to their residual carrying amount as follows: Buildings Machinery and equipment Other plant and equipment 33¹/3 years 5 to 15 years 3 to 12 years The net book values and useful economic lives are reviewed at each balance sheet date and adjusted where applicable. Gains and losses on the disposal of assets are measured as the difference between the disposal proceeds and the carrying amount and recognised through profit or loss. 2.6 Government grants Government grants are recognised at fair value if it can be assumed with reasonable assurance that the grant will be received and that the Group has satisfied the necessary conditions for this. Government grants for investments are deducted from cost to arrive at the carrying amount for the assets to which they relate. They are distributed as a re- duction in expenses over the expected useful life of the related assets using the straight-line method. Such grants are granted to hospitals within the framework of investment finance legislation. Grants not yet used for their intended purpose are stated under “Other liabilities” at the balance sheet date. Government grants are recognised on a systematic basis either in profit or loss, and during periods in which the Company applies cor- responding expenditures which the government grants are intended to cover as expenses. The Group assesses on every balance sheet date whether there are any indications that an asset might be impaired. If such indications exist or if an annual impairment test has to be performed in relation to an asset, the Group estimates the recoverable amount. If it is not possible for independent inflows to be allocated to the individual asset, the Group estimates the recoverable amount for the cash gen- erating unit to which the asset belongs. The recoverable amount is the higher of the fair value of the asset less costs to sell it and its value in use. If the carrying amount of an asset exceeds its recoverable amount, the asset is considered to be impaired and is written down to its recoverable amount. In order to calculate the value-in-use, the estimated future cash flows are discounted to their present value using a discount rate before taxes which reflects the current market expectation with regard to the interest effect and the specific risks of the asset. Impairments are shown in the income statement under the item Depreciation/amortisation. On every balance sheet date, a test is performed to establish whether there are any indications that an impairment recognised in previ- ous reporting periods no longer exists or might have diminished. If such an indication exists, the recoverable amount is estimated. An impairment previously recognised has to be reversed if there has been a change in the estimates used for determining the recover- able amount since the last impairment was recognised. If this is the case, the carrying amount of the asset has to be increased to the recoverable amount of the asset. However, this must not exceed the carrying amount which would have resulted after the recognition of depreciation/amortisation if no impairment had been recognised in previous years. Any such reversal of a prior impairment has to be recognised immediately in the profit or loss for the period. After a prior impairment has been reversed, the amount of depreciation/ amortisation in future reporting periods has to be adjusted in order to systematically distribute the revised carrying amount of the asset, less any residual value, over the remaining useful life of the asset. RHÖN-KLINIKUM AG | Annual Report 2021 85

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies 2.8.3 Assets measured at amortised cost Financial assets held as part of a business model whose purpose consists in holding assets to collect the contractual cash flows are measured at amortised cost provided that the assets also fulfil the cash flow conditions as defined in IFRS 9. When assessing whether cash flows are realised through collection of the contractually agreed payments from the financial asset, the frequency and scope of the sales in earlier periods are to be consid- ered, furthermore whether the assets sold were about to mature, as well as the reasons for such sales and the expectations with respect to the future sales activities. Within the Group of RHÖN-KLINIKUM AG, trade receivables, other financial assets as well as cash and cash equivalents are allocated to this category. 2.8.4 Assets measured at fair value directly in equity (fair value through other comprehensive income, with recycling) This category covers financial assets which fulfil the cash flow condi- tions as defined in IFRS 9 and whose purpose consists in collecting contractual cash flows and selling financial assets. Currently, no such financial assets exist at RHÖN-KLINIKUM AG. Investment property 2.9 Investment properties comprise land and buildings which are held for the purpose of generating rental income or for achieving capital gains, and which are not used for the company’s own provision of services, for administrative purposes or for revenues within the scope of ordinary operations. Investment properties are measured at cost less cumulative depreciation. Since RHÖN-KLINIKUM AG or its subsidiaries retain beneficial owner- ship in leased properties as lessor (operating lease), these properties are identified as such and reported separately in the balance sheet. Leased assets are recognised at cost and depreciated in accordance with the accounting principles for property, plant and equipment. Lease income is recognised on a straight-line basis over the term of the lease. 2.10 Inventories Inventories within the Group of RHÖN-KLINIKUM AG are materials and supplies. These are measured at the lower of cost (including transaction costs) and net realisable value. Cost of inventories is determined by the weighted-average method. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs to sell. 2.11 Trade receivables Trade receivables are initially recognised at the transaction price plus any transaction costs and subsequently measured at amortised cost less impairments. The Group generates over 90% of its revenue from the statutory health insurance funds. The material part of accounts receivable likewise is likewise due from statutory health insurance funds. For calculating expected credit losses, we have used the coun- try default risk for the Federal Republic of Germany as a basis for this category of receivables. In the case of the other receivables, the Group uses aged debtor lists and past experience as the basis for collectively estimating the percentage of expected credit losses as at the balance sheet date in relation to the period of time overdue. Macroeconom- ic risks are included with a time lag in the assessment through the country default risk of the Federal Republic of Germany or through the individual receivables defaults. Receivables are derecognised within the Group of RHÖN-KLINIKUM AG after expiry of the legal- ly prescribed limitation periods or after conclusion of unsuccessful insolvency proceedings. In addition, the Group recognises specific valuation allowances if, as a result of particular circumstances, it is not likely that trade receivables will be recovered. 2.12 Cash and cash equivalents Cash and cash equivalents comprise cash on hand, demand depos- its and other short-term, highly liquid financial assets with original maturities of up to three months. Utilised bank overdrafts are shown on the balance sheet as liabilities to banks under the item “Current financial liabilities”. 2.13 Equity Ordinary shares are classified as equity. Costs that are directly attrib- utable to the issuance of new shares are recognised in equity (net of tax) as a deduction from the issuance proceeds. RHÖN-KLINIKUM AG | Annual Report 2021 87

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies Actuarial gains and losses resulting from changes in actuarial assump- tions and/or from discrepancies between earlier actuarial assumptions and the actual development are recognised directly at equity in the period in which they occur giving due regard to deferred tax. In this way the balance sheet – after deduction of any existing plan assets – shows the full scope of the obligations avoiding fluctuations in expenses that may arise in particular in the case of changes in the calculation param- eters. The actuarial gains and losses recognised in the respective re- porting period are shown separately as “revaluations of defined benefit pension plans” in the statement of comprehensive income. Pursuant to IAS 19, past service cost, i.e. all changes in benefits di- minishing the defined benefit obligation, are fully recognised in the income statement at the time of the plan modification. Multi-employer plans On the basis of collective agreements, the Group pays contributions to the Federal and State Pension Scheme (VBL) and other public service pension schemes (Bayerische Versorgungskammer-Zusatzversorgung, BVK) for a certain number of employees. The supplementary pension schemes are public-law corporations or institutions. The contributions are paid on a pay-as-you-go (PAYGO) basis. This financing structure car- ries the risk of rising contributions through the levy of reform imposts that may be charged unilaterally or disproportionately to employers. The present plans are multi-employer plans (IAS 19.8) since the partici- pating companies share both the risk of the capital investment and the actuarial risk. In principle, the VBL/BVK benefit plan is to be classified as a defined benefit plan (IAS 19.38), but the information needed for an objectively correct representation of the Group’s share of the future payment is not available due to the existing PAYGO financing regime. Because of such PAYGO financing approach in which the levy rate is calculated for a certain coverage layer on the basis of the aggregate insurance portfolio and not on the basis of the individual risk of insu- rees, the benefit plan pursuant to IAS 19.34 is to be recognised as a defined contribution plan. Since no agreements within the meaning of IAS 19.37 exist, there is no recognition of a corresponding asset or liability. Any superordinated guarantee obligations of public-law enti- ties take precedence over the recognition of any liability item in the balance sheet. The current contributions to the VBL/BVK are reflected in the employee benefits item as pension expenses or post-employment benefits for the respective years. In addition to the levy, the VBL also levies reform imposts from the participating employers with compulsory insurees in the separately organised and managed settlement class Abrechnungsverband West. In financial year 2021, the reform impost amounted to 0.15% (previous year: 0.17%) of the insured remunerations. In the settlement class Abrechnungsverband West, the VBL finances its benefits through a PAYGO approach taking the form of a modified de- fined period-based funded approach (Abschnittsdeckungsverfahren). The current defined period covers 2016 to 2022. The levy rate is as- sessed in such a way that the contribution to be paid for the duration of the defined period together with the other income expected and the available assets suffices to settle the expenditures during the de- fined period and the period of six months thereafter. Since 1 January 2002, the levy rate has been 7.86% of the remuneration subject to supplementary pension payments, of which employers pay a share of 6.45% and employees a share of 1.41%. Since 1 July 2017, an additional employee contribution of 0.40% has applied. The contribution rate in the BVK, depending on the year of the employee’s entry, is between 4.80% and 7.75%. Given insufficient information, it is not possible to make any statement on the level of participation in the pension schemes based on the contributions paid by the Group of RHÖN-KLINIKUM AG compared with the aggregate payments to the VBL and other public service pension schemes (BVK). In the event of a VBL participation being terminated, the legal conse- quences arising therefrom are defined in section 23 of the VBL Rules. Termination of a VBL participation also triggers the end of the manda- tory insurance schemes. Since the VBL also continues to settle the pen- sion claims and entitlements arising up to the end of the participation, the withdrawing party, as compensation, is required to pay an equiva- lent value which does not include those components financed under the funded scheme. This equivalent value comprises the full funding of existing entitlements and coverage of administrative expenses as well as future benefit claims. The supplementary pension insurance scheme ZKV also stipulates a similar provision. Since in the case of withdrawal from PAYGO financing the risks of the other participants of the system also have to be compensated pro rata, a plausible actuarial calculation can be made only by the pension fund itself. RHÖN-KLINIKUM AG | Annual Report 2021 89

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Accounting policies 2.18.2 Interest income Interest income is recognised on a pro rata basis using the effective interest method. 2.18.3 Income from distribution and dividends Dividend income is recognised when the right to receive payment is established. 2.19 Leases Standard IFRS 16 defines a lease as a contract which conveys the right to use an asset for a period of time in exchange for consideration. As a rule, every lease is to be recognised with the lessee on the balance sheet in the form of a right of use and a lease liability. The lease liability is measured in accordance with the lease payments outstanding discounted with the incremental borrowing rate if it is not possible to calculate the interest rate implicit in the lease. The present value calculation is therefore as a rule based on the incre- mental borrowing rates. The right of use as a general rule is measured at the amount of the lease liability plus any initial direct cost. During the lease term, the right of use is to be depreciated and the lease liability updated using the effective interest method and taking into account the lease payments. For leases with a term of twelve months maximum as of 1 January 2019 as well as leases relating to low-value assets, no right of use and no lease liability will be applied in the balance sheet and the lease payments will continue to be recognised as an expense as thus with a negative effect on EBITDA in the income statement. 2.20 Costs of borrowing If borrowing takes place, the costs of borrowing are deducted from the corresponding items and are distributed using the effective- interest method. Moreover, the interest is then recognised as current expense. Costs of borrowing incurred in connection with the acquisition/construction of qualifying assets are capitalised during the entire production process until commissioning. Other costs of borrowing are recognised as an expense. 2.21 Dividend payments Shareholders’ claims to dividend payments are recognised as a liability in the period in which the corresponding resolution is adopted. 2.22 Financial risk management 2.22.1 Financial risk factors The assets, liabilities and planned transactions of RHÖN-KLINIKUM AG are exposed in particular to the following risks: – Credit risk – Liquidity risk – Interest rate risk The aim of financial risk management is to limit the above risks through ongoing operating activities as well as the use of derivative and non-derivative (e.g. fixed-interest loans) financial instruments. As a general rule, derivative financial instruments may be entered into for hedging purposes, i.e. they are not used for trading or speculative purposes. As a rule, financial instruments for limiting the counterparty risk are entered into only with leading financial institutions with at least an investment grade rating. Financial risk management is conducted by the division Accounting, Tax, Controlling, Finance and Investor Relations under the supervi- sion of the CFO in line with the guidelines adopted by the Board of Management and the Supervisory Board. Risks are identified and measured by the Board of Management working together with the operative units of the Group. The CFO defines both the principles for interdivisional risk management and the guidelines for certain areas such as the management of interest rate and credit risks, the use of derivative and non-derivative financial instruments as well as the investment of liquidity surpluses. 2.22.2 Credit risk The Group provides over 90% of its services for members of the statu- tory social insurance scheme, and the remainder to persons who pay medical invoices themselves and who have taken out private health insurance. There are no significant concentrations with respect to individual payers. The cost of hospital services is normally settled by payers within the legally prescribed period. With regard to the default risks in financial year 2021, please refer to our comments in the sec- tions “Trade receivables” and “Other financial assets”. The maximum risk of default is equal to the aggregate amount of the financial assets (less impairments) recognised on the balance sheet. Counterparty risks from entering into financial transactions are minimised by ad- herence to rules and limits. RHÖN-KLINIKUM AG | Annual Report 2021 91

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Critical estimates and assessments in accounting and valuation 3 | CRITICAL ESTIMATES AND ASSESSMENTS IN ACCOUNTING AND VALUATION 3.2 Revenue recognition The Group generates revenues essentially from the provision of medical services. The hospitals of RHÖN-KLINIKUM AG, like all other hospitals in Germany, are subject to the statutory regulations on fees. All estimates and assessments are subject to ongoing review and are based on past experience and other factors, including expectations with respect to future events which appear reasonable under the given circumstances. Revenue recognition is essentially based on a comparison of perfor- mance and consideration under a contract: a service performed gives rise to an asset, the consideration received to an obligation. The Group makes assessments and assumptions about the future. The estimates derived from these of course only rarely reflect actual future circumstances. These uncertainties in particular concern the following: – the planning parameters taken as a basis of the impairment test for goodwill, – assumptions made in determining pension obligations, – assumptions and probabilities for determining provision requirements, and – assumptions relating to the credit risk of trade receivables. The estimates and assumptions that entail a significant risk of a sub- stantial adjustment in carrying amounts of assets and liabilities during the next financial year are discussed in the following. Estimated impairment of goodwill 3.1 To determine goodwill at fair value less costs to sell, the operating cash flows of the individual hospitals, with their inpatient, semi-inpa- tient and outpatient care structures, were discounted at the weight- ed average cost of capital (WACC) after tax of 5.20% (previous year: 4.21%). The carrying amounts do not exceed fair value less cost of sale. Based on this calculation, no impairment requirement was ascer- tained. Key assumptions having a substantial influence on fair value less costs to sell are WACC and the average EBIT margin. See our Note under 6.1 for average growth in revenues. For the cash generating units, the recoverable amount is equal to the carrying amount as of an assumed cost of capital rate of 6.5% (previous year: 5.3%). Treatment contracts between hospitals and patients or their health insurance funds correspond to contracts for services pursuant to section 630a ff. BGB. Irrespective of who performs the payment in future, it is normally the case that the patient will likely be regarded as the customer. The scope of the performance obligations in the context of hospital treatment is essentially governed by statutory provisions. The prices charged to the payers are stipulated by numerous laws and regulations. The patient receives and consumes the benefit simulta- neous with performance of the service. Control is thus transferred and also revenue recognised for a specified period. Revenues are recognised in accordance with progress of service performance over the service performance period. In order to create planning and revenue certainty, the remunera- tion regulations normally provide for prospective fee agreements. In practice, however, these negotiations take place only in the course of the financial year or even thereafter, creating uncertainties as to the service volume for which consideration is received at the balance sheet date. These are reflected in the balance sheet through objec- tive, reliable estimates of receivables or liabilities based on empirical values. Past experience has shown that the inaccuracies relating to the estimates are negligible for the Group’s financial position and results of operations. RHÖN-KLINIKUM AG | Annual Report 2021 93

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Critical estimates and assessments in accounting and valuation Income taxes 3.3 Estimates are required for the recognition of tax provisions as well as deferred tax items. For determining the actual value of deferred tax assets, it is essential to assess the probability of the reversal of the valuation differences and the extent to which it is possible to use the tax loss carry-forwards that led to the recognition of deferred tax assets. This depends on the generation of future taxable profits during the periods in which tax valuation differences are reversed and tax loss carry-forwards can be utilised. Uncertainties exist with regard to the interpretation of complex tax regulations as well as the amount and timing of future taxable income that result in changes in the tax income or expense in future periods. The Group recognises adequate provisions for the possible consequences of audits by the tax authorities. The amount of such provisions is based on various factors, such as experience from past tax audits and differing interpretations of substantive tax law by the taxable entity and the competent tax authorities on specific issues. The Regulation on Further Measures to Safeguard the Economic Via- bility of Hospitals (Verordnung zur Regelung weiterer Maßnahmen zur wirtschaftlichen Sicherung der Krankenhäuser), which entered into force on 9 April 2021, provides in 2021 for separate relief mechanisms for hospitals in connection with the relief payments made. Under this legislation, declines in a hospital’s revenues compared with a 2019 revenue basis lowered to 98% are offset in hospitals’ favour at a compensation rate of 85%. However, revenue increases compared with the 2019 revenue level attributable to relief payments received for beds kept available pursuant to section 21 (1a) or 1b or to care surcharges pursuant to section 21a (1) of the German Hospital Financ- ing Act (Krankenhausfinanzierungsgesetz, KHG) are subject to a full repayment obligation. At the same time, relief payments for beds kept available are applied at 85% in each case, the care surcharge created since 1 November 2021 at 50%, to 2021 the revenues. With the Healthcare Further Development Act (Gesundheitsver- sorgungsweiterentwicklungsgesetz, GVWG), which entered into force on 20 July 2021, the provisions on the nursing budget were clarified. For agreement year 2020, it provides for mandatory application of the clarification provision for agreement year 2021 if an agreement was still not concluded for the nursing budget for 2020. In this context, €61.7 million (previous year: €90.6 million) was reported within revenues in financial year 2021 as payment relating to COVID-19 legislation. These revenues are primarily attributable to income from keeping hospital beds available. Furthermore, €1.7 million (previous year: €3.3 million) were reported under other income as well as €0.9 million (previous year: €0.2 million) under the employee expense item. RHÖN-KLINIKUM AG | Annual Report 2021 95

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Company acquisitions Acquisition of doctor’s practices In financial year 2021, a total of 3.75 physicians’ practices were ac- quired for consideration whose conditions of validity as per agree- ment were satisfied during the reporting period of 2021. Consoli- dation in the Group also took place in financial year 2021. No costs were incurred from the acquisition of these doctor’s practices. The revenues and annual results generated since their inclusion in the consolidated statements are of minor importance for the Group of RHÖN-KLINIKUM AG. The final purchase price allocation has the following impact on the Group’s net assets in 2021: Deconsolidation of subsidiaries In the current financial year 2021, there were no sales of subsidiaries. In the previous year, this was the case of GPG and Medgate. GPG Gesellschaft für Projekt- und Grundstücksentwicklung GmbH Leipzig operating in Leipzig was sold with effect from 1 January 2020. With effect from 1 September 2020, RHÖN-KLINIKUM AG transferred 51% of its interests in Medgate Deutschland GmbH to its co-share- holder, Medgate Holding AG. The effects of the deconsolidation of the companies or interests sold in 2020 are set out below: in € million Fair value post acquisition Effects from deconsolidation of subsidiaries Carrying amount disposals 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.4 Acquired assets and liabilities Non-current assets Current assets Cash and cash equivalents Minorities Non-current liabilities Current liabilities Net assets/liabilities of Group sold Sale proceeds from deconsolidated subsidiaries Waiver of repayment of loan liabilities Expense from disposal of deconsolidated subsidiaries ./. Sold cash and cash equivalents Cash outflow ./. Purchase price payment outstanding Cash outflow on deconsolidated subsidiaries 0.8 0.0 0.3 0.3 –1.2 –0.3 –0.1 0.4 –1.2 –0.7 –0.3 –1.1 0.0 –1.1 in € million Purchase of physicians’ practices, January to December 2021 Acquired assets and liabilities Intangible assets Property, plant and equipment Other liabilities Net assets acquired + Goodwill Cost ./. Purchase price payments outstanding ./. Acquired cash and cash equivalents Cash outflow on transaction Goodwill amounting to €0.4 million essentially includes synergy effects expected from the expansion of medical care centres. The goodwill recognised is likely to be tax-deductible. Furthermore, 2.5 physicans’ practices were transferred during the reporting period from the physicians associations to the MVZ subsidiary at the Frankfurt (Oder) site without consideration. 0.75 physicians’ practices at the Bad Berka site as well as 1.5 physi- cians’ practices at the Giessen and Marburg site were returned to the physicians association. In financial year 2021, no physicians’ practices were acquired whose conditions of validity as per agreement will be satisfied only in 2022. RHÖN-KLINIKUM AG | Annual Report 2021 97

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement 5.3 Materials and consumables used in € million Cost of raw materials, consumables and supplies Cost of purchased services 2021 2020 388.7 41.7 430.4 381.0 41.4 422.4 Compared with the same period of the previous year, materials and consumables used witnessed a rise in financial year 2021, dispropor- tionately moderate to the rise in revenues, by €8.0 million or 1.9%. The materials ratio declined from 31.0% to 30.7%. Materials and consumables used moreover includes expenditures for the medica- mentous treatment of spinal muscle atrophy and multiple sclerosis which are remunerated in nearly the same amount and reported under revenues or other income. 5.4 Employee benefits expense In financial year 2021, contribution payments to the pension scheme VBL were made in the amount of €21.6 million (previous year: €24.1 million). Payments to the BVK amounted to €0.8 million (previous year: €0.9 million) in 2021. As at the reporting date of 31 December 2021, 9,038 employees (previous year: 9,060 employees) with a claim to supplementary pension benefits were registered with VBL and 360 employees (previous year: 407 employees) with the BVK. Reimbursements for maternity leave, income from integration grants as well as reimbursements of personnel expenses for quarantined employees were recognised in the amount of €13.4 million (previous year: €10.7 million) in expenses for wages and salaries. Employee benefits expenses include a figure of €1.7 million (previous year: €2.5 million) for severance payments. 5.5 Depreciation and impairment This item includes amortisation of intangible assets and depreciation of property, plant and equipment and investment property. Com- pared with the same period last year, the depreciation/amortisation item increased by €1.1 million (or 1.6%) to €70.7 million as a result of our investment activities. in € million 2021 2020 5.6 Other expenses Other operating expenses break down as shown in the following table: Wages and salaries Social insurance contributions Expenditure for post-employment benefits Defined contribution plans Defined benefit plans 768.7 66.3 86.1 0.3 921.4 758.5 64.0 83.6 0.6 906.7 Expenses for defined contribution plans concern the statutory pen- sion insurance agency, payments to the federal and state pension scheme (VBL) and to Bayerische Versorgungskammer-Zusatzver- sorgung (BVK). The defined benefit plans relate to the benefit com- mitments of Group companies, and comprise commitments for retirement pensions, invalidity pensions and pensions for surviving dependants as well as severance payments for members of the Board of Management after termination of the employment relationship. in € million 2021 2020 Maintenance Charges, subscriptions and consulting fees Insurance Administrative and IT costs Other personnel and continuing training costs Rents and leaseholds Travelling, entertaining and representation expenses Losses on disposal of non-current assets Secondary taxes Other 56.8 42.9 10.5 9.7 5.3 3.8 1.2 0.1 0.2 16.8 147.3 57.9 43.0 13.3 10.9 5.6 4.0 1.5 0.3 0.2 9.9 146.6 Other expenses saw a moderate increase from €146.6 million by €0.7 million to €147.3 million. The other expense ratio declined slight- ly from 10.8% to 10.5%. RHÖN-KLINIKUM AG | Annual Report 2021 99

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated income statement The net interest income under IFRS 9 for financial assets and liabilities which are not included in the category “financial assets and liabilities shown at fair value in profit and loss” amounted to €4.1 million in financial year 2021 (previous year: €4.6 million). The amount compris- es income of €0.2 million (previous year: €0.2 million) and expenses of €4.3 million (previous year: €4.8 million). 5.10 Income taxes Income taxes consist of the corporate income tax including the sol- idarity surcharge, and to a lesser extent of trade tax. This item also includes deferred taxes resulting from differences between the IFRS and tax balance sheets as well as from consolidation adjustments and expected realisable tax loss carry-forwards which, as a rule, have no expiry date. Income tax comprises the following: in € million Current income tax Deferred taxes 2021 2020 –2.4 –0.5 –2.9 2.8 –1.3 1.5 At an unchanged tax assessment basis, consolidated profit in financial year 2021 was helped by income tax recognised at €2.9 million (income tax expenditure of previous year: €1.5 million). The improvement is attributable among other things to the reversal of provisions in financial year 2021 (€5.1 million) formed in the con- text of risk provisioning for income tax risks relating to the sale of subsidiaries. Moreover, the effect of a higher tax assessment basis in financial year 2021 was recognised with effect on the income statement. The income tax relief stands at 10.5% (previous year: income tax burden of 38.9%). The nominal tax expense for earnings before taxes is reconciled with the income tax expense as follows: in € million 2021 2020 in % in % Earnings before taxes 27.4 100.0 3.9 100.0 Nominal tax expense (tax rate 15.0%) Solidarity surcharge (tax rate 5.5%) Recognition of previous loss carry-forwards not recognised/ Derecognition of loss carry-forwards recognised and loss carry-forwards not applied Trade tax Increase in tax liability due to non-deductible charges Taxes, previous years Additional expense from dividend payment Elimination of items not relevant for taxation Effective income tax expense 4.1 0.2 15.0 0.8 0.1 0.9 0.4 –3.5 0.4 3.3 1.5 –12.8 0.6 0.0 2.3 0.5 0.1 –0.1 15.0 0.8 59.0 12.8 2.6 –2.6 0.0 0.0 0.1 2.6 –5.1 –2.9 –18.6 –10.5 –2.0 1.5 –51.3 38.9 Tax of previous years includes income from trade tax resulting from the audit for previous years in the amount of €4.0 million. Items of no relevance for taxation include amounts not classified as taxable in the calculation of taxable income. This results in income from the reversal of tax provisions in the amount of €5.1 million (pre- vious year: €2.0 million). Further details of how deferred tax has been allocated to assets and liabilities are given in the Notes to the consolidated balance sheet. RHÖN-KLINIKUM AG | Annual Report 2021 101

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6 | NOTES TO THE CONSOLIDATED BALANCE SHEET 6.1 Goodwill and other intangible assets in € million in € million Other intangible assets Goodwill Total Other intangible assets Goodwill Cost 1 Jan. 2021 Changes in consolidated companies Additions Disposals Transfers Cost 164.8 55.2 220.0 1 Jan. 2020 0.4 0.0 0.0 0.0 0.0 4.6 0.6 0.1 0.4 4.6 0.6 0.1 Changes in consolidated companies Additions Disposals Transfers 31 Dec. 2021 165.2 59.3 224.5 31 Dec. 2020 Cumulative depreciation and impairment Cumulative depreciation and impairment 1 Jan. 2021 Depreciation Disposals Transfers 31 Dec. 2021 Balance sheet value as at 31 Dec. 2021 0.0 0.0 0.0 0.0 0.0 165.2 38.4 5.1 0.6 0.0 42.9 16.4 38.4 1 Jan. 2020 5.1 0.6 0.0 Depreciation Disposals Transfers 42.9 31 Dec. 2020 181.6 Balance sheet value as at 31 Dec. 2020 164.2 0.6 0.0 0.0 0.0 164.8 0.0 0.0 0.0 0.0 0.0 164.8 48.5 –0.8 7.9 0.4 0.0 55.2 34.6 4.2 0.4 0.0 38.4 16.8 Total 212.7 –0.2 7.9 0.4 0.0 220.0 34.6 4.2 0.4 0.0 38.4 181.6 The item “Other intangible assets” primarily includes software. There are no restrictions on title and/or other rights related to the assets. RHÖN-KLINIKUM AG | Annual Report 2021 103

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The assumptions for the other business generating units are comparable. The values of revenues in the ten-year planning period of the groups of cash generating units to which material goodwill was attributed are based on average organic growth rates of between 2.3% and 3.1% (previous year: 2.9% and 3.2%). In connection with the impairment test, a sensitivity analysis was also performed. Within the test the following assumptions were used: – EBIT declines by 10% – WACC increase by 0.5% As a result of the sensitivity analysis it was determined that a decline in EBIT by 10% does not result in any impairment requirement (previ- ous year: no impairment requirement). An increase in WACC by 0.5% likewise does not give rise to an impairment requirement (previous year: no impairment requirement). which is particularly sensitive to changes in assumptions on the long- term growth rate of revenues and on the discount rate. Whereas the discount rate was defined uniformly for all business generating units, the growth rate is defined individually per entity. The discount rate reflects the current market assessment of the entities’ specific risks. The growth rates take account of external macro-economic data and sector-specific trends. For planning purposes, the units accounting for the main portion of goodwill are assumed to have a homogenous structure. The table below shows the assumptions of long-term growth rates for revenues by which the company planning is projected by a further five years which were used in the impairment test of the business generating units to which material goodwill was attributed to de- termine fair value less cost of sale: in % 2021 2020 Long-term growth rate – revenues 3.00 3.00 Long-term growth rate – revenues 3.00 3.00 WACC 5.20 5.20 WACC 4.21 4.21 3.00 5.20 3.00 4.21 Universitäts- klinikum Gießen und Marburg Zentralklinik Bad Berka RHÖN-KLINIKUM Campus Bad Neustadt RHÖN-KLINIKUM AG | Annual Report 2021 105

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet During the financial year, borrowing costs of €1.0 million (previous year: €0.5 million) were related to financing the acquisition or produc- tion of qualifying assets and were recognised in addition to property, plant and equipment. An average interest rate of 2.4% (previous year: 2.2%) was used, which reflects the Group’s general costs of borrowing from banks. Similar to the previous year, the Group has no registered charges on real property as collateral for bank loans. Public grants related to assets are deducted from the cost of the asset for which they are given, reducing the depreciation over the period. The deducted amortised amount of assistance granted under the Hospital Financing Act (Krankenhausfinanzierungsgesetz, KHG) and which was invested in line with the applicable conditions totals €151.7 million (previous year: €161.2 million). To secure conditionally repayable single grants under the KHG (e.g. for the construction of new hospitals or major extensions) totalling €1.7 million (previous year: 1.9 million), the Group holds registered charges on real property in the amount of €4.1 million (previous year: €4.1 million). There are no reasons to assume that these grants will have to be repaid. Buildings, technical equipment and medical equipment include as at 31 December 2021 rights of use pursuant to IFRS 16 in which the Group is the lessee. The rights of use are as follows: in € million Land and buildings Operating and office equipment Cost 1 Jan. 2021 Addition to consolidated companies Additions Disposals 31 Dec. 2021 Cumulative depreciation and impairment 1 Jan. 2021 Depreciation Disposals 31 Dec. 2021 Balance sheet value as at 31 Dec. 2021 4.2 0.0 1.7 0.3 5.6 1.2 0.9 0.3 1.8 3.8 13.9 0.0 0.7 1.2 13.4 5.8 2.5 1.1 7.2 6.2 Total 18.1 0.0 2.4 1.5 19.0 7.0 3.4 1.4 9.0 10.0 in € million Cost 1 Jan. 2020 Addition to consolidated companies Additions Disposals 31 Dec. 2020 Cumulative depreciation and impairment 1 Jan. 2020 Depreciation Disposals 31 Dec. 2020 Balance sheet value as at 31 Dec. 2020 Land and buildings Operating and office equipment Total 3.7 0.2 0.5 0.2 4.2 0.6 0.7 0.1 1.2 3.0 13.4 17.1 0.0 0.9 0.4 0.2 1.4 0.6 13.9 18.1 3.6 2.6 0.4 5.8 8.1 4.2 3.3 0.5 7.0 11.1 6.3 Deferred tax assets Deferred tax assets and liabilities are netted if there is an enforceable right to offset current tax assets against current tax liabilities and if the deferred taxes exist against the same tax authority. The following amounts were netted: in € million Tax loss carry-forwards Property, plant and equipment/ Intangible assets Interest bearing liabilities Recognition differences for subsidiaries Other assets and liabilities Total Balance sheet value 31 Dec. 2021 31 Dec. 2020 Assets Liabilities Assets Liabilities 0.1 0.0 0.0 0.0 9.7 9.8 1.1 0.0 6.7 0.2 1.0 0.8 8.7 0.1 0.0 0.0 0.0 10.2 10.3 1.5 0.0 6.9 0.2 1.0 0.7 8.8 RHÖN-KLINIKUM AG | Annual Report 2021 107

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.4.2 Joint ventures The object of enterprise of the joint venture is to carry on, together with Stadtwerke Gießen, the supply of energy to the university hospital in Giessen. In addition to RHÖN-KLINIKUM AG with an interest of 50%, Stadtwerke Gießen AG holds an interest of 50% in the joint venture. The table below provides a summary of the aggregated results data and aggregated carrying amounts of the joint venture accounted for using the equity method: The interests are measured at fair value in accordance with IFRS 9. The investments are measured at fair value directly in equity (fair value through other comprehensive income, without recycling). The carry- ing amount of €17.5 million (previous year: €12.0 million) corresponds to the maximum default risk. Moreover, €0.0 million (previous year: €0.0 million) relates to immate- rial equity interests which are measured at fair value. in € million 2021 2020 Like at the previous year’s balance sheet date, no long-term fixed deposit investments were to be recognised at the balance sheet date of 31 December 2021. The development of the impairments recognised under the item of other financial assets (non-current) pursuant to IFRS 9 is shown in the table below: Results data and carrying amounts of joint venture accounted for using the equity method Revenues Earnings after tax Pro rata earnings after tax Pro rata total comprehensive income after tax Carrying amount of joint venture accounted for using the equity method 0.4 0.2 0.1 0.1 0.4 0.4 0.2 0.1 0.1 0.4 in € million Impairment As at 1 Jan. pursuant to IFRS 9 Changes in consolidated companies As at the balance sheet date, the joint venture reports assets of €0.9 million (previous year €0.9 million) as well as equity of €0.9 million (previous year: €0.8 million). Allocation Utilisation Write-back Other financial assets (non-current) 6.5 Other non-current financial assets break down as follows: Currency translation difference As at 31 Dec. pursuant to IFRS 9 2021 2020 – – – – – – – 0.2 – – – 0.2 – – in € million Participating interests Time deposits 31 Dec. 2021 31 Dec. 2020 17.5 – 17.5 12.0 – 12.0 The equity interests relate to interests held by the company RHÖN-Innovations GmbH in the companies Inovytec Medical Solutions Ltd., Telesofia Medical Ltd. and CLEW Medical Inc. Also included are interests in Tiplu GmbH and Siebensachen GmbH. The decline in impairments as at the balance sheet of the previous year to €0.0 million results from the expiry of long-term fixed deposit investments. Inventories 6.6 Inventories in the amount of €33.1 million (previous year: €35.2 million) are attributable to raw materials, consumables and supplies and mainly consist of medical supplies. Impairments of €3.7 million (previous year: €3.9 million) were effected. All invento- ries are owned by RHÖN-KLINIKUM AG and the companies affiliated with RHÖN-KLINIKUM AG. There are no assignments or pledges of inventories. RHÖN-KLINIKUM AG | Annual Report 2021 109

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.8 Other financial assets (current) Other financial assets (current) attributable to fixed deposits, as well as corresponding impairments within the meaning of IFRS 9 were divided into the following rating classes as at 31 December 2020: in € million Time deposit < 1 year Receivables under the KHEntgG Remaining other financial assets 31 Dec. 2021 31 Dec. 2020 in € million < 1 year < 1 year 165.8 50.5 7.6 223.9 166.4 56.0 8.8 231.2 Impairment matrix according to S&P rating classes 31 Dec. 2020 A BBB Total Gross carrying amount Expected credit loss 110.0 57.0 167.0 0.1 0.5 0.6 The remaining other financial assets (current, not including fixed deposits) as well as the corresponding impairments within the mean- ing of IFRS 9 show the following maturity structure as at the balance sheet date of 31 December 2021: in € million Impairment matrix 31 Dec. 2021 Not overdue Between 0 and 30 days overdue Between 31 and 90 days overdue Between 91 and 180 days overdue More than 180 days overdue Total Gross carrying amount Expected credit loss 57.6 0.5 0.1 0.1 0.1 58.4 0.1 0.1 0.0 0.0 0.1 0.3 Receivables under the German Hospital Remuneration Act (Kranken- hausentgeltgesetz, KHEntgG) relate to compensation claims under federal hospital compensation legislation (Hospital Remuneration Act (Krankenhausentgeltgesetz, KHEntgG)) and the Federal Hospital Nursing Rate Ordinance (Bundespflegesatzverordnung, BPflV) as well as compensation claims against the training fund. Stated receivables under the KHEntgG do not include any impairments. Remaining other financial assets relate among others to receivables from services rendered which are not primarily related to patient treatments at hospitals (€6.5 million, previous year: €7.4 million), receivables due from employees in particular from invoices as part of the liquidation right of head physicians (€2.0 million, previous year: €1.9 million), as well as trade receivables (€0.7 million, previous year: €0.7 million). The remaining other financial assets include impair- ments amounting to €1.8 million (previous year: €1.6 million). No reversals of impairment losses were made. Other financial assets (current) attributable to fixed deposits, as well as corresponding impairments within the meaning of IFRS 9 are divided into the following rating classes as at 31 December 2021: in € million Impairment matrix according to S&P rating classes 31 Dec. 2021 A BBB Total Gross carrying amount Expected credit loss 80.0 87.0 167.0 0.2 1.0 1.2 RHÖN-KLINIKUM AG | Annual Report 2021 111

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The rise in cash with banks and cash on hand is attributable to the interest rate environment for time deposits relative to overnight money investments with rising custodian fees. The high level of cash with banks and cash on hand ensures flexibility in controlling cash outflows in connection with extensive construction measures. As far as possible, freely disposable funds were reallocated at matching maturities into fixed deposit investments with a remaining term of < 1 year (> 3 months) and > 1 year and reported under the item “Other financial assets (current)”. As at the balance sheet date, the ef- fective interest rate for bank balances with an initial term < 3 months was 0.00% (previous year: 0.00%). The average remaining term of these deposits was 30 days (previous year: 30 days). The item includes demand deposits with restricted use in the amount of €0.9 million (previous year: €1.1 million). Cash and bank overdrafts are aggregated as follows for the purpose of the statement of cash flows: in € million Cash and cash equivalents Bank overdrafts Cash position 31 Dec. 2021 31 Dec. 2020 126.3 0.0 126.3 91.0 0.0 91.0 6.12 Equity The registered share capital of RHÖN-KLINIKUM AG was €167,406,175 (previous year: €167,406,175). It is divided into 66,962,470 (previous year: 66,962,470) fully paid-up non-par value bearer shares each with a notional value in the registered share capital of €2.50 per share. Arithmetic share in registered share capital in € Number Ordinary shares as at 1 Jan. 2021 66,962,470 167,406,175 Changes in 2021 – – Ordinary shares as at 31 Dec. 2021 66,962,470 167,406,175 The premium from the capital increase in the amount of €396.0 million (previous year: €396.0 million) as well as the amounts of €178.2 million (previous year: €178.2 million) attributable to the shares redeemed in the previous years are reported in the capital reserve. Other reserves at the balance sheet date amounting to €456.8 million (previous year: €423.8 million) comprise earnings generated in pri- or years of companies included in the consolidated annual report amounting (to the extent not paid out to shareholders) in the amount of €456.8 million (previous year: €423.8 million) as well as effects of consolidation adjustments. The total result (sum of consolidated profit and other earnings) for financial year 2021 stands at €34.9 million (previous year: €4.8 million). This includes gains from the revaluation of defined benefit pension plans amounting to €0.0 million after tax (previous year: €0.3 million) as well as income from changes in the fair value of equity investments in the amount of €4.7 million (previous year: €2.1 million). Treasury shares are valued at €0.1 million (previous year: €0.1 million) and deducted from equity. The level of treasury shares developed as follows during the financial year: Treasury shares as at 1 Jan. 2021 Changes in 2021 Treasury shares as at 31 Dec. 2021 Number 24,000 – 24,000 In accordance with the provisions of the German Stock Corporation Act (Aktiengesetz, AktG), the amount of dividends distributable to shareholders is based on the net distributable profit shown in the an- nual financial statements of RHÖN-KLINIKUM AG which are prepared in accordance with the German Commercial Code (HGB). During the last Annual General Meeting, the shareholders approved the proposal of the Board of Management and of the Supervisory Board to waive a dividend payment in financial year 2021. RHÖN-KLINIKUM AG | Annual Report 2021 113

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet The contractual interest adjustment dates relating to the interest-bearing liabilities are as follows: in € million Fixed interest period ends Liabilities to banks 2022–2025 2026 2027 > 2027 Interest on loans 1 Weighted interest rate. 31 Dec. 2021 31 Dec. 2020 Interest rate in % 1 Original value Carrying amount of loans Interest rate in % 1 Original value Carrying amount of loans 1.25 – – 2.10 38.0 – – 112.0 150.0 37.9 – – 110.7 1.0 149.6 1.25 – – 2.10 38.0 – – 112.0 150.0 37.9 – – 110.6 0.9 149.4 The effective interest rates at balance sheet date are: in % 31 Dec. 2021 31 Dec. 2020 Liabilities to banks 1.90 1.91 The remaining terms of the financial liabilities are: in € million Up to 1 year Between 1 and 5 years More than 5 years Total 31 Dec. 2021 31 Dec. 2020 1.0 37.9 110.7 149.6 0.9 37.9 110.6 149.4 As in the previous year, the financial liabilities stated are not secured by registered charges on real property. 6.14 Provisions for post-employment benefits The Group provides post-retirement benefits for eligible employees under its company pension scheme, which comprises both defined benefit and defined contribution pension plans. Obligations under this scheme include current pension payments and future entitlements. Defined benefit obligations are financed by recognising provisions. Amounts relating to defined contribution plans are recognised immediately in profit or loss. Some members of the Board of Management are covered by a plan providing for post-retirement benefits. In addition to their regular remuneration, such members of the Board of Management, on termination of their employment as Board members, receive a post-retirement benefit depending on the length of service and level of remuneration and not exceeding 1.5 times the last annual remuneration. The scope of the obligation was calculated based on the individual contract terms and not on a uniform retirement age as with the other pension plans. In this connection there are risks associated with changes in the assessment basis. These essentially relate to the dependence on the last salary and last variable remuneration components. If the development of this assessment basis turns out to be different from what is assumed in the provision calculations, this might give rise to a subsequent financing requirement. RHÖN-KLINIKUM AG | Annual Report 2021 115

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.15 Other provisions Other provisions developed as follows in the financial year: in € million Liability risks Other provisions 1 Jan. 2021 Con- sumption Write-back Allocation 31 Dec. 2021 of which < 1 year of which > 1 year 7.1 25.3 32.4 0.3 16.5 16.8 0.0 0.0 0.0 3.9 12.7 16.6 10.7 21.5 32.2 10.7 21.5 32.2 0.0 0.0 0.0 The provisions for liability risks relate to claims for damages by third parties. These compare with repayment claims from insurers in the amount of €3.6 million (previous year: €1.7 million) against insurers; these are shown under other assets (current). In the assessment of the Board of Management, the settlement of these liability events using the provisions will not entail any significant additional expenses. The timing of cash outflows from liability risks, which generally may occur in the short term, essentially depends on the course and outcome of specific liability cases. The other provisions include provisions for recovery risks in the amount of €15.8 million (previous year: €15.6 million) as well as for risk provisioning for legal and non-income-tax risks in the amount of €5.7 million (previous year: €9.7 million). Compared with the previous year, their maturities are as follows: in € million Liability risks Other provisions 31 Dec. 2021 of which < 1 year of which > 1 year 31 Dec. 2020 of which < 1 year of which > 1 year 10.7 21.5 32.2 10.7 21.5 32.2 0.0 0.0 0.0 7.1 25.3 32.4 7.1 25.3 32.4 0.0 0.0 0.0 The Group of RHÖN-KLINIKUM AG has contingent liabilities of up to €0.0 million (previous year: €0.0 million). These constitute liabilities as part of the performance process. At the present time RHÖN-KLINIKUM AG does not expect any significant usage in future. RHÖN-KLINIKUM AG | Annual Report 2021 117

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.19 Current income tax liabilities Current income tax liabilities in the amount of €14.6 million (previ- ous year: €11.4 million) comprise corporate income tax, solidarity surcharge and trade tax not yet assessed for the past financial year and previous years. The rise is the result of a higher tax assessment basis for 2021. Moreover, an amount of €5.1 million in provisions for tax risks relating to the sale of subsidiaries was recognised in the pre- vious year which materialised in the current year and were reversed. 6.20 Derivative financial instruments As at the previous year’s balance sheet date, no derivative financial instruments exist. 6.18 Other liabilities in € million 31 Dec. 2021 31 Dec. 2020 < 1 year > 1 year < 1 year > 1 year 79.7 27.1 14.0 9.8 0.4 10.0 0.0 0.0 0.0 0.0 0.0 0.0 76.8 21.5 13.2 10.7 0.6 10.2 0.0 0.0 0.0 0.0 0.0 0.0 141.0 0.0 133.0 0.0 Personnel liabilities Liabilities according to the KHG Operating taxes and social security contributions Deferred income Pre-payments Other liabilities Other liabilities (non-financial instruments) Personnel liabilities relate to performance-linked remuneration, ob- ligations arising from still outstanding holiday leave entitlement as well as overtime obligations and on-call services. Moreover, severance payment obligations are recognised under this item. The liabilities under the KHG relate to government grants not yet used in accordance with the conditions for their use granted under state legislation for hospital financing. The remaining liabilities essentially include third-party funds from, among other things, ongoing studies not yet appropriated. RHÖN-KLINIKUM AG | Annual Report 2021 119

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 31 Dec. 2021 Financial instruments 31 Dec. 2020 Financial instruments of which of which Carrying amount Fair value Carrying amount Fair value 17.5 17.5 0.0 0.0 436.8 126.3 148.6 17.6 10.5 7.1 72.5 1.0 12.1 9.0 3.1 17.5 17.5 0.0 0.0 436.8 126.3 148.6 17.6 10.5 7.1 72.5 1.0 12.1 9.0 3.1 563.1 17.5 0.0 241.6 17.5 17.5 0.0 0.0 436.8 126.3 158.4 10.9 10.9 – 72.5 1.0 9.0 9.0 – 563.1 17.5 0.0 251.8 12.0 12.0 0.0 0.0 425.1 91.0 148.5 16.5 8.4 8.1 80.7 0.9 14.9 11.8 3.1 12.0 12.0 0.0 0.0 425.1 91.0 148.5 16.5 8.4 8.1 80.7 0.9 14.9 11.8 3.1 516.1 12.0 0.0 250.3 12.0 12.0 0.0 0.0 425.1 91.0 172.3 9.1 9.1 – 80.7 0.9 11.8 11.8 – 516.1 12.0 0.0 274.8 RHÖN-KLINIKUM AG | Annual Report 2021 121

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Notes to the consolidated balance sheet 6.21.2 Net gains or losses by measurement category The net result by measurement category according to IFRS 9 for financial year 2021 is as follows: in € million Financial assets measured at amortised cost Total + = cost, – = income From subsequent measurement From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 0.8 0.8 Net result 2021 5.3 5.3 From disposal 4.5 4.5 The net result by measurement category according to IFRS 9 for financial year 2020 is as follows: in € million Financial assets measured at amortised cost Total + = cost, – = income From subsequent measurement Net result From share price gains At fair value Impairment 0.0 0.0 0.0 0.0 0.0 0.0 From disposal 7.6 7.6 2020 7.6 7.6 RHÖN-KLINIKUM AG | Annual Report 2021 123

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Statement of cash flows In financial year 2021, financial liabilities changed as follows: in € million 31 Dec. 2020 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2021 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 11.2 0.9 148.5 160.6 –3.5 –0.9 – –4.4 2.5 1.0 0.0 3.5 – – – 0.0 10.2 1.0 148.5 159.7 Financial liabilities changed in financial year 2020 as follows: in € million 31 Dec. 2019 Cash changes Non-cash changes Change in consolidated companies 31 Dec. 2020 Lease obligations Current financial liabilities Non-current financial liabilities Total liabilities from finance activities 13.0 0.9 158.3 172.2 –3.4 –0.9 –10.0 –14.3 1.4 0.9 0.2 2.5 0.2 – – 0.2 11.2 0.9 148.5 160.6 RHÖN-KLINIKUM AG | Annual Report 2021 125

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Shareholdings in € ’000 8.2 Other companies according to section 313 (2) No. 2 et seq. HGB Interest held in % Result for the year Equity in € ’000 Other companies/shelf companies Energiezentrale Universitätsklinikum Gießen GmbH, Giessen Kinderhort Salzburger Leite gemeinnützige Gesellschaft mbH, Bad Neustadt a. d. Saale KLINIK “HAUS FRANKEN” GMBH Bad Neustadt/Saale i. L., Bad Neustadt a. d. Saale Marburger Ionenstrahl-Therapie Betriebs-Gesellschaft mbH, Bad Neustadt a. d. Saale Psychosomatische Klinik GmbH Bad Neustadt/Saale, Bad Neustadt a. d. Saale PTZ GmbH, Marburg RHÖN-KLINIKUM Energie für Gesundheit GmbH, Bad Neustadt a. d. Saale1 RHÖN-Innovations GmbH, Bad Neustadt a. d. Saale RK Klinik Betriebs GmbH Nr. 35 i. L., Bad Neustadt a. d. Saale Wolfgang Schaffer GmbH i. L., Bad Neustadt a. d. Saale 50.0 100.0 872 191 100.0 688 174 17 –6 100.0 –37,414 1,750 100.0 100.0 11 320 100.0 1,500 –8 –15 0 100.0 5,222 –241 100.0 100.0 107 555 –7 –7 1 The company claims the exemptions pursuant to section 264 (3) HGB from preparing notes and, to the extent required by law, from preparing a management report as well as disclosure. Interest held in % Result for the year Equity 4QD – Qualitätskliniken.de GmbH, Berlin1 20.0 283 –195 Bäderland Bayerische Rhön GmbH & Co. KG, Bad Kissingen1 CLEW Medical Inc., Delaware (USA)2 HOSPIZ MITTELHESSEN gemeinnützige GmbH, Wetzlar1 Inovytec Medical Solutions Ltd., Hod Hasharon (Israel)2 TipluBIKE GmbH, Hamburg (vormals: proDRG GmbH, Hamburg)1, 3 Projektanker GmbH, Hamburg1, 3 Robast Robic Assistant GmbH, Hamburg1, 3 Seniorenpflegeheim GmbH Bad Neustadt a. d. Saale, Bad Neustadt a. d. Saale1 Siebensachen GmbH, Hamburg1 Telesofia Medical Ltd., Tel Aviv (Israel)2 Tiplu GmbH, Hamburg Tiplu Schweiz AG, Zurich1, 3 0.1 8.8 9 1 2,073 –4,552 13.6 531 6 10.2 8,994 7,754 5.0 1.2 2.3 25.0 0.004 12.2 5.0 5.0 28 68 12 –1 o, A, o, A, 1,511 49 –114 4,756 –16 1,157 –163 2,010 o, A, o, A, 1 Figures according to annual financial statements of 31 December 2020. 2 Figures according to annual financial statements of 31 December 2020, converted at closing/ average exchange rate on 31 December 2021. 3 Equity interest of Tiplu GmbH, Hamburg. RHÖN-KLINIKUM AG | Annual Report 2021 127

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures 9.3 Leases within the Group Standard IFRS 16 defines a lease as a contract which conveys the right to use an asset for a period of time in exchange for consideration. Within the Group, the modified retroactive approach was applied. Numerous property leases contain renewal options. Investment property 9.3.2 The Group lets residential space to employees, office and commercial space to third parties (e.g. cafeteria), as well as premises to doctors cooperating with the hospital and to joint laboratories as part of cancellable operating leases. For leases with a term of twelve months maximum amounting to €0.1 million (previous year: €0.4 million) as well as for leases relating to low-value assets in the amount of €0.4 million (previous year: €0.2 million), no rights of use and no lease liabilities are recognised within the Group of RHÖN-KLINIKUM AG. The lease rates are rec- ognised as before within the income statement. Interest expenses from leases amounting to €0.2 million (previous year: €0.2 million) in financial year 2021. Further details on leases are provided in sections 6.2, 6.17 and 6.21.3. Obligations of lessees 9.3.1 Under leases, the Group mainly rents copier and printer systems as well as laboratory equipment. In the Group, there is a principle of always acquiring ownership of operating assets. in € million Liabilities from leases – minimum lease payments Due in subsequent year Due in 2 to 5 years Due in 5 years Future financing costs under leases Present value of liabilities under leases in € million Present value of liabilities under leases Due in subsequent year Due in 2 to 5 years Due in 5 years 2021 2020 3.1 6.5 0.9 10.5 –0.3 10.2 3.2 7.3 1.2 11.7 –0.5 11.2 2021 2020 3.1 7.1 – 10.2 3.1 8.1 – 11.2 RHÖN-KLINIKUM AG | Annual Report 2021 The most significant operating lease contracts by amount stem from the letting of property to third parties. The largest item in absolute terms is the letting of a property to a nursing home operator. Based on the provisions of IFRS 13.97, fair value is calculated for the assets to be stated according to IAS 40. The fair value determined in this regard cannot be observed on an active market nor can it be derived from a quoted market price and is thus classified to Level 3 of the fair value hierarchy of IFRS 13. The fair value is determined using a capitalised value approach in which the corresponding components of the income cost approach such as gross profit, expected return on land value and standard land value are used as input factors. On the basis of the capitalised value of potential earnings, no material differences between the fair value of the properties and their carrying amounts shown below are seen. For this reason, no external fair-value expertise was obtained. Depreciation is recognised on a straight-line basis over a useful life of 331/3 years. Since the lease agreement with the operator of a re- tirement and nursing home was terminated in the current financial year, the useful life was adjusted to the termination notice period. Rental income of €0.4 million (previous year: €0.4 million) was re- ceived for this in financial year 2021. Based on the higher deprecia- tion, the operating costs for the investment properties amounted to €1.0 million in the financial year (previous year: €0.2 million). These are accounted for entirely by properties with which rental income was generated. in € million Cost 1 Jan. Additions Disposals 31 Dec. Cumulative depreciation 1 Jan. Depreciation Disposals 31 Dec. Balance sheet value as at 31 Dec. 2021 2020 Total Total 5.0 0.0 0.0 5.0 2.8 0.9 0.0 3.7 1.3 5.0 0.0 0.0 5.0 2.6 0.2 0.0 2.8 2.2 129

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures The members of management in key positions as well as close family relatives are treated as related parties. The Board of Management of RHÖN-KLINIKUM AG, the members of the Supervisory Board, as well as the members of management in key positions of a parent company were included among the members of management in key positions. Direct and indirect parent companies are the companies specified under Note 1 “General information” as well as Dr Bernard große Broermann. In the year under review, members of the Supervisory Board of RHÖN-KLINIKUM AG, or companies and entities related with these as well as companies within the meaning of IAS 24, rendered the following services at arm’s length terms: in € '000 Related party Companies as defined by IAS 24 Nature of services Expenses 2021 2020 Dr Bernard große Broermann Asklepios-Kliniken Group of which Asklepios Kliniken GmbH & Co. KGaA Services, pharmacy services and medical products Services and medical products Prof. Dr Gerhard Ehninger (until 15 January 2021) AgenDix – Applied Genetic Diagnostics – Gesellschaft für angewandte molekulare Diagnostik mbH Laboratory services B. Braun Konzern (primarily B. Braun Melsungen AG and Aesculap AG) (until 3 July 2020) Peter Berghöfer Klaus Hanschur (until 19 August 2020) Hafid Rifi (from 19 August 2020) Marco Walker (from 9 March 2021) Regina Dickey (from 19 August 2020) Supervisory board activity at an affiliated company Purchase of medical products Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company Supervisory board activity at an affiliated company 4,027 2,127 1 – – 5 – 2 3 1 1,996 1,740 20 3 5,304 2 2 2 – – Eugen Münch Fee for services 656 193 As in the previous year, the expenses were recognised in the income statement under the materials and consumables item as well as the other expenses item. As in the previous year, no impairments were to be recognised in financial year 2021. RHÖN-KLINIKUM AG | Annual Report 2021 131

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures As at the balance sheet date of 31 December 2021, the following trade receivables existed: in Tsd. € Related party Companies as defined by IAS 24 Nature of services 2021 2020 Receivables Dr Bernard große Broermann Asklepios-Kliniken Group of which Asklepios Kliniken GmbH & Co. KGaA Services, pharmacy services and medical products Services and medical products Dr Stefan Stranz Services 283 0 1 81 0 – The employee representatives on the Supervisory Board employed at RHÖN-KLINIKUM AG or its subsidiaries received the following remuneration within the scope of their employment contracts in the past financial year: in € ’000 Peter Berghöfer Regina Dickey (from 19 August 2020) Peter Ducke (from 19 August 2020) Prof. (apl.) Dr med. Leopold Eberhart (from 19. August 2020) Stefan Härtel (until 19 August 2020) Klaus Hanschur (until 19 August 2020) Dr med. Martin Mandewirth (from 19 August 2020) PD Dr med Thomas Pillukat (from 19 August 2020) Oliver Salomon Evelin Schiebel (until 19 August 2020) Natascha Weihs (until 19 August 2020) Fixed Profit- linked Total 2021 201 47 37 192 – – 154 155 55 – – 841 10 1 1 0 – – 2 14 1 – – 29 211 48 38 192 – – 156 169 56 – – 870 The above costs are shown under employee benefit expenses in the income statement. RHÖN-KLINIKUM AG | Annual Report 2021 Total 2020 210 19 14 67 36 27 51 51 53 30 33 591 133

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures The total payments of the Board of Management break down as follows: in € ’000 Incumbent member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing Total payments/total remuneration 1 Remuneration granted and owed in financial year. in € ’000 Incumbent member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing Total payments Pension expense1 Total remuneration (chairman of Board of Management from 5 November 2020; member of Board of Management from 15 August 2020) Dr Christian Höftberger Remuneration earned in financial year Inflow1 2021 in % 2020 in % 2021 (min.) 2021 (max.) 2021 in % 2020 in % 500 9 509 158 666 75 1 76 24 100 188 21 209 94 303 62 7 69 31 100 500 9 509 0 509 500 9 509 250 759 500 9 509 94 603 83 1 84 16 100 188 21 209 0 209 90 10 100 0 100 Prof. Dr Bernd Griewing (member of Board of Management) Remuneration earned in financial year Inflow2 2021 in % 2020 in % 2021 (min.) 2021 (max.) 2021 in % 2020 in % 192 12 204 1,008 1,212 159 1,371 14 1 15 74 88 12 192 12 204 1,008 1,212 165 14 1 15 73 88 12 192 12 204 1,008 1,212 159 192 12 204 1,308 1,512 159 192 12 204 1,008 1,212 0 16 1 17 83 100 0 192 12 204 1,008 1,212 0 100 1,377 100 1,371 1,671 1,212 100 1,212 16 1 17 83 100 0 100 1 Pension expenditure includes past service cost according to IAS 19. 2 Remuneration granted and owed in financial year. RHÖN-KLINIKUM AG | Annual Report 2021 135

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures in € ’000 Former member of Board of Management Base salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Management profit sharing Total payments Pension expense1 Severance payments Total remuneration (chairman of Board of Management until 16 June 2020; member of Board of Management until 22 June 2020; service relationship until 30 September 2020) Stephan Holzinger Remuneration earned in financial year Inflow2 2021 in % 2020 in % 2021 (min.) 2021 (max.) 2021 in % 2020 in % 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,350 8 1,358 0 1,358 63 1,872 3,293 41 0 41 0 41 2 57 100 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1,350 8 1,358 0 1,358 825 1,872 4,055 33 0 33 0 33 20 46 100 1 Pension expenditure includes past service cost according to IAS 19. 2 Remuneration granted and owed in financial year. RHÖN-KLINIKUM AG | Annual Report 2021 137

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Other disclosures 9.6 Declaration of Compliance with the German Corporate Governance Code By joint resolution of the Supervisory Board and the Board of Management of RHÖN-KLINIKUM AG of 10 November 2021, the Company made the declaration pursuant to section 161 of the German Stock Corporation Act (AktG) regarding the application of the German Corporate Governance Code in financial year 2021. These have been published on the website of RHÖN-KLINIKUM AG and thus made available to the general public. 9.7 Disclosure of the fees recognised as expenses (including reimbursement of outlays and excluding VAT) for the statutory auditors In financial year 2021, expenses resulting from fees for statutory au- ditors amounting to €0.8 million (previous year: €1.3 million) were incurred Group-wide. A breakdown of these fees (including outlays and excluding VAT) by service rendered is provided below: 9.8 Events after the reporting date On 14 January 2022, the Board of Management of RHÖN-KLINIKUM AG and the management body of Universitätsklinikum Gießen und Marburg GmbH (UKGM) decided to sign a Letter of Intent of the Federal State of Hesse with regard to the grant of investment fund- ing for UKGM. In this Declaration of Intent, the Federal State of Hesse offered the prospect of investment funding for UKGM of up to €45 million per year for a period of ten years, to be increased over the term in the first five years by 1.5% p. a. and in the five years after that by 2.5% p.a. The prospective investment funding offered can cover part of the investment that will be needed to maintain the university hospital structures. Continuation of the existing separate accounting scheme is also planned. At the same time, the Declaration of Intent provides for numerous provisions on further matters, including an obligation to reinvest prof- its of UKGM during this period, provisions in the event of a change in control, as well as a prohibition on outsourcing and the exclusion of redundancies. in € ’000 Fees for auditing financial statements Fees for other statutory auditing services Fees for tax advice Fees for other services 2021 2020 617 200 5 3 825 749 250 13 270 1,282 All provisions stipulated in the Letter of Intent are subject to the con- dition of a legally binding agreement being entered into between RHÖN-KLINIKUM AG, Asklepios Kliniken GmbH & Co. KGaA, Universi- tätsklinikum Gießen und Marburg GmbH, the Federal State of Hesse and the Universities of Giessen and Marburg with their faculties of medicine. The conclusion of this agreement is moreover subject to the condition precedent of the required funds being approved by the budgetary legislator of the Federal State of Hesse. The fees for the other statutory auditing services essentially cover certificates for hospital legislation purposes as well as for review of the separate non-financial report. The tax advisory services include fees for support services in the preparation of tax declarations and in the assessment of tax matters. Other services relate to fees for project-related advisory services. Of the total fee (excluding VAT), no fees are attributable to other statutory auditors who are not auditors of the consolidated financial statements. The previous year’s statement relates to the fees for the activity of the statutory auditor PricewaterhouseCoopers GmbH up to and including 2020. In addition, we draw attention to one change in the Supervisory Board after the end of financial year 2021: Ms. Nicole Mooljee Damani no- tified the Company in December 2021 that she was resigning her man- date as member of the Supervisory Board of the Company. She thus left the Supervisory Board on 8 January 2022. The Supervisory Board therefore resolved already in January 2022 on the recommendation of the Nomination Committee to propose Dr Cornelia Süfke, head of the Medical Law, Insurance and Compliance division of Asklepios Kliniken GmbH und Co. KGaA, Hamburg, for the election to be held at the 2022 Annual General Meeting, to succeed Nicole Mooljee Damani as member of the Supervisory Board of RHÖN-KLINIKUM AG for the remaining term of office. The application of the Board of Management of the Company to the Local Court of Schweinfurt was made on 3 February 2022. RHÖN-KLINIKUM AG | Annual Report 2021 139

CONSOLIDATED FINANCIAL STATEMENTS | Notes | Corporate bodies of RHÖN-KLINIKUM AG Irmtraut Gürkan Alsbach, Dipl.-Volkswirtin (economist) PD Dr med. Thomas Pillukat Bad Neustadt a. d. Saale, MD Also a member of the Supervisory Board of: – Charité Universitätsmedizin Berlin, Berlin Christine Reißner Sülzfeld, merchant Other mandates: – Eurotransplant International Foundation, Leiden, Netherlands (Member of the Supervisory Board) – Stiftung Alice-Hospital vom Roten Kreuz zu Darmstadt, Oliver Salomon Bad Berka, nurse Marco Walker Business address at Hamburg, Chief Operating Officer of Asklepios Kliniken GmbH & Co. KGaA Also a member of the Supervisory Board of: – MEDICLIN Aktiengesellschaft, Offenburg – Meierhofer Aktiengesellschaft, Munich – Universitätsklinikum Gießen und Marburg GmbH, Giessen Darmstadt (Member of the Board of Trustees) – Universitätsspital Basel, Basel, Switzerland (Member of the Board of Directors) – Georg-August-Universität Göttingen, Göttingen (member of the Foundation Council) – Universitätsmedizin Göttingen, Göttingen (deputy chairman of the Foundation Committee) – Biolife Germany AG, Heidelberg Kai Hankeln Business address at Hamburg, Chief Executive Officer of Asklepios Kliniken GmbH & Co. KGaA Also a member of the Supervisory Board of: – Asklepios Fachklinikum Stadtroda GmbH, Stadtroda (Chairman of the Supervisory Board) – MEDICLIN Aktiengesellschaft, Offenburg Dr med. Martin Mandewirth Oberelsbach, Facharzt für Herzchirurgie (MD, specialist in heart surgery) RHÖN-KLINIKUM AG | Annual Report 2021 141

CONSOLIDATED FINANCIAL STATEMENTS | Responsibility statement Responsibility statement We assure to the best of our knowledge that based on the account- ing principles to be applied the Consolidated Financial Statements of RHÖN-KLINIKUM AG give a true and fair view of the net assets, financial position and results of operations of the Group and that the Group Management Report presents the business performance including the business results and the situation of the Group in such a way as to give a true and fair view of the same as well as a description of the material risks and opportunities involved in the probable development of the Group of RHÖN-KLINIKUM AG. Bad Neustadt a. d. Saale, 4 March 2022 RHÖN-KLINIKUM Aktiengesellschaft THE BOARD OF MANAGEMENT Prof. Dr Bernd Griewing Dr Christian Höftberger Dr Stefan Stranz Dr Gunther K. Weiß RHÖN-KLINIKUM AG | Annual Report 2021 143

CONSOLIDATED FINANCIAL STATEMENTS | Independent auditor’s report Please refer to Section 3.2 in the notes to the consolidated financial statements for information on the accounting policies applied. RISK FOR THE FINANCIAL STATEMENTS EUR 1,402.0 million of the revenue recognised in the Company’s consolidated financial statements mainly relate to hospital services. As at the reporting date, for settlement reasons revenue is based on a series of management assumptions which involve estimate uncer- tainties. As the budget negotiations relevant for performance often take place towards the end of the financial year, the remunerated service volumes are estimates as at the reporting date. Also at the reporting date, management estimates a revenue adjustment on the change rate (case deductions) implemented by the Medizinischer Dienst [German Medical Service]. The estimated impact of the mea- sures decreed by the legislator due to the coronavirus SARS CoV-2 pandemic results in estimate uncertainties for revenue. Due to the complexity of the judgements described, there is the risk for the consolidated financial statements that revenue cannot be appropriately assigned to the relevant reporting period. There is also the risk that the support payments received during the year as a result of the coronavirus SARS CoV-2 pandemic are recognised in revenue at an inappropriately high level. OUR AUDIT APPROACH In order to evaluate the appropriateness of the revenue recognised as at the reporting date, we gave consideration to the established Company processes to recognise revenue from hospital services performed and the revenue adjustments required and verified the methodological approach of the management in making the rev- enue adjustments. To audit the appropriate accrual of revenue, we examined the design, establishment and effectiveness of the internal controls in respect to case processing (dual control principle). Based on our audit, on the basis of a risk-based selective sample which included the contractual documentation presented to us and other correspondence, we obtained an overview relating to the status of the various budget agreements of the hospitals in the RHÖN-KLINIKUM Group on the reporting date and the respective re- munerated service volumes. For the budget negotiations which had not been concluded as at the reporting date, we gave consideration to the appropriateness of the estimates on the budget recognition, on the costs relevant to the care budget and on the revenue set- tlement. We also validated the management assumptions on the service volumes to be remunerated as at the reporting date on the basis of the detailed information we were provided. In order to assess the estimation accuracy, we compared the revenue corrections with the results of the negotiations with the health insurance companies from previous years (taking into account the transition to outsourced diagnosis related groups). In respect to the revenue settlement, in addition to the reconciliations in the context of the revenue vali- dation on the basis of the performance statistics provided by the patient management system and the underlying agreements, we also examined the process for calculating the revenue settlement including the costs relevant to the care budget. In doing so, we also validated the implementation of the legal regulations. In reference to possible adjustments by the Medizinischer Dienst [German Medical Service], we gave consideration to the process for determining the service quantities (coding system) and for deter- mining the relevant adjustments and assessed the appropriateness of the estimates on revenue adjustments as a result of audits by the Medizinischer Dienst [German Medical Service]. We also assessed the management assumptions and the account- ing-related documentation for the level and timing of the amounts from compensation payments recognised as a result of the coronavi- rus SARS CoV-2 and assessed the estimate uncertainties in reference to the compensation methodology. OUR CONCLUSIONS The assumptions underlying revenue recognition are appropriate. – Recoverability of goodwill Please refer to Section 2.4. 1 in the notes to the consolidated financial statements for information on the accounting policies applied and the assumptions used. Disclosures on the amount of goodwill can be found in Section 6.1 of the notes to the consolidated financial statements. RHÖN-KLINIKUM AG | Annual Report 2021 145

CONSOLIDATED FINANCIAL STATEMENTS | Independent auditor’s report Other information Management respectively Supervisory Board are responsible for the other information. The other information comprises the following components of the group management report, whose content was not audited: – The combined non-financial declaration of the Company and the Group, referred to in the management report, in line with Section 289b (3) and Section 315d HGB and, – The group governance statement referred to in the manage- ment report, The other information also includes the remaining parts of the annual report. The other information does not include the consolidated financial statements, the group management report information audited for content and our auditor’s report thereon. In preparing the consolidated financial statements, management is responsible for assessing the Group’s ability to continue as a going concern. They also have the responsibility for disclosing, as applicable, matters related to going concern. In addition, they are responsible for financial reporting based on the going concern basis of accounting unless there is an intention to liquidate the Group or to cease oper- ations, or there is no realistic alternative but to do so. Furthermore, management is responsible for the preparation of the group management report that, as a whole, provides an appropriate view of the Group’s position and is, in all material respects, consistent with the consolidated financial statements, complies with German legal requirements, and appropriately presents the opportunities and risks of future development. In addition, management is responsible for such arrangements and measures (systems) as they have consid- ered necessary to enable the preparation of a group management report that is in accordance with the applicable German legal require- ments, and to be able to provide sufficient appropriate evidence for the assertions in the group management report. Our opinions on the consolidated financial statements and on the group management report do not cover the other information, and consequently we do not express an opinion or any other form of assurance conclusion thereon. The supervisory board is responsible for overseeing the Group’s finan- cial reporting process for the preparation of the consolidated financial statements and of the group management report. In connection with our audit, our responsibility is to read the other in- formation and, in so doing, to consider whether the other information – is materially inconsistent with the consolidated financial state- ments, with the group management report information audited for content or our knowledge obtained in the audit, or – otherwise appears to be materially misstated. Responsibilities of management and the Supervisory Board for the consolidated financial statements and the group management report Management is responsible for the preparation of the consolidated financial statements that comply, in all material respects, with IFRSs as adopted by the EU and the additional requirements of German com- mercial law pursuant to Section 315e (1) HGB and that the consoli- dated financial statements, in compliance with these requirements, give a true and fair view of the assets, liabilities, financial position, and financial performance of the Group. In addition, management is re- sponsible for such internal control as they have determined necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error. Auditor’s responsibilities for the audit of the consolidated financial statements and of the group management report Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and whether the group management report as a whole provides an appropriate view of the Group’s position and, in all material respects, is consistent with the consolidated financial statements and the knowledge obtained in the audit, complies with the German legal requirements and appropriate- ly presents the opportunities and risks of future development, as well as to issue an auditor’s report that includes our opinions on the con- solidated financial statements and on the group management report. Reasonable assurance is a high level of assurance, but is not a guaran- tee that an audit conducted in accordance with Section 317 HGB and the EU Audit Regulation and in compliance with German Generally Accepted Standards for Financial Statement Audits promulgated by the Institut der Wirtschaftsprüfer (IDW) will always detect a material misstatement. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements and this group management report. RHÖN-KLINIKUM AG | Annual Report 2021 147

CONSOLIDATED FINANCIAL STATEMENTS | Independent auditor’s report We conducted our assurance work on the reproduction of the con- solidated financial statements and of the group management report contained in the above-mentioned electronic file in accordance with Section 317 (3a) HGB and the IDW Assurance Standard: Assurance Work on the Electronic Reproduction of Financial Statements and Management Reports Prepared for Publication Purposes in Accor- dance with Section 317 (3a) HGB (IDW AsS 410 (10.2021)). Accordingly, our responsibilities are further described below. Our audit firm has applied the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QS 1). The Company’s management is responsible for the preparation of the ESEF documents including the electronic reproduction of the consolidated financial statements and the group management report in accordance with Section 328 (1) sentence 4 item 1 HGB and for the tagging of the consolidated financial statements in accordance with Section 328 (1) sentence 4 item 2 HGB. In addition, the Company’s management is responsible for the inter- nal control they consider necessary to enable the preparation of ESEF documents that are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB for the electronic reporting format. The Supervisory Board is responsible for overseeing the preparation the ESEF documents as part of the financial reporting process. Our objective is to obtain reasonable assurance about whether the ESEF documents are free from material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB. We exercise professional judgement and maintain professional scepticism throughout the assurance work. We also: – Identify and assess the risks of material intentional or unintentional non-compliance with the requirements of Section 328 (1) HGB, design and perform assurance procedures responsive to those risks, and obtain assurance evidence that is sufficient and appro- priate to provide a basis for our assurance opinion. We provide those charged with governance with a statement that we have complied with the relevant independence requirements, and communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and the safeguards put in place to protect against this. From the matters communicated with those charged with gover- nance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor’s report unless laws or regulation precludes public disclosure about the matter. Other legal and regulatory requirements Report on the assurance in accordance with Section 317 (3a) HGB on the electronic reproduction of the consolidated financial statements and the group management report prepared for publication purposes We have performed assurance work in accordance with Section 317 (3a) HGB to obtain reasonable assurance about whether the reproduc- tion of the consolidated financial statements and the group manage- ment report (hereinafter the “ESEF documents”) contained in the elec- tronic file „RhoenKlinikumAG-2021-12-31-de.zip“ (SHA256 hash value: be1e2d5706ca228d25533297de0c2e28bcb4ca0b3e51f447385d01f- 2c8787a06) made available and prepared for publication purposes complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format (“ESEF format”). In accordance with German legal requirements, this assurance work extends only to the conversion of the information contained in the consolidated financial statements and the group management report into the ESEF format and therefore relates neither to the information contained in this reproduction nor to any other information con- tained in the above-mentioned electronic file. In our opinion, the reproduction of the consolidated financial statements and the group management report contained in the above-mentioned electronic file and prepared for publication pur- poses complies in all material respects with the requirements of Section 328 (1) HGB for the electronic reporting format. We do not express any opinion on the information contained in this reproduc- tion nor on any other information contained in the above-mentioned file beyond this reasonable assurance opinion and our audit opinion on the accompanying consolidated financial statements and the ac- companying group management report for the financial year from 1 January to 31 December 2021 contained in the “Report on the audit of the consolidated financial statements and the group management report” above. RHÖN-KLINIKUM AG | Annual Report 2021 149

SUMMARY REPORT OF RHÖN-KLINIKUM AG | Balance sheet and income statement Balance sheet and income statement BALANCE SHEET INCOME STATEMENT in € million in € million 31 Dec. 2021 31 Dec. 2020 2021 2020 Assets Intangible assets Property, plant and equipment Financial assets Fixed assets Inventories Receivables and other assets Securities, cash and cash equivalents Current assets Prepaid expenses Deferred tax assets 8.8 283.0 602.9 894.7 7.0 119.7 258.6 385.3 2.0 7.6 Revenues Changes in services in progress Other operating income Materials and consumables used Employee benefits expense Depreciation Other operating expenses Operating result Investment result Finance result Taxes 8.0 285.6 617.1 910.7 6.8 106.6 228.3 341.7 2.1 7.6 1,289.6 1,262.1 Net profit for the year/net loss Profit carried forward from previous year Net distributable profit 282.3 0.2 8.8 93.0 152.0 22.9 35.8 –12.4 5.3 6.0 –8.7 7.6 193.2 200.8 273.3 –1.2 8.5 92.1 149.1 22.5 39.1 –22.2 6.2 3.0 –2.7 –10.3 203.5 193.2 in € million 31 Dec. 2021 31 Dec. 2020 Shareholders’ equity and liabilities Subscribed capital/issued capital Capital reserve Retained earnings Net distributable profit Shareholders’ equity Contribution to finance fixed assets Provisions Liabilities 167.4 589.0 0.1 200.8 957.3 11.0 48.8 272.5 167.4 589.0 0.1 193.2 949.7 12.4 58.8 241.2 1,289.6 1,262.1 The annual financial statements as at 31 December 2021 and the Management Report for financial year 2021 of RHÖN-KLINIKUM Aktiengesellschaft were issued by KPMG AG Wirtschaftsprüfungs- gesellschaft with an unqualified auditor’s report. They are published in the Federal Gazette. The annual financial report can be obtained from the Company on request. RHÖN-KLINIKUM AG | Annual Report 2021 151

FURTHER INFORMATION | Limited Assurance Report of the Independent Auditor regarding the combined separate non-financial report Limited Assurance Report OF THE INDEPENDENT AUDITOR REGARDING THE COMBINED SEPARATE NON-FINANCIAL REPORT1 To the Supervisory Board of RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale We have performed an independent limited assurance engagement on the combined separate non-financial report as well as the by reference qualified part “Basic Characteristics of the RHÖN-KLINIKUM Group” of RHÖN-KLINIKUM Aktiengesellschaft, Bad Neustadt a. d. Saale, (further “Company” or “RHÖN-KLINIKUM”), which consists of the sections of the Corporate-Social-Responsibility-Report (further “combined separate non-financial report”) marked with a tick (√) for the period from January 1 to December 31, 2021. Management’s Responsibility The legal representatives of the Company are responsible for the preparation of the combined separate non-financial report in accordance with §§ 315b, 315c in conjunction with 289b to 289e HGB and with Article 8 of REGULATION (EU) 2020/852 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 18 June 2020 on the establishment of a framework to facilitate sustainable invest- ment, and amending Regulation (EU) 2019/2088 (further “EU Tax- onomy Regulation“) and the supplementing Delegated Acts as well as the interpretation of the wordings and terms contained in the EU Taxonomy Regulation and in the supplementing Delegated Acts by the Company as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. This responsibility of the legal representatives includes the selection and application of appropriate methods to prepare the combined separate non-financial report and the use of assumptions and estimates for individual disclosures which are reasonable under the given circumstances. Furthermore, the legal representatives are responsible for the internal controls they deem necessary for the preparation of the combined separate non-financial report that is free of – intended or unintended – material misstatements. The EU Taxonomy Regulation and the supplementing Delegated Acts contain wordings and terms that are still subject to substantial uncertainties regarding their interpretation and for which not all clarifications have been published yet. Therefore, the legal represen- tatives have included a description of their interpretation in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. They are responsible for its tenability. Due to the innate risk of diverging interpretations of vague legal concepts, the legal conformity of these interpretations is subject to uncertainty. Practitioner’s Responsibility It is our responsibility to express a conclusion on the combined separate non-financial report based on our work performed within a limited assurance engagement. We conducted our work in the form of a limited assurance engage- ment in accordance with the International Standard on Assurance Engagements (ISAE) 3000 (Revised): “Assurance Engagements other than Audits or Reviews of Historical Financial Information”, published by IAASB. Accordingly, we have to plan and perform the assurance engagement in such a way that we obtain limited assurance as to whether any matters have come to our attention that cause us to believe that the combined separate non-financial report of the Company for the period from January 1 to December 31, 2021 has not been prepared, in all material respects, in accordance with §§ 315b and 315c in conjunction with 289b to 289e HGB and with the EU Taxonomy Regulation and the supplementing Delegated Acts as well as the interpretation of the wordings and terms con- tained in the EU Taxonomy Regulation and in the supplementing Delegated Acts by the legal representatives as disclosed in Section “Reporting according to EU taxonomy” of the combined separate non-financial report. We do not, however, issue a separate conclu- sion for each disclosure. As the assurance procedures performed in a limited assurance engage ment are less comprehensive than in a reasonable assurance engagement, the level of assurance obtained is substantially lower. The choice of assurance procedures is subject to the auditor’s own judgement. 1 Our engagement applied to the German version of the combined separate non-financial report. This text is a translation of the Independent Assurance Report issued in German, whereas the German text is authoritative. RHÖN-KLINIKUM AG | Annual Report 2021 153

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG A | Introduction Fixed remuneration Performance-linked annual management profit-sharing bonus (tantieme) a) Determination and application of performance criteria b) No recovery of variable remuneration components Fringe benefits Post-retirement benefits Total target remuneration or remuneration caps Benefits in the event of early termination of Board of Management activity B | Remuneration of the Board of Management Structure of remuneration of the Board of Management in financial year 2021 1. 2. 3. 4. 5. 6. Individual remuneration of members of the Board of Management 1. 2. Overview of post-retirement benefits 3. Additional disclosures Level of remuneration of members of the Board of Management for financial year 2021 I. II. C | Remuneration of the Supervisory Board Remuneration of the Supervisory Board according to the Articles of Association Individual remuneration of members of the Supervisory Board for financial year 2021 and in comparison with the 2020 financial year I. II. D | Comparative presentation 156 156 156 157 157 157 158 158 158 158 159 159 159 163 163 163 163 165 168 RHÖN-KLINIKUM AG | Annual Report 2021 155

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG 1. Fixed remuneration The annual basic salary is a fixed cash remuneration with reference to the full year and paid in twelve equal monthly instalments. achievement of targets for the past financial year, the Supervisory Board reserves the right to decide on performance criteria for the new financial year at the beginning of such financial year. The fixed remuneration is to guarantee a basic market remuneration for exercising the office and in this way ensure that the Company is able to attract the best-qualified candidates to implement its corpor- ate strategy and manage the Company. 2. Performance-linked annual management profit-sharing bonus (tantieme) The members of the Board of Management receive a perfor- mance-linked annual management profit-sharing bonus (tantieme) based on an annual target agreement to be entered into each year. The Supervisory Board and the members of the Board of Manage- ment renegotiate the criteria for the amount of the tantieme to be paid for each financial year before or at the commencement of such financial year. In the event the negotiations fail, the Supervisory Board is entitled to define the criteria according to its reasonably exercised discretion (section 315 of the German Civil Code (Bürger- liches Gesetzbuch – BGB)). The amount of the annual management profit-sharing bonus (tanti- eme) is defined after expiry of the reference period. The Supervisory Board and the members of the Board of Management try to reach agreement on the extent to which the non-financial targets are to be achieved. If no agreement can be reached, it is defined by the Supervisory Board according to its reasonably exercised discretion. The payment is made as a one-off payment at the earliest after the corresponding values have been calculated for the reference period. When agreeing the performance criteria for the variable remuner- ation, the Supervisory Board ensures that the financial and non- financial targets will promote the business strategy and make a contribution towards a long-term development of the Company. If consolidated profit or EBITDA (earnings before interest, taxes, depreci- ation and amortisation) pursuant to IFRS consolidated financial state- ments is defined as the performance criterion, this provides incentives to strengthen the Company’s operative earnings strength. The non-fi- nancial criteria are oriented on strategic targets in the interest of a sustainable corporate development. In this regard the Supervisory Board takes into account the strategic focus issues for the respective remuneration year. For these reasons the Supervisory Board did not see any need to provide for further abstract requirements for defining long-term-ori- ented targets and their relationship to short-term-oriented targets, nor to provide for a share-based variable remuneration, in order to implement the remuneration scheme of the Board of Management. Lastly, based on the specific terms of the variable remuneration there is also no reason in the view of the Supervisory Board to provide for rights of retention or recovery. To enable the Supervisory Board to take a comprehensive decision in connection with defining the The Old Contracts with Prof. Dr Griewing and Dr Weiß applying to financial year 2021 contain deviating provisions on (partial) variable remuneration components. The Board of Management contracts entered into in 2020 with Dr Höftberger and Dr Stranz as well as the follow-on service contract entered into with Dr Weiß for the period beginning from 1 January 2022 in terms of their variable remunera- tion components are in line with the remuneration scheme adopted by the Supervisory Board in March 2021. a) Determination and application of performance criteria The Board of Management contracts of Dr Höftberger and Dr Stranz, on the one hand, and of Dr Weiß and Prof. Dr Griewing, on the other, differ in terms of the form of variable remuneration. The Board of Management contracts of Dr Höftberger and Dr Stranz provide that both are entitled to receive a performance-linked annual management profit-sharing bonus (tantieme) based on a target agreement to be entered into each year. This totals a maxi- mum amount of €250,000 in each case. In this regard, 50% of the performance criteria is made up of financial targets (Tranche 1) and 50% of non-financial targets (Tranche 2). For the financial targets of Tranche 1, the achievement of targets is measured in each case using a range with reference to EBITDA of the consolidated finan- cial statements of RHÖN-KLINIKUM Aktiengesellschaft according to IFRS. For the non-financial targets of Tranche 2, five equally weighted sub-targets were agreed by the Supervisory Board for 2021 which for both Management Board members relate to sustainably improving processes and the quality of the hospitals, streamlining processes and group structures, reducing the workload of employees, and thus overall increasing the satisfaction of patients and employees. For Dr Höftberger, the Supervisory Board resolved in March 2022 with respect to the target achievement for financial year 2021 that Tranche 1 in the amount of €32,500 and Tranche 2 in the amount of €125,000 are earned. For financial year 2021 this results in a management prof- it-sharing bonus (tantieme) in the total amount of €157,500. For Dr Stranz, the Supervisory Board resolved in March 2022 with respect to the target achievement for financial year 2021 that Tranche 1 in the amount of €32,500 and Tranche 2 in the amount of €125,000 are earned. For financial year 2021 this results in a management profit-sharing bonus (tantieme) in the total amount of €157,500. The Old Contracts of Prof. Dr Griewing and Dr Weiß provide that the annual management profit-sharing bonuses are calculated on the basis of a weighted view of consolidated profit according to IFRS over a period of three years, with the Supervisory Board being entit- led to adjust the assessment basis to take account of extraordinary developments and results as well as one-off or accounting effects. RHÖN-KLINIKUM AG | Annual Report 2021 157

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG fits) – irrespective of whether it is paid out in this financial year or at a later time – is limited for the individual members of the Board of Management to a maximum amount (“maximum remuneration”). The contractual maximum remuneration for the annual basic salary and the variable remuneration amounts to €750,000.00 (plus fringe benefits such as company car and personal accident insurance) for Dr Höftberger and Dr Stranz, respectively. of Management. At the most, however, the member of the Board of Management shall receive payments equal to double an annual remuneration (basic salary and tantieme). In this regard, the amount of the annual remuneration of the financial year ending before the termination, or of the financial year under way upon termination, is to be applied, whichever annual remuneration is lower. The maturity of the payments is governed by the maturity that would apply if the service contract had been continued. For Prof. Dr Griewing, the maximum amount made up of annual basic salary plus variable remuneration on the basis of the Old Contract entered into before the Board of Management remuneration scheme was adopted in March 2021 is €1,500,000.00 (likewise plus fringe ben- efits such as company car and personal accident insurance as well as the post-retirement benefits described below). For Dr Weiß, the maximum amount made up of annual basic salary plus variable remuneration on the basis of the Old Contract valid until 31 December 2021 is €1,500,000.00; as of 1 January 2022, the maximum remuneration also in the case of Dr Weiß based on the concluded follow-on service contract amounts to €750,000.00 (like- wise plus fringe benefits such as company car and personal accident insurance as well as the post-retirement benefits described below). In addition, Prof. Dr Griewing and Dr Weiß receive what are referred to as post-retirement benefits. The expense of such post-retirement benefits (service costs) in the case of Prof. Dr Griewing amounts to 12.5% of the relevant annual payments, in the case of Dr Weiß up to 31 December 2021 likewise 12.5% of the annual payments relevant up to that time and then from 1 January 2022 12.5% of the aforemen- tioned annual basic salary plus variable remuneration. The contractual remuneration caps for financial year 2021 were ob- served. Since all contracts with the currently incumbent members of the Board of Management were entered into before the Board of Manage- ment remuneration scheme was adopted by the Supervisory Board in March 2021, these contracts currently do not provide for any explicit maximum amount for the fringe benefits described above. 6. Benefits in the event of early termination of Board of Management activity If a member of the Board of Management is removed before expiry of the appointment period, the service contract remains in force. In the event of early removal, the member of the Board of Management is entitled to terminate the service contract on two weeks' notice for the end of the month following the removal. In such case he is entit- led to 80% of the total remuneration (basic salary and management profit-sharing bonus (tantieme)) which he still would have received in the event of his contract having been continued to its end in accor- dance with the contractual provisions, unless the removal was validly effected for good cause attributable to the member of the Board If the member of the Board of Management resigns his Board of Man- agement mandate, the remuneration claim under the service con- tract ends at the same time. If the resignation is submitted for good cause, however, the member of the Board of Management receives the aforementioned payments as in the case of a self-termination after removal without good cause, unless at the same time a good cause for a removal or for a termination of the service contract by the Company exists. II. Individual remuneration of members of the Board of Management 1. Level of remuneration of members of the Board of Management for financial year 2021 This section presents an individualised statement of the remunera- tion “granted and owed” to the incumbent members of the Board of Management within the meaning of section 162 (2) sentence 1 of the German Stock Corporation Act (AktG). These terms were included in the German Stock Corporation Act on entry into force of the Act Implementing the Second Shareholder Rights Directive (ARUG II) and thus replace the remuneration definitions of the GCGC (old version) used hitherto. In which Remuneration Report a remuneration component pursuant to section 162 (1) sentence 2 no. 1 AktG is to be stated depends on whether it is granted or owed in the financial year for which the Remuneration Report is prepared. Since section 162 AktG does not tie remuneration reporting to the existence of an expense, reporting is not to be based on an expense recognition approach. The legislation wording does not state whether or under what con- ditions a remuneration component is “granted”. According to the leg- islative materials, a remuneration is granted and thus, pursuant to section 162 (1) sentence 2 no. 1 AktG, to be disclosed, if it effectively, i.e. actually, accrues to the director or officer and thus accrues to the latter’s assets, irrespective of whether the accrual takes place to fulfil an obligation or without a legal reason. Accordingly, a remuneration pursuant to section 162 (1) sentence 2 no. 1 AktG is to be disclosed in the Remuneration Report (only) for the financial year in which it actually accrues. This is largely consistent with the accrual principle of the GCGC (old version). By contrast, a remuneration is “owed” if the company has a legal- ly existing obligation towards the director or officer which is due RHÖN-KLINIKUM AG | Annual Report 2021 159

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG in € ’000 Incumbent member of Board of Management Basic salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Tantieme Total payments/total remuneration 1 Remuneration granted and owed in financial year. in € ’000 Incumbent member of Board of Management (member of Board of Management from 1 September 2020) Dr Stefan Stranz Remuneration earned in financial year Accrual1 2021 in % 2020 in % 2021 (min.) 2021 (max.) 2021 in % 2020 in % 500 43 543 158 700 71 6 78 22 100 167 14 181 83 264 63 5 69 31 100 500 43 543 0 543 500 43 543 250 793 500 43 543 83 626 80 7 87 13 100 167 14 181 0 181 92 8 100 0 100 Dr Gunther K. Weiß (member of Board of Management) Remuneration earned in financial year Accrual2 2021 in % 2020 in % 2021 (min.) 2021 (max.) 2021 in % 2020 in % Basic salary (fixed remuneration) Fringe benefits Total One-year variable remuneration Tantieme Total payments/total remuneration Post-retirement expense1 Total remuneration 192 17 209 708 917 114 19 2 20 69 89 11 192 17 209 708 917 130 18 2 20 68 88 12 192 17 209 708 917 114 192 17 209 1,308 1,517 114 1,031 100 1,047 100 1,031 1,631 192 17 209 708 917 0 917 21 2 23 77 100 0 100 192 17 209 708 917 0 917 21 2 23 77 100 0 100 1 Post-retirement expense includes past service cost according to IAS 19. 2 Remuneration granted and owed in financial year. RHÖN-KLINIKUM AG | Annual Report 2021 161

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG 2. Overview of post-retirement benefits The table below provides an overview of the commitments to the payment of benefits made to Prof. Dr Griewing and Dr Weiß in the event of termination of their activity, notably at their present value and the amount spent or provisions made for this by the Company during the last financial year: in € ’000 Post-retirement benefits Incumbent members of Board of Management Prof. Dr Bernd Griewing Dr Gunther K. Weiß Total Provision as at 31 Dec. 2020 Change in post-retire- ment benefits Provision as at 31 Dec. 2021 808 306 1,114 128 123 251 936 429 1,365 Nominal amount on expiry of contract 1 1,350 694 2,044 1 Claim according to scheduled expiry of Board of Management contract of incumbent members of Board of Management on the basis of payments received. 3. Additional disclosures If individual members of the Board of Management exercise man- dates in affiliates of the Company and receive separate remuneration for this, they are required to pay such remuneration amounts to the Company. C. REMUNERATION OF THE SUPERVISORY BOARD The remuneration of the Supervisory Board is governed by section 14 of the Company’s Articles of Association and was confirmed by the Annual General Meeting on 9 June 2021. The task of the Supervisory Board is to advise and supervise the Board of Management as it directs the Company under its own responsibility and manages its business activities. The members of the Supervisory Board are entitled to a reasonable remuneration taking into consider- ation, in terms of both its structure and amount, the requirements of the Supervisory Board office, the time commitment involved as well as the responsibility assumed by the Supervisory Board members for the Company. The remuneration of the Supervisory Board in this context – in addition to the attendance fee and reimbursement for outlays – consists of a purely fixed remuneration. The independence of the remuneration of the Supervisory Board from results-based key ratios is to ensure that the members of the Supervisory Board per- form their duties in a neutral and objective manner. The grant of a purely fixed remuneration is consistent with Recommendation G.18 Sentence 1 GCGC. I. Remuneration of the Supervisory Board according to the Articles of Association Section 14 of the Articles of Association contains the following provi- sions on the remuneration of the members of the Supervisory Board: Each member of the Supervisory Board shall receive a fixed annual remuneration in the amount of €25,000.00. For the work in the committees of the Supervisory Board, the mem- bers of the Supervisory Board shall additionally receive remuneration as follows: – the chairman of the Audit Committee €25,000.00, each other member of the Audit Committee €5,000.00; – the chairman of another committee €10,000.00, each other member of another committee €2,500.00 if such other commit- tee in each case has acted at least once during the financial year. Membership on the Nomination Committee and on committees formed on an ad hoc basis shall not be taken into consideration. If a member of the Supervisory Board exercises more than one office simultaneously, that member shall receive only the remuneration for the highest remunerated office. In derogation from the remuneration previously specified, the chair- man of the Supervisory Board shall receive a fixed annual remunera- tion of €75,000.00, his deputy chairmen a fixed annual remuneration of €50,000.00 in each case. This shall also compensate their member- ships on committees. RHÖN-KLINIKUM AG | Annual Report 2021 163

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG II. Individual remuneration of members of the Supervisory Board for financial year 2021 and in comparison with the 2020 financial year The members of the Supervisory Board received the following remuneration for the financial year: Total payments for 2021 Attendance fee 2021 Fixed annual remuneration Activity on the committees Total € ’000 in % € ’000 in % € ’000 in % € ’000 Dr Jan Liersch (from 3 June 2020) [Chairman] Georg Schulze [First Deputy Chairman] Hafid Rifi (from 19 August 2020) [Second Deputy Chairman] Peter Berghöfer Nicole Mooljee Damani Dr Julia Dannath-Schuh Regina Dickey Peter Ducke Prof. (apl.) Dr med. Leopold Eberhart Prof. Dr Gerhard Ehninger (until 15 January 2021) Irmtraut Gürkan Kai Hankeln Dr Martin Mandewirth Dr Thomas Pillukat Christine Reißner Oliver Salomon Marco Walker (from 9 March 2021) Total 21 7 17 11 4 5 12 6 11 0 11 6 7 6 7 6 4 141 22 12 25 27 14 17 29 18 27 0 27 18 22 18 22 19 16 21 75 50 50 25 25 25 25 25 25 2 25 25 25 25 25 25 21 498 78 88 75 61 86 83 60 74 61 100 61 74 78 74 78 81 84 75 0 0 0 5 0 0 5 2 5 0 5 3 0 2 0 0 0 27 0 0 0 12 0 0 12 9 12 0 12 9 0 9 0 0 0 4 96 57 67 41 29 30 42 33 41 2 41 34 32 33 32 31 25 666 RHÖN-KLINIKUM AG | Annual Report 2021 165

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG Total payments in 2020 according to “old version of Articles of Association” Attendance fee Fixed total remuneration Fixed basic remuneration Total € ’000 in % € ’000 in % € ’000 in % € ’000 Dr Jan Liersch (from 3 June 2020) [Chairman] Georg Schulze [First Deputy Chairman] Hafid Rifi (from 19 August 2020) [Second Deputy Chairman] Peter Berghöfer Nicole Mooljee Damani (from 19 August 2020) Dr Julia Dannath-Schuh (from 3 June 2020) Regina Dickey (from 19 August 2020) Peter Ducke (from 19 August 2020) Prof. (apl.) Dr med. Leopold Eberhart (from 19 August 2020) Prof. Dr Gerhard Ehninger (until 15 January 2021) Irmtraut Gürkan (from 19 August 2020) Kai Hankeln (from 19 August 2020) Dr med. Martin Mandewirth (from 19 August 2020) PD Dr med. Thomas Pillukat (from 19 August 2020) Christine Reißner Oliver Salomon Marco Walker (from 9 March 2021) Dr Annette Beller (until 3 June 2020) Jan Hacker (until 19 August 2020) Stefan Härtel (from 19 August 2020) Klaus Hanschur (until 19 August 2020) Meike Jäger (until 19 August 2020) Dr Brigitte Mohn (until 19 August 2020) Eugen Münch (until 19 August 2020) Wolfgang Mündel (until 19 August 2020) Evelin Schiebel (until 19 August 2020) Dr Katrin Vernau (until 3 June 2020) Natascha Weihs (until 19 August 2020) 11 31 2 21 2 8 3 2 3 13 3 2 2 2 19 15 0 32 16 14 12 20 10 32 44 16 16 16 Total 367 37 32 100 27 100 29 100 100 100 24 100 100 100 100 26 25 0 39 28 25 24 29 23 15 22 28 29 28 27 10 16 0 30 0 11 0 0 0 12 0 0 0 0 27 16 0 34 16 16 15 27 10 111 101 16 23 16 507 33 16 0 40 0 39 0 0 0 24 0 0 0 0 40 29 0 41 28 29 30 39 23 51 52 28 41 28 37 9 51 0 25 0 9 0 0 0 25 0 0 0 0 23 25 0 17 25 25 23 23 23 76 51 25 17 25 497 30 52 0 33 0 32 0 0 0 51 0 0 0 0 34 45 0 20 44 45 46 33 53 35 26 44 30 44 36 RHÖN-KLINIKUM AG | Annual Report 2021 30 98 2 76 2 28 3 2 3 50 3 2 2 2 69 56 0 83 57 55 50 70 43 219 196 57 56 57 1,371 167

Remuneration Report of RHÖN-KLINIKUM Aktiengesellschaft pursuant to section 162 AktG Total 2021 Total 2020 Deviation Deviation in % 96 57 67 41 29 30 42 34 41 2 41 34 32 34 32 31 25 0 0 0 0 0 0 0 0 0 0 0 67 122 27 91 18 40 18 15 20 68 18 16 18 15 81 70 0 83 57 55 50 70 43 219 196 57 56 57 666 1,647 29 – 65 40 – 50 11 – 10 24 19 21 – 66 23 18 14 19 – 49 – 39 25 – 83 – 57 – 55 – 50 – 70 – 43 – 219 – 196 – 57 – 56 – 57 – 981 43 – 53 148 – 55 61 – 25 133 123 105 – 97 128 109 78 123 – 60 – 56 > 100 – 100 – 100 – 100 – 100 – 100 – 100 – 100 – 100 – 100 – 100 – 100 – 60 € ’000 Total payments of Supervisory Board Dr Jan Liersch (from 3 June 2020) [Chairman] Georg Schulze [First Deputy Chairman] Hafid Rifi (from 19 August 2020) [Second Deputy Chairman] Peter Berghöfer Nicole Mooljee Damani (from 19 August 2020) Dr Julia Dannath-Schuh (from 3 June 2020) Regina Dickey (from 19 August 2020) Peter Ducke (from 19 August 2020) Prof. (apl.) Dr med. Leopold Eberhart (from 19 August 2020) Prof. Dr Gerhard Ehninger (until 15 January 2021) Irmtraut Gürkan (from 19 August 2020) Kai Hankeln (from 19 August 2020) Dr med. Martin Mandewirth (from 19 August 2020) PD Dr med. Thomas Pillukat (from 19 August 2020) Christine Reißner Oliver Salomon Marco Walker (from 9 March 2021) Dr Annette Beller (until 3 June 2020) Jan Hacker (until 19 August 2020) Stefan Härtel (from 19 August 2020) Klaus Hanschur (until 19 August 2020) Meike Jäger (until 19 August 2020) Dr Brigitte Mohn (until 19 August 2020) Eugen Münch (until 19 August 2020) Wolfgang Mündel (until 19 August 2020) Evelin Schiebel (until 19 August 2020) Dr Katrin Vernau (until 3 June 2020) Natascha Weihs (until 19 August 2020) Total RHÖN-KLINIKUM AG | Annual Report 2021 169

Independent Auditor’s Assurance Report on examination of the Remuneration Report pursuant to Section 162 (3) AktG Independent Auditor’s Assurance Report on Examination of the Remuneration Report pursuant to Section 162 (3) AktG To RHÖN-KLINIKUM AG, Bad Neustadt a. d. Saale Opinion We have formally examined the remuneration report of RHÖN-KLINIKUM AG, Bad Neustadt a. d. Saale, for the financial year from 1 January to 31 December 2021 to determine whether the dis- closures pursuant to Section 162 (1) and (2) AktG have been made in the remuneration report. In accordance with Section 162 (3) AktG, we have not examined the content of the remuneration report. In our opinion, the accompanying remuneration report complies, in all material respects, with the disclosure requirements pursuant to Section 162 (1) and (2) AktG. Our opinion does not cover the content of the remuneration report. Basis for Opinion We conducted our examination of the remuneration report in compli- ance with Section 162 (3) AktG taking into account the IDW assurance standard: Examination of the remuneration report pursuant to Sec- tion 162 (3) AktG (IDW AsS 870 (08.2021). Our responsibilities under this regulation and this standard are further described in the “Our Responsibilities” section of our assurance report. Our audit firm has applied the IDW Standard on Quality Management 1: Requirements for Quality Management in Audit Firms (IDW QS 1). We have complied with our professional duties pursuant to the German Public Accoun- tants Act (WPO) and the Professional Charter for Auditors/Chartered Accountants (BS WP/vBP), including the independence requirements. Responsibilities of the Management Board and the Supervisory Board The Management Board and the Supervisory Board are responsible for the preparation of the remuneration report, including the related disclosures, in accordance with the requirements of Section 162 AktG. The management and the Supervisory Board are also responsible for such internal control as they have determined necessary to enable the preparation of the remuneration report that is free from material misstatement, whether due to fraud or error. Our Responsibilities Our objectives are to obtain reasonable assurance about whether the remuneration report complies, in all material respects, with the disclosure requirements pursuant to Section 162 (1) and (2) AktG, and to issue an assurance report that includes our opinion. We planned and performed our examination to obtain evidence about the formal completeness of the remuneration report by com- paring the disclosures made in the remuneration report with the disclosures required by Section 162 (1) and (2) AktG. In accordance with Section 162 (3) AktG, we have not examined whether the dis- closures are correct or individual disclosures are complete or whether the remuneration report is fairly presented. Frankfurt am Main, 23 March 2022 KPMG AG Wirtschaftsprüfungsgesellschaft Huber-Straßer Wirtschaftsprüferin (German public auditor) Schrum Wirtschaftsprüfer (German public auditor) RHÖN-KLINIKUM AG | Annual Report 2021 171